1
|
Veroniki AA, Thirugnanasampanthar SS, Konstantinidis M, Dourka J, Ghassemi M, Neupane D, Khan P, Nincic V, Corry M, Robson R, Parker A, Soobiah C, Sinilaite A, Doyon-Plourde P, Gil A, Siu W, Moqueet N, Stevens A, English K, Florez ID, Yepes-Nuñez JJ, Hutton B, Muller M, Moja L, Straus S, Tricco AC. Trivalent and quadrivalent seasonal influenza vaccine in adults aged 60 and older: a systematic review and network meta-analysis. BMJ Evid Based Med 2024:bmjebm-2023-112767. [PMID: 38604619 DOI: 10.1136/bmjebm-2023-112767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/02/2024] [Indexed: 04/13/2024]
Abstract
OBJECTIVES To compare the efficacy of influenza vaccines of any valency for adults 60 years and older. DESIGN AND SETTING Systematic review with network meta-analysis (NMA) of randomised controlled trials (RCTs). MEDLINE, EMBASE, JBI Evidence-Based Practice (EBP) Database, PsycINFO, and Cochrane Evidence -Based Medicine database were searched from inception to 20 June 20, 2022. Two reviewers screened, abstracted, and appraised articles (Cochrane Risk of Bias (ROB) 2.0 tool) independently. We assessed certainty of findings using Confidence in Network Meta-Analysis and Grading of Recommendations, Assessment, Development and Evaluations approaches. We performed random-effects meta-analysis and network meta-analysis (NMA), and estimated odds ratios (ORs) for dichotomous outcomes and incidence rate ratios (IRRs) for count outcomes along with their corresponding 95% confidence intervals (CIs) and prediction intervals. PARTICIPANTS Older adults (≥60 years old) receiving an influenza vaccine licensed in Canada or the USA (vs placebo, no vaccine, or any other licensed vaccine), at any dose. MAIN OUTCOME MEASURES Laboratory-confirmed influenza (LCI) and influenza-like illness (ILI). Secondary outcomes were the number of vascular adverse events, hospitalisation for acute respiratory infection (ARI) and ILI, inpatient hospitalisation, emergency room (ER) visit for ILI, outpatient visit, and mortality, among others. RESULTS We included 41 RCTs and 15 companion reports comprising 8 vaccine types and 206 032 participants. Vaccines may prevent LCI compared with placebo, with high-dose trivalent inactivated influenza vaccine (IIV3-HD) (NMA: 9 RCTs, 52 202 participants, OR 0.23, 95% confidence interval (CI) (0.11 to 0.51), low certainty of evidence) and recombinant influenza vaccine (RIV) (OR 0.25, 95%CI (0.08 to 0.73), low certainty of evidence) among the most efficacious vaccines. Standard dose trivalent IIV3 (IIV3-SD) may prevent ILI compared with placebo, but the result was imprecise (meta-analysis: 2 RCTs, 854 participants, OR 0.39, 95%CI (0.15 to 1.02), low certainty of evidence). Any HD was associated with prevention of ILI compared with placebo (NMA: 9 RCTs, 65 658 participants, OR 0.38, 95%CI (0.15 to 0.93)). Adjuvanted quadrivalent IIV (IIV4-Adj) may be associated with the least vascular adverse events, but the results were very uncertain (NMA: eight 8 RCTs, 57 677 participants, IRR 0.18, 95%CI (0.07 to 0.43), very low certainty of evidence). RIV on all-cause mortality may be comparable to placebo (NMA: 20 RCTs, 140 577 participants, OR 1.01, 95%CI (0.23 to 4.49), low certainty of evidence). CONCLUSIONS This systematic review demonstrated efficacy associated with IIV3-HD and RIV vaccines in protecting older persons against LCI. RIV vaccine may reduce all-cause mortality when compared with other vaccines, but the evidence is uncertain. Differences in efficacy between influenza vaccines remain uncertain with very low to moderate certainty of evidence. PROSPERO REGISTRATION NUMBER CRD42020177357.
Collapse
Affiliation(s)
- Areti Angeliki Veroniki
- Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
- Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
| | - Sai Surabi Thirugnanasampanthar
- Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
| | - Menelaos Konstantinidis
- Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
- Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
| | - Jasmeen Dourka
- Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
| | - Marco Ghassemi
- Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
| | - Dipika Neupane
- Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
| | - Paul Khan
- Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
| | - Vera Nincic
- Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
| | - Margarita Corry
- Trinity College Dublin School of Nursing and Midwifery, Dublin, Ireland
| | - Reid Robson
- Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
| | - Amanda Parker
- Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
| | - Charlene Soobiah
- Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
- Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
| | | | | | - Anabel Gil
- Public Health Agency, Ottawa, Ontario, Canada
| | - Winnie Siu
- Public Health Agency, Ottawa, Ontario, Canada
| | | | | | - Kelly English
- Patient Partner, Strategy for Patient Oriented-Research Evidence Alliance (SPOR EA), St Michael's Hospital, Toronto, Ontario, Canada
| | - Ivan D Florez
- Department of Pediatrics, University of Antioquia Faculty of Medicine, Medellin, Colombia
- School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada
- Pediatric Intensive Care Unit, Clinica Las Américas-AUNA, Medellin, Colombia
| | - Juan J Yepes-Nuñez
- University of los Andes Faculty of Medicine, Bogota, Cundinamarca, Colombia
- Pulmonology Service, Internal Medicine Section, University Hospital of the Fundacion Santa Fe de Bogota, Bogota, Colombia
| | - Brian Hutton
- Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
| | - Matthew Muller
- Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
- Department of Medicine, St Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
- Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada
| | - Lorenzo Moja
- Department of Biomedical Sciences and Technologies, University of Milan, Milano, Lombardia, Italy
| | - Sharon Straus
- Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
- Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
- Department of Geriatric Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Andrea C Tricco
- Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
- Epidemiology Division & Institute of Health Policy, Management, and Evaluation, University of Toronto Dalla Lana School of Public Health, Toronto, Ontario, Canada
| |
Collapse
|
2
|
Kuhnl A, Roddie C, Kirkwood AA, Chaganti S, Norman J, Lugthart S, Osborne W, Gibb A, Gonzalez Arias C, Latif A, Uttenthal B, Seymour F, Jones C, Springell D, Brady JL, Illidge T, Stevens A, Alexander E, Hawley L, O'Rourke N, Bedi C, Prestwich R, Frew J, Burns D, O'Reilly M, Sanderson R, Sivabalasingham S, Mikhaeel NG. Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK. Br J Haematol 2024. [PMID: 38594876 DOI: 10.1111/bjh.19453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2024] [Revised: 03/07/2024] [Accepted: 03/27/2024] [Indexed: 04/11/2024]
Abstract
Radiotherapy (RT) has potential synergistic effects with chimeric antigen receptor (CAR) T but is not widely used as bridging therapy due to logistical challenges and lack of standardised protocols. We analysed RT bridging in a multicentre national cohort of large B-cell lymphoma patients approved for 3L axicabtagene ciloleucel or tisagenlecleucel across 12 UK centres. Of 763 approved patients, 722 were leukapheresed, 717 had data available on bridging therapy. 169/717 (24%) received RT bridging, 129 as single modality and 40 as combined modality treatment (CMT). Of 169 patients, 65.7% had advanced stage, 36.9% bulky disease, 86.5% elevated LDH, 41.7% international prognostic index (IPI) ≥3 and 15.2% double/triple hit at the time of approval. Use of RT bridging varied from 11% to 32% between centres and increased over time. Vein-to-vein time and infusion rate did not differ between bridging modalities. RT-bridged patients had favourable outcomes with 1-year progression-free survival (PFS) of 56% for single modality and 47% for CMT (1-year PFS 43% for systemic bridging). This is the largest cohort of LBCL patients receiving RT bridging prior to CAR T reported to date. Our results show that RT bridging can be safely and effectively used even in advanced stage and high-risk disease, with low dropout rates and excellent outcomes.
Collapse
Affiliation(s)
- A Kuhnl
- Department of Haematology, King's College Hospital, London, UK
| | - C Roddie
- University College London Hospitals, London, UK
- UCL Cancer Institute, University College London, London, UK
| | - A A Kirkwood
- Cancer Research UK & UCL Cancer Trials Centre, UCL Cancer Institute, UCL, London, UK
| | - S Chaganti
- Queen Elizabeth Hospital, Birmingham, UK
| | - J Norman
- Department of Haematology, Manchester Royal Infirmary, Manchester, UK
| | - S Lugthart
- University Hospitals Bristol and Weston, Bristol, UK
| | - W Osborne
- Freeman Hospital, Newcastle, UK
- Newcastle University, Newcastle, UK
| | - A Gibb
- Department of Medical Oncology, The Christie Hospital, Manchester, UK
| | | | - A Latif
- Queen Elizabeth University Hospital, Glasgow, UK
| | - B Uttenthal
- Department of Haematology, Addenbrooke's Hospital, Cambridge, UK
| | | | - C Jones
- Department of Haematology, University Hospital of Wales, Cardiff, UK
| | - D Springell
- University College London Hospitals, London, UK
| | - J L Brady
- Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - T Illidge
- Cancer Sciences, University of Manchester Christie NHS Trust, Manchester NIHR BRC, Manchester, UK
| | - A Stevens
- Queen Elizabeth Hospital, Birmingham, UK
| | | | - L Hawley
- University Hospitals Bristol and Weston, Bristol, UK
| | - N O'Rourke
- Queen Elizabeth University Hospital, Glasgow, UK
| | - C Bedi
- Western General Hospital, Edinburgh, UK
| | | | - J Frew
- Freeman Hospital, Newcastle, UK
| | - D Burns
- Queen Elizabeth Hospital, Birmingham, UK
| | - M O'Reilly
- University College London Hospitals, London, UK
| | - R Sanderson
- Department of Haematology, King's College Hospital, London, UK
| | | | - N G Mikhaeel
- Guy's and St Thomas' NHS Foundation Trust, London, UK
| |
Collapse
|
3
|
Forbes RA, Crossley R, Stevens A, James R, Black M, Foster CR, Such E. What's love got to do with it? Exploring social love and public health. Perspect Public Health 2024:17579139231220557. [PMID: 38270083 DOI: 10.1177/17579139231220557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2024]
Affiliation(s)
- R A Forbes
- School of Health and Related Research (ScHARR), The University of Sheffield, Regent Street, Sheffield S1 4DA, UK
| | - R Crossley
- School of Health and Related Research (ScHARR), The University of Sheffield, Sheffield, UK
| | - A Stevens
- Yorkshire and Humber School of Public Health, Leeds, UK
| | - R James
- Faculty of Medicine and Health, University of Leeds, Leeds, UK
| | - M Black
- School of Health and Related Research, The University of Sheffield, Sheffield, UK
| | - C R Foster
- School of Health and Related Research (ScHARR), The University of Sheffield, Sheffield, UK
| | - E Such
- Anne McLaren Fellow, School of Health Sciences, Queen's Medical Centre, University of Nottingham, Nottingham, UK
| |
Collapse
|
4
|
Sayfi S, Charide R, Elliott SA, Hartling L, Munan M, Stallwood L, Butcher NJ, Richards DP, Mathew JL, Suvada J, Akl EA, Kredo T, Mbuagbaw L, Motilall A, Baba A, Scott SD, Falavigna M, Klugar M, Friessová T, Lotfi T, Stevens A, Offringa M, Schünemann HJ, Pottie K. A multimethods randomized trial found that plain language versions improved adults understanding of health recommendations. J Clin Epidemiol 2024; 165:111219. [PMID: 38008266 DOI: 10.1016/j.jclinepi.2023.11.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Revised: 10/17/2023] [Accepted: 11/17/2023] [Indexed: 11/28/2023]
Abstract
OBJECTIVES To make informed decisions, the general population should have access to accessible and understandable health recommendations. To compare understanding, accessibility, usability, satisfaction, intention to implement, and preference of adults provided with a digital "Plain Language Recommendation" (PLR) format vs. the original "Standard Language Version" (SLV). STUDY DESIGN AND SETTING An allocation-concealed, blinded, controlled superiority trial and a qualitative study to understand participant preferences. An international on-line survey. 488 adults with some English proficiency. 67.8% of participants identified as female, 62.3% were from the Americas, 70.1% identified as white, 32.2% had a bachelor's degree as their highest completed education, and 42% said they were very comfortable reading health information. In collaboration with patient partners, advisors, and the Cochrane Consumer Network, we developed a plain language format of guideline recommendations (PLRs) to compare their effectiveness vs. the original standard language versions (SLVs) as published in the source guideline. We selected two recommendations about COVID-19 vaccine, similar in their content, to compare our versions, one from the World Health Organization (WHO) and one from Centers for Disease Control and Prevention (CDC). The primary outcome was understanding, measured as the proportion of correct responses to seven comprehension questions. Secondary outcomes were accessibility, usability, satisfaction, preference, and intended behavior, measured on a 1-7 scale. RESULTS Participants randomized to the PLR group had a higher proportion of correct responses to the understanding questions for the WHO recommendation (mean difference [MD] of 19.8%, 95% confidence interval [CI] 14.7-24.9%; P < 0.001) but this difference was smaller and not statistically significant for the CDC recommendation (MD of 3.9%, 95% CI -0.7% to 8.3%; P = 0.096). However, regardless of the recommendation, participants found the PLRs more accessible, (MD of 1.2 on the seven-point scale, 95% CI 0.9-1.4%; P < 0.001) and more satisfying (MD of 1.2, 95% CI 0.9-1.4%; P < 0.001). They were also more likely to follow the recommendation if they had not already followed it (MD of 1.2, 95% CI 0.7-1.8%; P < 0.001) and share it with other people they know (MD of 1.9, 95% CI 0.5-1.2%; P < 0.001). There was no significant difference in the preference between the two formats (MD of -0.3, 95% CI -0.5% to 0.03%; P = 0.078). The qualitative interviews supported and contextualized these findings. CONCLUSION Health information provided in a PLR format improved understanding, accessibility, usability, and satisfaction and thereby has the potential to shape public decision-making behavior.
Collapse
Affiliation(s)
- Shahab Sayfi
- Department of Biology, Faculty of Science, University of Ottawa, Ottawa, Ontario K1N 6N5, Canada; Schulich School of Medicine & Dentistry, Western University, London, Ontario N6A 5C1, Canada; Department of Health Research Methods, Evidence and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, 1280 Main St. W., Hamilton, Ontario L8S 4K1, Canada
| | - Rana Charide
- Department of Health Research Methods, Evidence and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, 1280 Main St. W., Hamilton, Ontario L8S 4K1, Canada
| | - Sarah A Elliott
- Department of Pediatrics, Faculty of Medicine and Dentistry, Alberta Research Center for Health Evidence, University of Alberta, Edmonton, Alberta, Canada; Cochrane Child Health, University of Alberta, Edmonton, Alberta, Canada
| | - Lisa Hartling
- Department of Pediatrics, Faculty of Medicine and Dentistry, Alberta Research Center for Health Evidence, University of Alberta, Edmonton, Alberta, Canada; Cochrane Child Health, University of Alberta, Edmonton, Alberta, Canada
| | - Matthew Munan
- Department of Pediatrics, Faculty of Medicine and Dentistry, Alberta Research Center for Health Evidence, University of Alberta, Edmonton, Alberta, Canada
| | - Lisa Stallwood
- Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, Ontario M5G 0A4, Canada
| | - Nancy J Butcher
- Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, Ontario M5G 0A4, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario M5T 1R8, Canada
| | | | - Joseph L Mathew
- Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Jozef Suvada
- National Evidence and Quality Platform, St. Elizabeth University of Public Health and Social Science, Research Dept., Nam. 1. Maja 1, 81000 Bratislava, Slovak Republic; Experts Consortium for COVID-19, Advisor to Government of Slovak Republic, Bratislava, Slovak Republic; WHO Executive Board, Geneva, Switzerland
| | - Elie A Akl
- Department of Health Research Methods, Evidence and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, 1280 Main St. W., Hamilton, Ontario L8S 4K1, Canada; Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
| | - Tamara Kredo
- Cochrane South Africa, South African Medical Research Council, Capetown, South Africa; Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa
| | - Lawrence Mbuagbaw
- Department of Health Research Methods, Evidence and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, 1280 Main St. W., Hamilton, Ontario L8S 4K1, Canada; Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada; Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada; Biostatistics Unit, Father Sean O'Sullivan Research Centre, St Joseph's Healthcare, Hamilton, Ontario, Canada; Centre for Development of Best Practices in Health (CDBPH), Yaoundé Central Hospital, Yaoundé, Cameroon; Division of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch University, Cape Town, South Africa
| | - Ashley Motilall
- Department of Health Research Methods, Evidence and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, 1280 Main St. W., Hamilton, Ontario L8S 4K1, Canada
| | - Ami Baba
- Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, Ontario M5G 0A4, Canada
| | - Shannon D Scott
- Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada
| | - Maicon Falavigna
- National Institute for Health Technology Assessment, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
| | - Miloslav Klugar
- Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic; Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic
| | - Tereza Friessová
- Department of Health Sciences, Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | - Tamara Lotfi
- Department of Health Research Methods, Evidence and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, 1280 Main St. W., Hamilton, Ontario L8S 4K1, Canada
| | - Adrienne Stevens
- Centre for Immunization Readiness, Public Health Agency of Canada, Ottawa, Ontario K1A 0K9, Canada
| | - Martin Offringa
- Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, Ontario M5G 0A4, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario M5T 3M6, Canada; Division of Neonatology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario M5G 1X8, Canada
| | - Holger J Schünemann
- Department of Health Research Methods, Evidence and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, 1280 Main St. W., Hamilton, Ontario L8S 4K1, Canada; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
| | - Kevin Pottie
- Schulich School of Medicine & Dentistry, Western University, London, Ontario N6A 5C1, Canada; Department of Family Medicine, Western University, London, Ontario, Canada.
| |
Collapse
|
5
|
Akl EA, Cuker A, Mustafa RA, Nieuwlaat R, Stevens A, Schünemann HJ. Prospective collaborative recommendation development: a novel model for more timely and trustworthy guidelines. J Clin Epidemiol 2023; 162:156-159. [PMID: 37648070 DOI: 10.1016/j.jclinepi.2023.08.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2023] [Revised: 08/14/2023] [Accepted: 08/23/2023] [Indexed: 09/01/2023]
Affiliation(s)
- Elie A Akl
- Department of Internal Medicine, American University of Beirut, Beirut, Lebanon; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
| | - Adam Cuker
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Outcomes and Implementation Research Unit, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
| | - Reem A Mustafa
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
| | - Robby Nieuwlaat
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
| | - Adrienne Stevens
- Centre for Immunization Readiness, Public Health Agency of Canada, Ottawa, Ontario, Canada
| | - Holger J Schünemann
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
| |
Collapse
|
6
|
Dale M, Mancini M, Stevens A, Brumbach B, Prewitt A, Harker G, Silva-Batista C, Ragothaman A, Folmer R, Quinn J, Horak F. C-STIM: Protocol for a randomized, single-blind, crossover study of cerebellar repetitive transcranial magnetic stimulation (rTMS) for postural instability in people with progressive supranuclear palsy (PSP). Contemp Clin Trials Commun 2023; 35:101165. [PMID: 37538197 PMCID: PMC10393598 DOI: 10.1016/j.conctc.2023.101165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2023] [Revised: 05/12/2023] [Accepted: 06/18/2023] [Indexed: 08/05/2023] Open
Abstract
Background Methods for modulating the cerebellum with transcranial magnetic stimulation (TMS) are well established, and preliminary data from our group and others has shown evidence of transient improvements in balance after cerebellar repetitive transcranial magnetic stimulation (rTMS) in progressive suprancuclear palsy (PSP). This study examines extensive posturography measures before and after 10 sessions of cerebellar rTMS and sham TMS in PSP. Methods Thirty subjects with PSP and postural instability will undergo cerebellar active and sham rTMS in a single-blind, crossover design with a randomized order of a 10-day intervention. Primary outcomes will be changes in sway area and medio-lateral range of sway with eyes open while standing on a stationary force-plate, and safety, tolerability, and blindedness. Secondary outcomes will include posturography and gait analysis with body-worn, triaxial inertial sensors, clinical balance scales and questionnaires, and a bedside test of vestibular function. Exploratory outcomes are changes in functional near infrared spectroscopy (fNIRS) signal over the prefrontal, supplementary motor, and primary motor cortices while standing and walking, and speech samples for future analysis. Discussion The C-STIM crossover intervention study adds a longer duration of stimulation and extensive posturography measures to more finely measure the improvements in balance and exploratory functional near-infrared spectroscopy (fNIRS) over the prefronal, supplementary motor, and primary motor cortices during balance assessments before and after 10 sessions of cerebellar rTMS and 10 sessions of sham cerebellar TMS. This project will improve our understanding of the importance of the cerebellum for control of postural stability in PSP.
Collapse
Affiliation(s)
- M.L. Dale
- Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, USA
| | - M. Mancini
- Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, USA
| | - A. Stevens
- Advanced Imaging Research Center, Oregon Health & Science University, Portland, OR, USA
| | - B.H. Brumbach
- OHSU-PSU School of Public Health, Biostatistics and Design Program, Oregon Health & Science University, Portland, OR, USA
| | - A. Prewitt
- Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, USA
| | - G. Harker
- Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, USA
| | - C. Silva-Batista
- Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, USA
| | - A. Ragothaman
- Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, USA
| | - R.L. Folmer
- National Center for Rehabilitative Auditory Research (NCRAR), VA Portland Medical Center, Portland, OR, USA
- Department of Otolaryngology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, USA
| | - J.F. Quinn
- Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, USA
| | - F.B. Horak
- Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, USA
| |
Collapse
|
7
|
Aalbers J, Akerib DS, Akerlof CW, Al Musalhi AK, Alder F, Alqahtani A, Alsum SK, Amarasinghe CS, Ames A, Anderson TJ, Angelides N, Araújo HM, Armstrong JE, Arthurs M, Azadi S, Bailey AJ, Baker A, Balajthy J, Balashov S, Bang J, Bargemann JW, Barry MJ, Barthel J, Bauer D, Baxter A, Beattie K, Belle J, Beltrame P, Bensinger J, Benson T, Bernard EP, Bhatti A, Biekert A, Biesiadzinski TP, Birch HJ, Birrittella B, Blockinger GM, Boast KE, Boxer B, Bramante R, Brew CAJ, Brás P, Buckley JH, Bugaev VV, Burdin S, Busenitz JK, Buuck M, Cabrita R, Carels C, Carlsmith DL, Carlson B, Carmona-Benitez MC, Cascella M, Chan C, Chawla A, Chen H, Cherwinka JJ, Chott NI, Cole A, Coleman J, Converse MV, Cottle A, Cox G, Craddock WW, Creaner O, Curran D, Currie A, Cutter JE, Dahl CE, David A, Davis J, Davison TJR, Delgaudio J, Dey S, de Viveiros L, Dobi A, Dobson JEY, Druszkiewicz E, Dushkin A, Edberg TK, Edwards WR, Elnimr MM, Emmet WT, Eriksen SR, Faham CH, Fan A, Fayer S, Fearon NM, Fiorucci S, Flaecher H, Ford P, Francis VB, Fraser ED, Fruth T, Gaitskell RJ, Gantos NJ, Garcia D, Geffre A, Gehman VM, Genovesi J, Ghag C, Gibbons R, Gibson E, Gilchriese MGD, Gokhale S, Gomber B, Green J, Greenall A, Greenwood S, van der Grinten MGD, Gwilliam CB, Hall CR, Hans S, Hanzel K, Harrison A, Hartigan-O'Connor E, Haselschwardt SJ, Hernandez MA, Hertel SA, Heuermann G, Hjemfelt C, Hoff MD, Holtom E, Hor JYK, Horn M, Huang DQ, Hunt D, Ignarra CM, Jacobsen RG, Jahangir O, James RS, Jeffery SN, Ji W, Johnson J, Kaboth AC, Kamaha AC, Kamdin K, Kasey V, Kazkaz K, Keefner J, Khaitan D, Khaleeq M, Khazov A, Khurana I, Kim YD, Kocher CD, Kodroff D, Korley L, Korolkova EV, Kras J, Kraus H, Kravitz S, Krebs HJ, Kreczko L, Krikler B, Kudryavtsev VA, Kyre S, Landerud B, Leason EA, Lee C, Lee J, Leonard DS, Leonard R, Lesko KT, Levy C, Li J, Liao FT, Liao J, Lin J, Lindote A, Linehan R, Lippincott WH, Liu R, Liu X, Liu Y, Loniewski C, Lopes MI, Lopez Asamar E, López Paredes B, Lorenzon W, Lucero D, Luitz S, Lyle JM, Majewski PA, Makkinje J, Malling DC, Manalaysay A, Manenti L, Mannino RL, Marangou N, Marzioni MF, Maupin C, McCarthy ME, McConnell CT, McKinsey DN, McLaughlin J, Meng Y, Migneault J, Miller EH, Mizrachi E, Mock JA, Monte A, Monzani ME, Morad JA, Morales Mendoza JD, Morrison E, Mount BJ, Murdy M, Murphy ASJ, Naim D, Naylor A, Nedlik C, Nehrkorn C, Neves F, Nguyen A, Nikoleyczik JA, Nilima A, O'Dell J, O'Neill FG, O'Sullivan K, Olcina I, Olevitch MA, Oliver-Mallory KC, Orpwood J, Pagenkopf D, Pal S, Palladino KJ, Palmer J, Pangilinan M, Parveen N, Patton SJ, Pease EK, Penning B, Pereira C, Pereira G, Perry E, Pershing T, Peterson IB, Piepke A, Podczerwinski J, Porzio D, Powell S, Preece RM, Pushkin K, Qie Y, Ratcliff BN, Reichenbacher J, Reichhart L, Rhyne CA, Richards A, Riffard Q, Rischbieter GRC, Rodrigues JP, Rodriguez A, Rose HJ, Rosero R, Rossiter P, Rushton T, Rutherford G, Rynders D, Saba JS, Santone D, Sazzad ABMR, Schnee RW, Scovell PR, Seymour D, Shaw S, Shutt T, Silk JJ, Silva C, Sinev G, Skarpaas K, Skulski W, Smith R, Solmaz M, Solovov VN, Sorensen P, Soria J, Stancu I, Stark MR, Stevens A, Stiegler TM, Stifter K, Studley R, Suerfu B, Sumner TJ, Sutcliffe P, Swanson N, Szydagis M, Tan M, Taylor DJ, Taylor R, Taylor WC, Temples DJ, Tennyson BP, Terman PA, Thomas KJ, Tiedt DR, Timalsina M, To WH, Tomás A, Tong Z, Tovey DR, Tranter J, Trask M, Tripathi M, Tronstad DR, Tull CE, Turner W, Tvrznikova L, Utku U, Va'vra J, Vacheret A, Vaitkus AC, Verbus JR, Voirin E, Waldron WL, Wang A, Wang B, Wang JJ, Wang W, Wang Y, Watson JR, Webb RC, White A, White DT, White JT, White RG, Whitis TJ, Williams M, Wisniewski WJ, Witherell MS, Wolfs FLH, Wolfs JD, Woodford S, Woodward D, Worm SD, Wright CJ, Xia Q, Xiang X, Xiao Q, Xu J, Yeh M, Yin J, Young I, Zarzhitsky P, Zuckerman A, Zweig EA. First Dark Matter Search Results from the LUX-ZEPLIN (LZ) Experiment. Phys Rev Lett 2023; 131:041002. [PMID: 37566836 DOI: 10.1103/physrevlett.131.041002] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Revised: 03/06/2023] [Accepted: 06/07/2023] [Indexed: 08/13/2023]
Abstract
The LUX-ZEPLIN experiment is a dark matter detector centered on a dual-phase xenon time projection chamber operating at the Sanford Underground Research Facility in Lead, South Dakota, USA. This Letter reports results from LUX-ZEPLIN's first search for weakly interacting massive particles (WIMPs) with an exposure of 60 live days using a fiducial mass of 5.5 t. A profile-likelihood ratio analysis shows the data to be consistent with a background-only hypothesis, setting new limits on spin-independent WIMP-nucleon, spin-dependent WIMP-neutron, and spin-dependent WIMP-proton cross sections for WIMP masses above 9 GeV/c^{2}. The most stringent limit is set for spin-independent scattering at 36 GeV/c^{2}, rejecting cross sections above 9.2×10^{-48} cm at the 90% confidence level.
Collapse
Affiliation(s)
- J Aalbers
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - D S Akerib
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - C W Akerlof
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
| | - A K Al Musalhi
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - F Alder
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - A Alqahtani
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - S K Alsum
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - C S Amarasinghe
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
| | - A Ames
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - T J Anderson
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - N Angelides
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - H M Araújo
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - J E Armstrong
- University of Maryland, Department of Physics, College Park, Maryland 20742-4111, USA
| | - M Arthurs
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
| | - S Azadi
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - A J Bailey
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - A Baker
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - J Balajthy
- University of California, Davis, Department of Physics, Davis, California 95616-5270, USA
| | - S Balashov
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - J Bang
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - J W Bargemann
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - M J Barry
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - J Barthel
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - D Bauer
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - A Baxter
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - K Beattie
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - J Belle
- Fermi National Accelerator Laboratory (FNAL), Batavia, Illinois 60510-5011, USA
| | - P Beltrame
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
- University of Edinburgh, SUPA, School of Physics and Astronomy, Edinburgh EH9 3FD, United Kingdom
| | - J Bensinger
- Brandeis University, Department of Physics, Waltham, Massachusetts 02453, USA
| | - T Benson
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - E P Bernard
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - A Bhatti
- University of Maryland, Department of Physics, College Park, Maryland 20742-4111, USA
| | - A Biekert
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - T P Biesiadzinski
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - H J Birch
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - B Birrittella
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - G M Blockinger
- University at Albany (SUNY), Department of Physics, Albany, New York 12222-0100, USA
| | - K E Boast
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - B Boxer
- University of California, Davis, Department of Physics, Davis, California 95616-5270, USA
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - R Bramante
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - C A J Brew
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - P Brás
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - J H Buckley
- Washington University in St. Louis, Department of Physics, St. Louis, Missouri 63130-4862, USA
| | - V V Bugaev
- Washington University in St. Louis, Department of Physics, St. Louis, Missouri 63130-4862, USA
| | - S Burdin
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - J K Busenitz
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - M Buuck
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - R Cabrita
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - C Carels
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - D L Carlsmith
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - B Carlson
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - M C Carmona-Benitez
- Pennsylvania State University, Department of Physics, University Park, Pennsylvania 16802-6300, USA
| | - M Cascella
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - C Chan
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - A Chawla
- Royal Holloway, University of London, Department of Physics, Egham, TW20 0EX, United Kingdom
| | - H Chen
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - J J Cherwinka
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - N I Chott
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - A Cole
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - J Coleman
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - M V Converse
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - A Cottle
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
- Fermi National Accelerator Laboratory (FNAL), Batavia, Illinois 60510-5011, USA
| | - G Cox
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
- Pennsylvania State University, Department of Physics, University Park, Pennsylvania 16802-6300, USA
| | - W W Craddock
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
| | - O Creaner
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - D Curran
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - A Currie
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - J E Cutter
- University of California, Davis, Department of Physics, Davis, California 95616-5270, USA
| | - C E Dahl
- Fermi National Accelerator Laboratory (FNAL), Batavia, Illinois 60510-5011, USA
- Northwestern University, Department of Physics & Astronomy, Evanston, Illinois 60208-3112, USA
| | - A David
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - J Davis
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - T J R Davison
- University of Edinburgh, SUPA, School of Physics and Astronomy, Edinburgh EH9 3FD, United Kingdom
| | - J Delgaudio
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - S Dey
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - L de Viveiros
- Pennsylvania State University, Department of Physics, University Park, Pennsylvania 16802-6300, USA
| | - A Dobi
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - J E Y Dobson
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - E Druszkiewicz
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - A Dushkin
- Brandeis University, Department of Physics, Waltham, Massachusetts 02453, USA
| | - T K Edberg
- University of Maryland, Department of Physics, College Park, Maryland 20742-4111, USA
| | - W R Edwards
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - M M Elnimr
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - W T Emmet
- Yale University, Department of Physics, New Haven, Connecticut 06511-8499, USA
| | - S R Eriksen
- University of Bristol, H.H. Wills Physics Laboratory, Bristol, BS8 1TL, United Kingdom
| | - C H Faham
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - A Fan
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - S Fayer
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - N M Fearon
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - S Fiorucci
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - H Flaecher
- University of Bristol, H.H. Wills Physics Laboratory, Bristol, BS8 1TL, United Kingdom
| | - P Ford
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - V B Francis
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - E D Fraser
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - T Fruth
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - R J Gaitskell
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - N J Gantos
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - D Garcia
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - A Geffre
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - V M Gehman
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - J Genovesi
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - C Ghag
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - R Gibbons
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - E Gibson
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - M G D Gilchriese
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - S Gokhale
- Brookhaven National Laboratory (BNL), Upton, New York 11973-5000, USA
| | - B Gomber
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - J Green
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - A Greenall
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - S Greenwood
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | | | - C B Gwilliam
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - C R Hall
- University of Maryland, Department of Physics, College Park, Maryland 20742-4111, USA
| | - S Hans
- Brookhaven National Laboratory (BNL), Upton, New York 11973-5000, USA
| | - K Hanzel
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - A Harrison
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - E Hartigan-O'Connor
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - S J Haselschwardt
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - M A Hernandez
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
| | - S A Hertel
- University of Massachusetts, Department of Physics, Amherst, Massachusetts 01003-9337, USA
| | - G Heuermann
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
| | - C Hjemfelt
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - M D Hoff
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - E Holtom
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - J Y-K Hor
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - M Horn
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - D Q Huang
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - D Hunt
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - C M Ignarra
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - R G Jacobsen
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - O Jahangir
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - R S James
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - S N Jeffery
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - W Ji
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - J Johnson
- University of California, Davis, Department of Physics, Davis, California 95616-5270, USA
| | - A C Kaboth
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
- Royal Holloway, University of London, Department of Physics, Egham, TW20 0EX, United Kingdom
| | - A C Kamaha
- University at Albany (SUNY), Department of Physics, Albany, New York 12222-0100, USA
- University of Califonia, Los Angeles, Department of Physics and Astronomy, Los Angeles, California 90095-1547
| | - K Kamdin
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - V Kasey
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - K Kazkaz
- Lawrence Livermore National Laboratory (LLNL), Livermore, California 94550-9698, USA
| | - J Keefner
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - D Khaitan
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - M Khaleeq
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - A Khazov
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - I Khurana
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - Y D Kim
- IBS Center for Underground Physics (CUP), Yuseong-gu, Daejeon, Korea
| | - C D Kocher
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - D Kodroff
- Pennsylvania State University, Department of Physics, University Park, Pennsylvania 16802-6300, USA
| | - L Korley
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
- Brandeis University, Department of Physics, Waltham, Massachusetts 02453, USA
| | - E V Korolkova
- University of Sheffield, Department of Physics and Astronomy, Sheffield S3 7RH, United Kingdom
| | - J Kras
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - H Kraus
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - S Kravitz
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - H J Krebs
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
| | - L Kreczko
- Brookhaven National Laboratory (BNL), Upton, New York 11973-5000, USA
| | - B Krikler
- Brookhaven National Laboratory (BNL), Upton, New York 11973-5000, USA
| | - V A Kudryavtsev
- University of Sheffield, Department of Physics and Astronomy, Sheffield S3 7RH, United Kingdom
| | - S Kyre
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - B Landerud
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - E A Leason
- University of Edinburgh, SUPA, School of Physics and Astronomy, Edinburgh EH9 3FD, United Kingdom
| | - C Lee
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - J Lee
- IBS Center for Underground Physics (CUP), Yuseong-gu, Daejeon, Korea
| | - D S Leonard
- IBS Center for Underground Physics (CUP), Yuseong-gu, Daejeon, Korea
| | - R Leonard
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - K T Lesko
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - C Levy
- University at Albany (SUNY), Department of Physics, Albany, New York 12222-0100, USA
| | - J Li
- IBS Center for Underground Physics (CUP), Yuseong-gu, Daejeon, Korea
| | - F-T Liao
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - J Liao
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - J Lin
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - A Lindote
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - R Linehan
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - W H Lippincott
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
- Fermi National Accelerator Laboratory (FNAL), Batavia, Illinois 60510-5011, USA
| | - R Liu
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - X Liu
- University of Edinburgh, SUPA, School of Physics and Astronomy, Edinburgh EH9 3FD, United Kingdom
| | - Y Liu
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - C Loniewski
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - M I Lopes
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - E Lopez Asamar
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - B López Paredes
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - W Lorenzon
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
| | - D Lucero
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - S Luitz
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
| | - J M Lyle
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - P A Majewski
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - J Makkinje
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - D C Malling
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - A Manalaysay
- University of California, Davis, Department of Physics, Davis, California 95616-5270, USA
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - L Manenti
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - R L Mannino
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - N Marangou
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - M F Marzioni
- University of Edinburgh, SUPA, School of Physics and Astronomy, Edinburgh EH9 3FD, United Kingdom
| | - C Maupin
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - M E McCarthy
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - C T McConnell
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - D N McKinsey
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - J McLaughlin
- Northwestern University, Department of Physics & Astronomy, Evanston, Illinois 60208-3112, USA
| | - Y Meng
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - J Migneault
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - E H Miller
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - E Mizrachi
- University of Maryland, Department of Physics, College Park, Maryland 20742-4111, USA
- Lawrence Livermore National Laboratory (LLNL), Livermore, California 94550-9698, USA
| | - J A Mock
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University at Albany (SUNY), Department of Physics, Albany, New York 12222-0100, USA
| | - A Monte
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
- Fermi National Accelerator Laboratory (FNAL), Batavia, Illinois 60510-5011, USA
| | - M E Monzani
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
- Vatican Observatory, Castel Gandolfo, V-00120, Vatican City State
| | - J A Morad
- University of California, Davis, Department of Physics, Davis, California 95616-5270, USA
| | - J D Morales Mendoza
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - E Morrison
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - B J Mount
- Black Hills State University, School of Natural Sciences, Spearfish, South Dakota 57799-0002, USA
| | - M Murdy
- University of Massachusetts, Department of Physics, Amherst, Massachusetts 01003-9337, USA
| | - A St J Murphy
- University of Edinburgh, SUPA, School of Physics and Astronomy, Edinburgh EH9 3FD, United Kingdom
| | - D Naim
- University of California, Davis, Department of Physics, Davis, California 95616-5270, USA
| | - A Naylor
- University of Sheffield, Department of Physics and Astronomy, Sheffield S3 7RH, United Kingdom
| | - C Nedlik
- University of Massachusetts, Department of Physics, Amherst, Massachusetts 01003-9337, USA
| | - C Nehrkorn
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - F Neves
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - A Nguyen
- University of Edinburgh, SUPA, School of Physics and Astronomy, Edinburgh EH9 3FD, United Kingdom
| | - J A Nikoleyczik
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - A Nilima
- University of Edinburgh, SUPA, School of Physics and Astronomy, Edinburgh EH9 3FD, United Kingdom
| | - J O'Dell
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - F G O'Neill
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
| | - K O'Sullivan
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - I Olcina
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - M A Olevitch
- Washington University in St. Louis, Department of Physics, St. Louis, Missouri 63130-4862, USA
| | - K C Oliver-Mallory
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - J Orpwood
- University of Sheffield, Department of Physics and Astronomy, Sheffield S3 7RH, United Kingdom
| | - D Pagenkopf
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - S Pal
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - K J Palladino
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - J Palmer
- Royal Holloway, University of London, Department of Physics, Egham, TW20 0EX, United Kingdom
| | - M Pangilinan
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - N Parveen
- University at Albany (SUNY), Department of Physics, Albany, New York 12222-0100, USA
| | - S J Patton
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - E K Pease
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - B Penning
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
- Brandeis University, Department of Physics, Waltham, Massachusetts 02453, USA
| | - C Pereira
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - G Pereira
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - E Perry
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - T Pershing
- Lawrence Livermore National Laboratory (LLNL), Livermore, California 94550-9698, USA
| | - I B Peterson
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - A Piepke
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - J Podczerwinski
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - D Porzio
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - S Powell
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - R M Preece
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - K Pushkin
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
| | - Y Qie
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - B N Ratcliff
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
| | - J Reichenbacher
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - L Reichhart
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - C A Rhyne
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - A Richards
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - Q Riffard
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - G R C Rischbieter
- University at Albany (SUNY), Department of Physics, Albany, New York 12222-0100, USA
| | - J P Rodrigues
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - A Rodriguez
- Black Hills State University, School of Natural Sciences, Spearfish, South Dakota 57799-0002, USA
| | - H J Rose
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - R Rosero
- Brookhaven National Laboratory (BNL), Upton, New York 11973-5000, USA
| | - P Rossiter
- University of Sheffield, Department of Physics and Astronomy, Sheffield S3 7RH, United Kingdom
| | - T Rushton
- University of Sheffield, Department of Physics and Astronomy, Sheffield S3 7RH, United Kingdom
| | - G Rutherford
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - D Rynders
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - J S Saba
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - D Santone
- Royal Holloway, University of London, Department of Physics, Egham, TW20 0EX, United Kingdom
| | - A B M R Sazzad
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - R W Schnee
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - P R Scovell
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - D Seymour
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - S Shaw
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - T Shutt
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - J J Silk
- University of Maryland, Department of Physics, College Park, Maryland 20742-4111, USA
| | - C Silva
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - G Sinev
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - K Skarpaas
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
| | - W Skulski
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - R Smith
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - M Solmaz
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - V N Solovov
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - P Sorensen
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - J Soria
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - I Stancu
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - M R Stark
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - A Stevens
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - T M Stiegler
- Texas A&M University, Department of Physics and Astronomy, College Station, Texas 77843-4242, USA
| | - K Stifter
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
- Fermi National Accelerator Laboratory (FNAL), Batavia, Illinois 60510-5011, USA
| | - R Studley
- Brandeis University, Department of Physics, Waltham, Massachusetts 02453, USA
| | - B Suerfu
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - T J Sumner
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - P Sutcliffe
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - N Swanson
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - M Szydagis
- University at Albany (SUNY), Department of Physics, Albany, New York 12222-0100, USA
| | - M Tan
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - D J Taylor
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - R Taylor
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - W C Taylor
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - D J Temples
- Northwestern University, Department of Physics & Astronomy, Evanston, Illinois 60208-3112, USA
| | - B P Tennyson
- Yale University, Department of Physics, New Haven, Connecticut 06511-8499, USA
| | - P A Terman
- Texas A&M University, Department of Physics and Astronomy, College Station, Texas 77843-4242, USA
| | - K J Thomas
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - D R Tiedt
- University of Maryland, Department of Physics, College Park, Maryland 20742-4111, USA
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - M Timalsina
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - W H To
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - A Tomás
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - Z Tong
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - D R Tovey
- University of Sheffield, Department of Physics and Astronomy, Sheffield S3 7RH, United Kingdom
| | - J Tranter
- University of Sheffield, Department of Physics and Astronomy, Sheffield S3 7RH, United Kingdom
| | - M Trask
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - M Tripathi
- University of California, Davis, Department of Physics, Davis, California 95616-5270, USA
| | - D R Tronstad
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - C E Tull
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - W Turner
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - L Tvrznikova
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
- Yale University, Department of Physics, New Haven, Connecticut 06511-8499, USA
- Lawrence Livermore National Laboratory (LLNL), Livermore, California 94550-9698, USA
| | - U Utku
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - J Va'vra
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
| | - A Vacheret
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - A C Vaitkus
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - J R Verbus
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - E Voirin
- Fermi National Accelerator Laboratory (FNAL), Batavia, Illinois 60510-5011, USA
| | - W L Waldron
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - A Wang
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - B Wang
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - J J Wang
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - W Wang
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
- University of Massachusetts, Department of Physics, Amherst, Massachusetts 01003-9337, USA
| | - Y Wang
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - J R Watson
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - R C Webb
- Texas A&M University, Department of Physics and Astronomy, College Station, Texas 77843-4242, USA
| | - A White
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - D T White
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - J T White
- Texas A&M University, Department of Physics and Astronomy, College Station, Texas 77843-4242, USA
| | - R G White
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - T J Whitis
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - M Williams
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
- Brandeis University, Department of Physics, Waltham, Massachusetts 02453, USA
| | - W J Wisniewski
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
| | - M S Witherell
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - F L H Wolfs
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - J D Wolfs
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - S Woodford
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - D Woodward
- Pennsylvania State University, Department of Physics, University Park, Pennsylvania 16802-6300, USA
| | - S D Worm
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - C J Wright
- Brookhaven National Laboratory (BNL), Upton, New York 11973-5000, USA
| | - Q Xia
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - X Xiang
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
- Brookhaven National Laboratory (BNL), Upton, New York 11973-5000, USA
| | - Q Xiao
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - J Xu
- Lawrence Livermore National Laboratory (LLNL), Livermore, California 94550-9698, USA
| | - M Yeh
- Brookhaven National Laboratory (BNL), Upton, New York 11973-5000, USA
| | - J Yin
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - I Young
- Fermi National Accelerator Laboratory (FNAL), Batavia, Illinois 60510-5011, USA
| | - P Zarzhitsky
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - A Zuckerman
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - E A Zweig
- University of Califonia, Los Angeles, Department of Physics and Astronomy, Los Angeles, California 90095-1547
| |
Collapse
|
8
|
Smitherman EA, Chahine RA, Beukelman T, Lewandowski LB, Rahman AKMF, Wenderfer SE, Curtis JR, Hersh AO, Abulaban K, Adams A, Adams M, Agbayani R, Aiello J, Akoghlanian S, Alejandro C, Allenspach E, Alperin R, Alpizar M, Amarilyo G, Ambler W, Anderson E, Ardoin S, Armendariz S, Baker E, Balboni I, Balevic S, Ballenger L, Ballinger S, Balmuri N, Barbar‐Smiley F, Barillas‐Arias L, Basiaga M, Baszis K, Becker M, Bell‐Brunson H, Beltz E, Benham H, Benseler S, Bernal W, Beukelman T, Bigley T, Binstadt B, Black C, Blakley M, Bohnsack J, Boland J, Boneparth A, Bowman S, Bracaglia C, Brooks E, Brothers M, Brown A, Brunner H, Buckley M, Buckley M, Bukulmez H, Bullock D, Cameron B, Canna S, Cannon L, Carper P, Cartwright V, Cassidy E, Cerracchio L, Chalom E, Chang J, Chang‐Hoftman A, Chauhan V, Chira P, Chinn T, Chundru K, Clairman H, Co D, Confair A, Conlon H, Connor R, Cooper A, Cooper J, Cooper S, Correll C, Corvalan R, Costanzo D, Cron R, Curiel‐Duran L, Curington T, Curry M, Dalrymple A, Davis A, Davis C, Davis C, Davis T, De Benedetti F, De Ranieri D, Dean J, Dedeoglu F, DeGuzman M, Delnay N, Dempsey V, DeSantis E, Dickson T, Dingle J, Donaldson B, Dorsey E, Dover S, Dowling J, Drew J, Driest K, Du Q, Duarte K, Durkee D, Duverger E, Dvergsten J, Eberhard A, Eckert M, Ede K, Edelheit B, Edens C, Edens C, Edgerly Y, Elder M, Ervin B, Fadrhonc S, Failing C, Fair D, Falcon M, Favier L, Federici S, Feldman B, Fennell J, Ferguson I, Ferguson P, Ferreira B, Ferrucho R, Fields K, Finkel T, Fitzgerald M, Fleming C, Flynn O, Fogel L, Fox E, Fox M, Franco L, Freeman M, Fritz K, Froese S, Fuhlbrigge R, Fuller J, George N, Gerhold K, Gerstbacher D, Gilbert M, Gillispie‐Taylor M, Giverc E, Godiwala C, Goh I, Goheer H, Goldsmith D, Gotschlich E, Gotte A, Gottlieb B, Gracia C, Graham T, Grevich S, Griffin T, Griswold J, Grom A, Guevara M, Guittar P, Guzman M, Hager M, Hahn T, Halyabar O, Hammelev E, Hance M, Hanson A, Harel L, Haro S, Harris J, Harry O, Hartigan E, Hausmann J, Hay A, Hayward K, Heiart J, Hekl K, Henderson L, Henrickson M, Hersh A, Hickey K, Hill P, Hillyer S, Hiraki L, Hiskey M, Hobday P, Hoffart C, Holland M, Hollander M, Hong S, Horwitz M, Hsu J, Huber A, Huggins J, Hui‐Yuen J, Hung C, Huntington J, Huttenlocher A, Ibarra M, Imundo L, Inman C, Insalaco A, Jackson A, Jackson S, James K, Janow G, Jaquith J, Jared S, Johnson N, Jones J, Jones J, Jones J, Jones K, Jones S, Joshi S, Jung L, Justice C, Justiniano A, Karan N, Kaufman K, Kemp A, Kessler E, Khalsa U, Kienzle B, Kim S, Kimura Y, Kingsbury D, Kitcharoensakkul M, Klausmeier T, Klein K, Klein‐Gitelman M, Kompelien B, Kosikowski A, Kovalick L, Kracker J, Kramer S, Kremer C, Lai J, Lam J, Lang B, Lapidus S, Lapin B, Lasky A, Latham D, Lawson E, Laxer R, Lee P, Lee P, Lee T, Lentini L, Lerman M, Levy D, Li S, Lieberman S, Lim L, Lin C, Ling N, Lingis M, Lo M, Lovell D, Lowman D, Luca N, Lvovich S, Madison C, Madison J, Manzoni SM, Malla B, Maller J, Malloy M, Mannion M, Manos C, Marques L, Martyniuk A, Mason T, Mathus S, McAllister L, McCarthy K, McConnell K, McCormick E, McCurdy D, Stokes PM, McGuire S, McHale I, McMonagle A, McMullen‐Jackson C, Meidan E, Mellins E, Mendoza E, Mercado R, Merritt A, Michalowski L, Miettunen P, Miller M, Milojevic D, Mirizio E, Misajon E, Mitchell M, Modica R, Mohan S, Moore K, Moorthy L, Morgan S, Dewitt EM, Moss C, Moussa T, Mruk V, Murphy A, Muscal E, Nadler R, Nahal B, Nanda K, Nasah N, Nassi L, Nativ S, Natter M, Neely J, Nelson B, Newhall L, Ng L, Nicholas J, Nicolai R, Nigrovic P, Nocton J, Nolan B, Oberle E, Obispo B, O'Brien B, O'Brien T, Okeke O, Oliver M, Olson J, O'Neil K, Onel K, Orandi A, Orlando M, Osei‐Onomah S, Oz R, Pagano E, Paller A, Pan N, Panupattanapong S, Pardeo M, Paredes J, Parsons A, Patel J, Pentakota K, Pepmueller P, Pfeiffer T, Phillippi K, Marafon DP, Phillippi K, Ponder L, Pooni R, Prahalad S, Pratt S, Protopapas S, Puplava B, Quach J, Quinlan‐Waters M, Rabinovich C, Radhakrishna S, Rafko J, Raisian J, Rakestraw A, Ramirez C, Ramsay E, Ramsey S, Randell R, Reed A, Reed A, Reed A, Reid H, Remmel K, Repp A, Reyes A, Richmond A, Riebschleger M, Ringold S, Riordan M, Riskalla M, Ritter M, Rivas‐Chacon R, Robinson A, Rodela E, Rodriquez M, Rojas K, Ronis T, Rosenkranz M, Rosolowski B, Rothermel H, Rothman D, Roth‐Wojcicki E, Rouster – Stevens K, Rubinstein T, Ruth N, Saad N, Sabbagh S, Sacco E, Sadun R, Sandborg C, Sanni A, Santiago L, Sarkissian A, Savani S, Scalzi L, Schanberg L, Scharnhorst S, Schikler K, Schlefman A, Schmeling H, Schmidt K, Schmitt E, Schneider R, Schollaert‐Fitch K, Schulert G, Seay T, Seper C, Shalen J, Sheets R, Shelly A, Shenoi S, Shergill K, Shirley J, Shishov M, Shivers C, Silverman E, Singer N, Sivaraman V, Sletten J, Smith A, Smith C, Smith J, Smith J, Smitherman E, Soep J, Son M, Spence S, Spiegel L, Spitznagle J, Sran R, Srinivasalu H, Stapp H, Steigerwald K, Rakovchik YS, Stern S, Stevens A, Stevens B, Stevenson R, Stewart K, Stingl C, Stokes J, Stoll M, Stringer E, Sule S, Sumner J, Sundel R, Sutter M, Syed R, Syverson G, Szymanski A, Taber S, Tal R, Tambralli A, Taneja A, Tanner T, Tapani S, Tarshish G, Tarvin S, Tate L, Taxter A, Taylor J, Terry M, Tesher M, Thatayatikom A, Thomas B, Tiffany K, Ting T, Tipp A, Toib D, Torok K, Toruner C, Tory H, Toth M, Tse S, Tubwell V, Twilt M, Uriguen S, Valcarcel T, Van Mater H, Vannoy L, Varghese C, Vasquez N, Vazzana K, Vehe R, Veiga K, Velez J, Verbsky J, Vilar G, Volpe N, von Scheven E, Vora S, Wagner J, Wagner‐Weiner L, Wahezi D, Waite H, Walker J, Walters H, Muskardin TW, Waqar L, Waterfield M, Watson M, Watts A, Weiser P, Weiss J, Weiss P, Wershba E, White A, Williams C, Wise A, Woo J, Woolnough L, Wright T, Wu E, Yalcindag A, Yee M, Yen E, Yeung R, Yomogida K, Yu Q, Zapata R, Zartoshti A, Zeft A, Zeft R, Zhang Y, Zhao Y, Zhu A, Zic C. Childhood-Onset Lupus Nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short-Term Kidney Status and Variation in Care. Arthritis Care Res (Hoboken) 2023; 75:1553-1562. [PMID: 36775844 PMCID: PMC10500561 DOI: 10.1002/acr.25002] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Revised: 07/14/2022] [Accepted: 08/16/2022] [Indexed: 11/10/2022]
Abstract
OBJECTIVE The goal was to characterize short-term kidney status and describe variation in early care utilization in a multicenter cohort of patients with childhood-onset systemic lupus erythematosus (cSLE) and nephritis. METHODS We analyzed previously collected prospective data from North American patients with cSLE with kidney biopsy-proven nephritis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry from March 2017 through December 2019. We determined the proportion of patients with abnormal kidney status at the most recent registry visit and applied generalized linear mixed models to identify associated factors. We also calculated frequency of medication use, both during induction and ever recorded. RESULTS We identified 222 patients with kidney biopsy-proven nephritis, with 64% class III/IV nephritis on initial biopsy. At the most recent registry visit at median (interquartile range) of 17 (8-29) months from initial kidney biopsy, 58 of 106 patients (55%) with available data had abnormal kidney status. This finding was associated with male sex (odds ratio [OR] 3.88, 95% confidence interval [95% CI] 1.21-12.46) and age at cSLE diagnosis (OR 1.23, 95% CI 1.01-1.49). Patients with class IV nephritis were more likely than class III to receive cyclophosphamide and rituximab during induction. There was substantial variation in mycophenolate, cyclophosphamide, and rituximab ever use patterns across rheumatology centers. CONCLUSION In this cohort with predominately class III/IV nephritis, male sex and older age at cSLE diagnosis were associated with abnormal short-term kidney status. We also observed substantial variation in contemporary medication use for pediatric lupus nephritis between pediatric rheumatology centers. Additional studies are needed to better understand the impact of this variation on long-term kidney outcomes.
Collapse
|
9
|
Fernando IN, Lax S, Bowden SJ, Ahmed I, Steven JH, Churn M, Brunt AM, Agrawal RK, Canney P, Stevens A, Rea DW. Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity. Clin Oncol (R Coll Radiol) 2023; 35:397-407. [PMID: 37012180 PMCID: PMC10186116 DOI: 10.1016/j.clon.2023.03.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Revised: 02/03/2023] [Accepted: 03/10/2023] [Indexed: 04/03/2023]
Abstract
AIMS SECRAB was a prospective, open-label, multicentre, randomised phase III trial comparing synchronous to sequential chemoradiotherapy (CRT). Conducted in 48 UK centres, it recruited 2297 patients (1150 synchronous and 1146 sequential) between 2 July 1998 and 25 March 2004. SECRAB reported a positive therapeutic benefit of using adjuvant synchronous CRT in the management of breast cancer; 10-year local recurrence rates reduced from 7.1% to 4.6% (P = 0.012). The greatest benefit was seen in patients treated with anthracycline-cyclophosphamide, methotrexate, 5-fluorouracil (CMF) rather than CMF. The aim of its sub-studies reported here was to assess whether quality of life (QoL), cosmesis or chemotherapy dose intensity differed between the two CRT regimens. MATERIALS AND METHODS The QoL sub-study used EORTC QLQ-C30, EORTC QLQ-BR23 and the Women's Health Questionnaire. Cosmesis was assessed: (i) by the treating clinician, (ii) by a validated independent consensus scoring method and (iii) from the patients' perspective by analysing four cosmesis-related QoL questions within the QLQ-BR23. Chemotherapy doses were captured from pharmacy records. The sub-studies were not formally powered; rather, the aim was that at least 300 patients (150 in each arm) were recruited and differences in QoL, cosmesis and dose intensity of chemotherapy assessed. The analysis, therefore, is exploratory in nature. RESULTS No differences were observed in the change from baseline in QoL between the two arms assessed up to 2 years post-surgery (Global Health Status: -0.05; 95% confidence interval -2.16, 2.06; P = 0.963). No differences in cosmesis were observed (via independent and patient assessment) up to 5 years post-surgery. The percentage of patients receiving the optimal course-delivered dose intensity (≥85%) was not significantly different between the arms (synchronous 88% versus sequential 90%; P = 0.503). CONCLUSIONS Synchronous CRT is tolerable, deliverable and significantly more effective than sequential, with no serious disadvantages identified when assessing 2-year QoL or 5-year cosmetic differences.
Collapse
Affiliation(s)
- I N Fernando
- Cancer Centre, Queen Elizabeth Hospital, Birmingham, UK.
| | - S Lax
- Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK
| | - S J Bowden
- Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK
| | - I Ahmed
- Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK
| | - J H Steven
- Cancer Centre, Queen Elizabeth Hospital, Birmingham, UK
| | - M Churn
- Clinical Oncology, Worcestershire Royal Hospital, Worcester, UK
| | - A M Brunt
- Cancer Centre, Royal Stoke University Hospital, Stoke on Trent, UK; Keele University, Keele, UK
| | - R K Agrawal
- The Shrewsbury and Telford NHS Trust, Shrewsbury, UK
| | - P Canney
- Beatson West of Scotland Cancer Centre, Glasgow, UK
| | - A Stevens
- Cancer Centre, Queen Elizabeth Hospital, Birmingham, UK
| | - D W Rea
- Cancer Centre, Queen Elizabeth Hospital, Birmingham, UK; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK
| |
Collapse
|
10
|
Horn M, Mathias S, Colwell H, Heerdegen A, Bevans K, Li T, Stevens A, Sermon J, Fastenau J, Pierson R. 73P Qualitative research to evaluate perceptions around biomarker testing and patient-reported outcomes (PROs) for use in studies of non-small cell lung cancer (NSCLC). J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00327-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
11
|
Watson M, Filia K, Stevens A, Cotton S, Nelson B, Ratheesh A. A systematic review and meta-analysis of global and social functioning among people at risk of bipolar disorder. J Affect Disord 2023; 321:290-303. [PMID: 36306929 DOI: 10.1016/j.jad.2022.10.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 10/04/2022] [Accepted: 10/17/2022] [Indexed: 11/11/2022]
Abstract
BACKGROUND Functional status could predict development of bipolar disorder (BD) or have clinical significance. The relationship between BD risk and functioning is poorly understood. We undertook a systematic review examining the global and social functioning of those at risk for BD. METHODS We examined observational studies comparing a risk sample with healthy controls or full-threshold BD participants, using measures of global or social functioning. Risk status included family history of BD, meeting risk criteria, or having prodromal symptomatology, or premorbid functioning of persons with BD. Medline, PsycINFO, and Embase were searched. The Newcastle-Ottawa Scale for Cross-Sectional Studies was used to assess quality. Meta-analyses were performed where possible. RESULTS 7215 studies were screened and 40 studies were included (8474 participants). Risk samples had poorer functioning than controls, and superior functioning to participants with BD. Meta-analysis indicated poorer global functioning among persons with familial risk compared to healthy controls (mean global functional difference: 5.92; 95 % confidence interval: 7.90, 3.95; mean premorbid functioning difference: 2.31; 95 % confidence interval: 0.70, 3.92). Studies with higher proportions of female participants had slightly poorer global functioning. High heterogeneity was attributable functional measures and potentially functionally differential subgroups within the risk samples. LIMITATIONS Broader measures of functioning, such as neurocognition and behavioural measures, were excluded. Measures of global functioning are limited by conflating functioning and symptoms. CONCLUSIONS Functioning in the BD risk populations is intermediate to that of healthy controls and persons with BD, indicating their value in definitions of BD risk, in itself a likely heterogeneous state.
Collapse
Affiliation(s)
- M Watson
- The University of Melbourne, Centre for Youth Mental Health, Parkville 3052, Australia; The University of Melbourne, Melbourne Medical School, Parkville 3052, Australia
| | - K Filia
- Orygen, Parkville 3052, Australia
| | | | - S Cotton
- Orygen, Parkville 3052, Australia
| | - B Nelson
- Orygen, Parkville 3052, Australia
| | - A Ratheesh
- Orygen, Parkville 3052, Australia; The University of Melbourne, Centre for Youth Mental Health, Parkville 3052, Australia.
| |
Collapse
|
12
|
Charide R, Stallwood L, Munan M, Sayfi S, Hartling L, Butcher NJ, Offringa M, Elliott S, Richards DP, Mathew JL, Akl EA, Kredo T, Mbuagbaw L, Motillal A, Baba A, Prebeg M, Relihan J, Scott SD, Suvada J, Falavigna M, Klugar M, Lotfi T, Stevens A, Pottie K, Schünemann HJ. Knowledge mobilization activities to support decision-making by youth, parents, and adults using a systematic and living map of evidence and recommendations on COVID-19: protocol for three randomized controlled trials and qualitative user-experience studies. Trials 2023; 24:27. [PMID: 36641457 PMCID: PMC9840541 DOI: 10.1186/s13063-023-07067-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Accepted: 01/03/2023] [Indexed: 01/15/2023] Open
Abstract
INTRODUCTION The COVID-19 pandemic underlined that guidelines and recommendations must be made more accessible and more understandable to the general public to improve health outcomes. The objective of this study is to evaluate, quantify, and compare the public's understanding, usability, satisfaction, intention to implement, and preference for different ways of presenting COVID-19 health recommendations derived from the COVID-19 Living Map of Recommendations and Gateway to Contextualization (RecMap). METHODS AND ANALYSIS This is a protocol for a multi-method study. Through an online survey, we will conduct pragmatic allocation-concealed, blinded superiority randomized controlled trials (RCTs) in three populations to test alternative formats of presenting health recommendations: adults, parents, and youth, with at least 240 participants in each population. Prior to initiating the RCT, our interventions will have been refined with relevant stakeholder input. The intervention arm will receive a plain language recommendation (PLR) format while the control arm will receive the corresponding original recommendation format as originally published by the guideline organizations (standard language version). Our primary outcome is understanding, and our secondary outcomes are accessibility and usability, satisfaction, intended behavior, and preference for the recommendation formats. Each population's results will be analyzed separately. However, we are planning a meta-analysis of the results across populations. At the end of each survey, participants will be invited to participate in an optional one-on-one, virtual semi-structured interview to explore their user experience. All interviews will be transcribed and analyzed using the principles of thematic analysis and a hybrid inductive and deductive approach. ETHICS AND DISSEMINATION Through Clinical Trials Ontario, the Hamilton Integrated Research Ethics Board has reviewed and approved this protocol (Project ID: 3856). The University of Alberta has approved the parent portion of the trial (Project ID:00114894). Findings from this study will be disseminated through open-access publications in peer-reviewed journals and using social media. TRIAL REGISTRATION Clinicaltrials.gov NCT05358990 . Registered on May 3, 2022.
Collapse
Affiliation(s)
- Rana Charide
- grid.25073.330000 0004 1936 8227Michael G. DeGroote Cochrane Canada and McMaster GRADE Centres, Department of Health Research Methods, Evidence and Impact, McMaster University, 1280 Main St. W, Hamilton, Ontario L8S 4K1 Canada
| | - Lisa Stallwood
- grid.42327.300000 0004 0473 9646Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, Ontario Canada
| | - Matthew Munan
- grid.17089.370000 0001 2190 316XAlberta Research Centre for Health Evidence, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta Canada
| | - Shahab Sayfi
- grid.39381.300000 0004 1936 8884Schulich School of Medicine & Dentistry, Western University, London, Ontario Canada
| | - Lisa Hartling
- grid.17089.370000 0001 2190 316XAlberta Research Centre for Health Evidence, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta Canada ,grid.17089.370000 0001 2190 316XCochrane Child Health, Department of Pediatrics, University of Alberta, Edmonton, Alberta Canada
| | - Nancy J. Butcher
- grid.42327.300000 0004 0473 9646Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, Ontario Canada ,grid.17063.330000 0001 2157 2938Department of Psychiatry, University of Toronto, Toronto, Ontario Canada
| | - Martin Offringa
- grid.42327.300000 0004 0473 9646Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, Ontario Canada ,grid.17063.330000 0001 2157 2938Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario Canada ,grid.42327.300000 0004 0473 9646Division of Neonatology, The Hospital for Sick Children, Toronto, Ontario Canada
| | - Sarah Elliott
- grid.17089.370000 0001 2190 316XAlberta Research Centre for Health Evidence, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta Canada ,grid.17089.370000 0001 2190 316XCochrane Child Health, Department of Pediatrics, University of Alberta, Edmonton, Alberta Canada
| | - Dawn P. Richards
- Five02 Labs Inc, Toronto, Ontario Canada ,grid.498672.6Canadian Arthritis Patient Alliance, Toronto, Ontario Canada
| | - Joseph L. Mathew
- grid.415131.30000 0004 1767 2903Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Elie A. Akl
- grid.25073.330000 0004 1936 8227Michael G. DeGroote Cochrane Canada and McMaster GRADE Centres, Department of Health Research Methods, Evidence and Impact, McMaster University, 1280 Main St. W, Hamilton, Ontario L8S 4K1 Canada ,grid.22903.3a0000 0004 1936 9801Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
| | - Tamara Kredo
- grid.415021.30000 0000 9155 0024Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa ,grid.11956.3a0000 0001 2214 904XDivision of Clinical Pharmacology, Department of Medicine and Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa
| | - Lawrence Mbuagbaw
- grid.25073.330000 0004 1936 8227Michael G. DeGroote Cochrane Canada and McMaster GRADE Centres, Department of Health Research Methods, Evidence and Impact, McMaster University, 1280 Main St. W, Hamilton, Ontario L8S 4K1 Canada ,grid.25073.330000 0004 1936 8227Department of Anesthesia, McMaster University, Hamilton, Ontario Canada ,grid.25073.330000 0004 1936 8227Department of Pediatrics, McMaster University, Hamilton, Ontario Canada ,grid.416721.70000 0001 0742 7355Biostatistics Unit, Father Sean O’Sullivan Research Centre, St Joseph’s Healthcare, Hamilton, Ontario Canada ,grid.460723.40000 0004 0647 4688Centre for Development of Best Practices in Health (CDBPH), Yaoundé Central Hospital, Yaoundé, Cameroon ,grid.11956.3a0000 0001 2214 904XDivision of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch University, Cape Town, South Africa
| | - Ashley Motillal
- grid.25073.330000 0004 1936 8227Michael G. DeGroote Cochrane Canada and McMaster GRADE Centres, Department of Health Research Methods, Evidence and Impact, McMaster University, 1280 Main St. W, Hamilton, Ontario L8S 4K1 Canada
| | - Ami Baba
- grid.42327.300000 0004 0473 9646Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, Ontario Canada
| | - Matthew Prebeg
- grid.155956.b0000 0000 8793 5925Centre for Addiction and Mental Health, Toronto, Ontario Canada
| | - Jacqueline Relihan
- grid.155956.b0000 0000 8793 5925Centre for Addiction and Mental Health, Toronto, Ontario Canada
| | - Shannon D. Scott
- grid.17089.370000 0001 2190 316XFaculty of Nursing, University of Alberta, Edmonton, Alberta Canada
| | - Jozef Suvada
- Departments of Science and International Studies, St. Elizabeth University of Public Health and Social Science, Bratislava, Slovak Republic
| | - Maicon Falavigna
- grid.8532.c0000 0001 2200 7498National Institute for Health Technology Assessment, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
| | - Miloslav Klugar
- grid.10267.320000 0001 2194 0956Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
| | - Tamara Lotfi
- grid.25073.330000 0004 1936 8227Michael G. DeGroote Cochrane Canada and McMaster GRADE Centres, Department of Health Research Methods, Evidence and Impact, McMaster University, 1280 Main St. W, Hamilton, Ontario L8S 4K1 Canada
| | - Adrienne Stevens
- grid.415368.d0000 0001 0805 4386Centre for Immunization Readiness, Public Health Agency of Canada, Ottawa, Canada
| | - Kevin Pottie
- grid.39381.300000 0004 1936 8884Schulich School of Medicine & Dentistry, Western University, London, Ontario Canada ,grid.39381.300000 0004 1936 8884Department of Family Medicine, Western University, London, Ontario Canada
| | - Holger J. Schünemann
- grid.25073.330000 0004 1936 8227Michael G. DeGroote Cochrane Canada and McMaster GRADE Centres, Department of Health Research Methods, Evidence and Impact, McMaster University, 1280 Main St. W, Hamilton, Ontario L8S 4K1 Canada ,grid.452490.eDepartment of Biomedical Sciences, Humanitas University, Milan, Italy
| |
Collapse
|
13
|
Dewidar O, Lotfi T, Langendam M, Parmelli E, Saz Parkinson Z, Solo K, Chu DK, Mathew JL, Akl EA, Brignardello-Petersen R, Mustafa RA, Moja L, Iorio A, Chi Y, Canelo-Aybar C, Kredo T, Karpusheff J, Turgeon AF, Alonso-Coello P, Wiercioch W, Gerritsen A, Klugar M, Rojas MX, Tugwell P, Welch VA, Pottie K, Munn Z, Nieuwlaat R, Ford N, Stevens A, Khabsa J, Nasir Z, Leontiadis GI, Meerpohl JJ, Piggott T, Qaseem A, Matthews M, Schünemann HJ. Which actionable statements qualify as good practice statements In Covid-19 guidelines? A systematic appraisal. BMJ Evid Based Med 2022; 27:361-369. [PMID: 35428695 PMCID: PMC9044517 DOI: 10.1136/bmjebm-2021-111866] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/28/2022] [Indexed: 12/14/2022]
Abstract
OBJECTIVES To evaluate the development and quality of actionable statements that qualify as good practice statements (GPS) reported in COVID-19 guidelines. DESIGN AND SETTING Systematic review . We searched MEDLINE, MedSci, China National Knowledge Infrastructure (CNKI), databases of Grading of Recommendations Assessment, Development and Evaluation (GRADE) Guidelines, NICE, WHO and Guidelines International Network (GIN) from March 2020 to September 2021. We included original or adapted recommendations addressing any COVID-19 topic. MAIN OUTCOME MEASURES We used GRADE Working Group criteria for assessing the appropriateness of issuing a GPS: (1) clear and actionable; (2) rationale necessitating the message for healthcare practice; (3) practicality of systematically searching for evidence; (4) likely net positive consequences from implementing the GPS and (5) clear link to the indirect evidence. We assessed guideline quality using the Appraisal of Guidelines for Research and Evaluation II tool. RESULTS 253 guidelines from 44 professional societies issued 3726 actionable statements. We classified 2375 (64%) as GPS; of which 27 (1%) were labelled as GPS by guideline developers. 5 (19%) were labelled as GPS by their authors but did not meet GPS criteria. Of the 2375 GPS, 85% were clear and actionable; 59% provided a rationale necessitating the message for healthcare practice, 24% reported the net positive consequences from implementing the GPS. Systematic collection of evidence was deemed impractical for 13% of the GPS, and 39% explained the chain of indirect evidence supporting GPS development. 173/2375 (7.3%) statements explicitly satisfied all five criteria. The guidelines' overall quality was poor regardless of the appropriateness of GPS development and labelling. CONCLUSIONS Statements that qualify as GPS are common in COVID-19 guidelines but are characterised by unclear designation and development processes, and methodological weaknesses.
Collapse
Affiliation(s)
- Omar Dewidar
- Methods Centre, Bruyère Research Institute, Ottawa, Ontario, Canada
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Tamara Lotfi
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada
| | - Miranda Langendam
- Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
| | - Elena Parmelli
- Joint Research Centre, European Commission, Ispra, Italy
| | - Zuleika Saz Parkinson
- Instituto de Salud Carlos III, Agencia de Evaluación de Tecnologías Sanitarias, Madrid, Spain
| | - Karla Solo
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada
| | - Derek K Chu
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Joseph L Mathew
- Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | - Elie A Akl
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
| | - Romina Brignardello-Petersen
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
| | - Reem A Mustafa
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Internal Medicine, Division of Nephrology and Hypertension, University of Kansas School of Medicine, Kansas City, Kansas, USA
| | - Lorenzo Moja
- Department of Health Product Policy and Standards, World Health Organization, Geneve, Switzerland
| | - Alfonso Iorio
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Yuan Chi
- Yealth Network, Beijing Yealth Technology Co., Ltd, Beijing, China
- Cochrane Campbell Global Ageing Partnership, London, UK
| | - Carlos Canelo-Aybar
- Iberoamerican Cochrane Center, Biomedical Research Institute Sant Pau-CIBERESP, Barcelona, Spain
| | - Tamara Kredo
- Cochrane South Africa, South African Medical Research Council, Cape Town, Western Cape, South Africa
- Clinical Pharmacology, Department of Medicine, Stellenbosch University, Stellenbosch, Western Cape, South Africa
| | | | - Alexis F Turgeon
- Centre de Recherche du Centre Hospitalier Affilié Universitaire de Québec (CHA), CHA-Hôpital de l'Enfant-Jésus, Université Laval, Quebec, Quebec, Canada
- Department of Anesthesiology and Critical Care Medicine, Université Laval, Québec City, Québec, Canada
| | - Pablo Alonso-Coello
- Iberoamerican Cochrane Center, Biomedical Research Institute Sant Pau-CIBERESP, Barcelona, Spain
| | - Wojtek Wiercioch
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada
| | - Annette Gerritsen
- Cochrane South Africa, South African Medical Research Council, Cape Town, Western Cape, South Africa
| | - Miloslav Klugar
- Czech National Centre for Evidence-Based Healthcare and Knowledge Translation, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
| | - María Ximena Rojas
- Department of Clinical Epidemiology and Public Health, Institut d'Investigació Biomèdica Sant Pau IIB Sant Pau, Barcelona, Spain
| | - Peter Tugwell
- Department of Medicine, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Vivian Andrea Welch
- Methods Centre, Bruyère Research Institute, Ottawa, Ontario, Canada
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Kevin Pottie
- Deparatment of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Zachary Munn
- Joanna Briggs Institute, University of Adelaide, Adelaide, South Australia, Australia
| | - Robby Nieuwlaat
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
| | - Nathan Ford
- Department of HIV, Hepatitis and Sexually Transmitted Infections, World Health Organization, Geneva, Switzerland
| | - Adrienne Stevens
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
| | - Joanne Khabsa
- Clinical Research Institute, American University of Beirut, Beirut, Lebanon
| | - Zil Nasir
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
| | - Grigorios I Leontiadis
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Joerg J Meerpohl
- Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany
- Medical Center - University of Freiburg, Institute for Evidence in Medicine, Freiburg, Germany
| | - Thomas Piggott
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada
| | - Amir Qaseem
- American College of Physicians, Philadelphia, Pennsylvania, USA
| | - Micayla Matthews
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada
| | - Holger J Schünemann
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada
- Department of Biomedical Sciences, Humanitas University, Milan, Italy
- Cochrane Canada, Hamilton, Ontario, Canada
| |
Collapse
|
14
|
Hahn T, Daymont C, Beukelman T, Groh B, Hays K, Bingham CA, Scalzi L, Abel N, Abulaban K, Adams A, Adams M, Agbayani R, Aiello J, Akoghlanian S, Alejandro C, Allenspach E, Alperin R, Alpizar M, Amarilyo G, Ambler W, Anderson E, Ardoin S, Armendariz S, Baker E, Balboni I, Balevic S, Ballenger L, Ballinger S, Balmuri N, Barbar-Smiley F, Barillas-Arias L, Basiaga M, Baszis K, Becker M, Bell-Brunson H, Beltz E, Benham H, Benseler S, Bernal W, Beukelman T, Bigley T, Binstadt B, Black C, Blakley M, Bohnsack J, Boland J, Boneparth A, Bowman S, Bracaglia C, Brooks E, Brothers M, Brown A, Brunner H, Buckley M, Buckley M, Bukulmez H, Bullock D, Cameron B, Canna S, Cannon L, Carper P, Cartwright V, Cassidy E, Cerracchio L, Chalom E, Chang J, Chang-Hoftman A, Chauhan V, Chira P, Chinn T, Chundru K, Clairman H, Co D, Confair A, Conlon H, Connor R, Cooper A, Cooper J, Cooper S, Correll C, Corvalan R, Costanzo D, Cron R, Curiel-Duran L, Curington T, Curry M, Dalrymple A, Davis A, Davis C, Davis C, Davis T, De Benedetti F, De Ranieri D, Dean J, Dedeoglu F, DeGuzman M, Delnay N, Dempsey V, DeSantis E, Dickson T, Dingle J, Donaldson B, Dorsey E, Dover S, Dowling J, Drew J, Driest K, Du Q, Duarte K, Durkee D, Duverger E, Dvergsten J, Eberhard A, Eckert M, Ede K, Edelheit B, Edens C, Edens C, Edgerly Y, Elder M, Ervin B, Fadrhonc S, Failing C, Fair D, Falcon M, Favier L, Federici S, Feldman B, Fennell J, Ferguson I, Ferguson P, Ferreira B, Ferrucho R, Fields K, Finkel T, Fitzgerald M, Fleming C, Flynn O, Fogel L, Fox E, Fox M, Franco L, Freeman M, Fritz K, Froese S, Fuhlbrigge R, Fuller J, George N, Gerhold K, Gerstbacher D, Gilbert M, Gillispie-Taylor M, Giverc E, Godiwala C, Goh I, Goheer H, Goldsmith D, Gotschlich E, Gotte A, Gottlieb B, Gracia C, Graham T, Grevich S, Griffin T, Griswold J, Grom A, Guevara M, Guittar P, Guzman M, Hager M, Hahn T, Halyabar O, Hammelev E, Hance M, Hanson A, Harel L, Haro S, Harris J, Harry O, Hartigan E, Hausmann J, Hay A, Hayward K, Heiart J, Hekl K, Henderson L, Henrickson M, Hersh A, Hickey K, Hill P, Hillyer S, Hiraki L, Hiskey M, Hobday P, Hoffart C, Holland M, Hollander M, Hong S, Horwitz M, Hsu J, Huber A, Huggins J, Hui-Yuen J, Hung C, Huntington J, Huttenlocher A, Ibarra M, Imundo L, Inman C, Insalaco A, Jackson A, Jackson S, James K, Janow G, Jaquith J, Jared S, Johnson N, Jones J, Jones J, Jones J, Jones K, Jones S, Joshi S, Jung L, Justice C, Justiniano A, Karan N, Kaufman K, Kemp A, Kessler E, Khalsa U, Kienzle B, Kim S, Kimura Y, Kingsbury D, Kitcharoensakkul M, Klausmeier T, Klein K, Klein-Gitelman M, Kompelien B, Kosikowski A, Kovalick L, Kracker J, Kramer S, Kremer C, Lai J, Lam J, Lang B, Lapidus S, Lapin B, Lasky A, Latham D, Lawson E, Laxer R, Lee P, Lee P, Lee T, Lentini L, Lerman M, Levy D, Li S, Lieberman S, Lim L, Lin C, Ling N, Lingis M, Lo M, Lovell D, Lowman D, Luca N, Lvovich S, Madison C, Madison J, Manzoni SM, Malla B, Maller J, Malloy M, Mannion M, Manos C, Marques L, Martyniuk A, Mason T, Mathus S, McAllister L, McCarthy K, McConnell K, McCormick E, McCurdy D, Stokes PMC, McGuire S, McHale I, McMonagle A, McMullen-Jackson C, Meidan E, Mellins E, Mendoza E, Mercado R, Merritt A, Michalowski L, Miettunen P, Miller M, Milojevic D, Mirizio E, Misajon E, Mitchell M, Modica R, Mohan S, Moore K, Moorthy L, Morgan S, Dewitt EM, Moss C, Moussa T, Mruk V, Murphy A, Muscal E, Nadler R, Nahal B, Nanda K, Nasah N, Nassi L, Nativ S, Natter M, Neely J, Nelson B, Newhall L, Ng L, Nicholas J, Nicolai R, Nigrovic P, Nocton J, Nolan B, Oberle E, Obispo B, O’Brien B, O’Brien T, Okeke O, Oliver M, Olson J, O’Neil K, Onel K, Orandi A, Orlando M, Osei-Onomah S, Oz R, Pagano E, Paller A, Pan N, Panupattanapong S, Pardeo M, Paredes J, Parsons A, Patel J, Pentakota K, Pepmueller P, Pfeiffer T, Phillippi K, Marafon DP, Phillippi K, Ponder L, Pooni R, Prahalad S, Pratt S, Protopapas S, Puplava B, Quach J, Quinlan-Waters M, Rabinovich C, Radhakrishna S, Rafko J, Raisian J, Rakestraw A, Ramirez C, Ramsay E, Ramsey S, Randell R, Reed A, Reed A, Reed A, Reid H, Remmel K, Repp A, Reyes A, Richmond A, Riebschleger M, Ringold S, Riordan M, Riskalla M, Ritter M, Rivas-Chacon R, Robinson A, Rodela E, Rodriquez M, Rojas K, Ronis T, Rosenkranz M, Rosolowski B, Rothermel H, Rothman D, Roth-Wojcicki E, Rouster-Stevens K, Rubinstein T, Ruth N, Saad N, Sabbagh S, Sacco E, Sadun R, Sandborg C, Sanni A, Santiago L, Sarkissian A, Savani S, Scalzi L, Schanberg L, Scharnhorst S, Schikler K, Schlefman A, Schmeling H, Schmidt K, Schmitt E, Schneider R, Schollaert-Fitch K, Schulert G, Seay T, Seper C, Shalen J, Sheets R, Shelly A, Shenoi S, Shergill K, Shirley J, Shishov M, Shivers C, Silverman E, Singer N, Sivaraman V, Sletten J, Smith A, Smith C, Smith J, Smith J, Smitherman E, Soep J, Son M, Spence S, Spiegel L, Spitznagle J, Sran R, Srinivasalu H, Stapp H, Steigerwald K, Rakovchik YS, Stern S, Stevens A, Stevens B, Stevenson R, Stewart K, Stingl C, Stokes J, Stoll M, Stringer E, Sule S, Sumner J, Sundel R, Sutter M, Syed R, Syverson G, Szymanski A, Taber S, Tal R, Tambralli A, Taneja A, Tanner T, Tapani S, Tarshish G, Tarvin S, Tate L, Taxter A, Taylor J, Terry M, Tesher M, Thatayatikom A, Thomas B, Tiffany K, Ting T, Tipp A, Toib D, Torok K, Toruner C, Tory H, Toth M, Tse S, Tubwell V, Twilt M, Uriguen S, Valcarcel T, Van Mater H, Vannoy L, Varghese C, Vasquez N, Vazzana K, Vehe R, Veiga K, Velez J, Verbsky J, Vilar G, Volpe N, von Scheven E, Vora S, Wagner J, Wagner-Weiner L, Wahezi D, Waite H, Walker J, Walters H, Muskardin TW, Waqar L, Waterfield M, Watson M, Watts A, Weiser P, Weiss J, Weiss P, Wershba E, White A, Williams C, Wise A, Woo J, Woolnough L, Wright T, Wu E, Yalcindag A, Yee M, Yen E, Yeung R, Yomogida K, Yu Q, Zapata R, Zartoshti A, Zeft A, Zeft R, Zhang Y, Zhao Y, Zhu A, Zic C. Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatr Rheumatol Online J 2022; 20:107. [PMID: 36434731 PMCID: PMC9701017 DOI: 10.1186/s12969-022-00770-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Accepted: 11/08/2022] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND Children with juvenile idiopathic arthritis (JIA) who achieve a drug free remission often experience a flare of their disease requiring either intraarticular steroids (IAS) or systemic treatment with disease modifying anti-rheumatic drugs (DMARDs). IAS offer an opportunity to recapture disease control and avoid exposure to side effects from systemic immunosuppression. We examined a cohort of patients treated with IAS after drug free remission and report the probability of restarting systemic treatment within 12 months. METHODS We analyzed a cohort of patients from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry who received IAS for a flare after a period of drug free remission. Historical factors and clinical characteristics and of the patients including data obtained at the time of treatment were analyzed. RESULTS We identified 46 patients who met the inclusion criteria. Of those with follow up data available 49% had restarted systemic treatment 6 months after IAS injection and 70% had restarted systemic treatment at 12 months. The proportion of patients with prior use of a biologic DMARD was the only factor that differed between patients who restarted systemic treatment those who did not, both at 6 months (79% vs 35%, p < 0.01) and 12 months (81% vs 33%, p < 0.05). CONCLUSION While IAS are an option for all patients who flare after drug free remission, it may not prevent the need to restart systemic treatment. Prior use of a biologic DMARD may predict lack of success for IAS. Those who previously received methotrexate only, on the other hand, are excellent candidates for IAS.
Collapse
Affiliation(s)
- Timothy Hahn
- Department of Pediatrics, Penn State Children's Hospital, 500 University Dr, Hershey, 90 Hope Drive, P.O. Box 855, Hershey, PA, 17033-0855, USA.
| | - Carrie Daymont
- grid.240473.60000 0004 0543 9901Department of Pediatrics, Penn State Children’s Hospital, 500 University Dr, Hershey, 90 Hope Drive, P.O. Box 855, Hershey, PA 17033-0855 USA
| | - Timothy Beukelman
- grid.265892.20000000106344187Department of Pediatrics, University of Alabama at Birmingham, CPPN G10, 1600 7th Ave South, Birmingham, AL 35233 USA
| | - Brandt Groh
- grid.240473.60000 0004 0543 9901Department of Pediatrics, Penn State Children’s Hospital, 500 University Dr, Hershey, 90 Hope Drive, P.O. Box 855, Hershey, PA 17033-0855 USA
| | | | - Catherine April Bingham
- grid.240473.60000 0004 0543 9901Department of Pediatrics, Penn State Children’s Hospital, 500 University Dr, Hershey, 90 Hope Drive, P.O. Box 855, Hershey, PA 17033-0855 USA
| | - Lisabeth Scalzi
- grid.240473.60000 0004 0543 9901Department of Pediatrics, Penn State Children’s Hospital, 500 University Dr, Hershey, 90 Hope Drive, P.O. Box 855, Hershey, PA 17033-0855 USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K, DeSancho MT, Diuguid D, Griffin DO, Kahn SR, Klok FA, Lee AI, Neumann I, Pai A, Righini M, Sanfilippo KM, Siegal DM, Skara M, Terrell DR, Touri K, Akl EA, Al Jabiri R, Al Jabiri Y, Barbara AM, Bognanni A, Boulos M, Brignardello-Petersen R, Charide R, Colunga-Lozano LE, Dearness K, Darzi AJ, Hussein H, Karam SG, Mansour R, Morgano GP, Morsi RZ, Muti-Schünemann G, Nadim MK, Philip BA, Qiu Y, Benitez YR, Stevens A, Solo K, Wiercioch W, Mustafa RA, Schünemann HJ. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Adv 2022; 6:4915-4923. [PMID: 35503027 PMCID: PMC9068240 DOI: 10.1182/bloodadvances.2022007561] [Citation(s) in RCA: 36] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Accepted: 04/18/2022] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND COVID-19-related acute illness is associated with an increased risk of venous thromboembolism (VTE). OBJECTIVE These evidence-based guidelines from the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in making decisions about the use of anticoagulation in patients with COVID-19. METHODS ASH formed a multidisciplinary guideline panel that included patient representatives and applied strategies to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process and performed systematic evidence reviews (through November 2021). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess evidence and make recommendations, which were subject to public comment. This is an update to guidelines published in February 2021 as part of the living phase of these guidelines. RESULTS The panel made one additional recommendation. The panel issued a conditional recommendation in favor of therapeutic-intensity over prophylactic-intensity anticoagulation in patients with COVID-19-related acute illness who do not have suspected or confirmed VTE. The panel emphasized the need for an individualized assessment of risk of thrombosis and bleeding. The panel also noted that heparin (unfractionated or low molecular weight) may be preferred because of a preponderance of evidence with this class of anticoagulants. CONCLUSION This conditional recommendation was based on very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials comparing different intensities of anticoagulation in patients with COVID-19-related acute illness.
Collapse
Affiliation(s)
- Adam Cuker
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - Eric K. Tseng
- Division of Hematology/Oncology, St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada
| | - Robby Nieuwlaat
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Pantep Angchaisuksiri
- Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | | | - Kathryn Dane
- Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD
| | - Maria T. DeSancho
- Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY
| | | | - Daniel O. Griffin
- Division of Infectious Diseases, College of Physicians & Surgeons of Columbia University, New York, NY
- Research and Development at United Health Group, Minnetonka, MN
- Prohealth NY, Lake Success, NY
| | - Susan R. Kahn
- Department of Medicine, McGill University, Montreal, QC, Canada
| | - Frederikus A. Klok
- Department of Medicine – Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands
| | - Alfred Ian Lee
- Section of Hematology, Yale School of Medicine, New Haven, CT
| | - Ignacio Neumann
- Department of Internal Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Ashok Pai
- Division of Hematology & Oncology, Kaiser Permanente, Oakland/Richmond, CA
| | - Marc Righini
- Division of Angiology and Hemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | | | - Deborah M. Siegal
- Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
| | | | - Deirdra R. Terrell
- Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK
| | | | - Elie A. Akl
- Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
| | | | | | - Angela M. Barbara
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Antonio Bognanni
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Mary Boulos
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Romina Brignardello-Petersen
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Rana Charide
- Clinical Research Institute, American University of Beirut, Beirut, Lebanon
| | - Luis E. Colunga-Lozano
- Department of Clinical Medicine, Health Science Center, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
| | - Karin Dearness
- Library Services, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada
| | - Andrea J. Darzi
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Heba Hussein
- Oral Medicine and Periodontology Department, Faculty of Dentistry, Cairo University, Cairo, Egypt
| | - Samer G. Karam
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Razan Mansour
- Office of Scientific Affairs and Research, King Hussein Cancer Center, Amman, Jordan
| | - Gian Paolo Morgano
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Rami Z. Morsi
- Department of Neurology, University of Chicago, Chicago, IL
| | - Giovanna Muti-Schünemann
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Menatalla K. Nadim
- Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
| | - Binu A. Philip
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Yuan Qiu
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Yetiani Roldan Benitez
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Adrienne Stevens
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Karla Solo
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Wojtek Wiercioch
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Reem A. Mustafa
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
- Department of Internal Medicine, Division of Nephrology, University of Kansas Medical Center, Kansas City, KS
| | - Holger J. Schünemann
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
- Institut für Evidence in Medicine, Medical Center & Faculty of Medicine, University of Freiburg, Freiburg, Germany
| |
Collapse
|
16
|
Cuker A, Tseng EK, Schünemann HJ, Angchaisuksiri P, Blair C, Dane K, DeSancho MT, Diuguid D, Griffin DO, Kahn SR, Klok FA, Lee AI, Neumann I, Pai A, Righini M, Sanfilippo KM, Siegal DM, Skara M, Terrell DR, Touri K, Akl EA, Al Jabiri R, Al Jabiri Y, Boulos M, Brignardello-Petersen R, Charide R, Colunga-Lozano LE, Dearness K, Darzi AJ, Karam SG, Morgano GP, Morsi RZ, Philip BA, Benitez YR, Stevens A, Solo K, Wiercioch W, Mustafa RA, Nieuwlaat R. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. Blood Adv 2022; 6:4975-4982. [PMID: 35748885 PMCID: PMC9236618 DOI: 10.1182/bloodadvances.2022007940] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Accepted: 06/13/2022] [Indexed: 11/21/2022] Open
Abstract
BACKGROUND COVID-19-related critical illness is associated with an increased risk of venous thromboembolism (VTE). OBJECTIVE These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for patients with COVID-19. METHODS ASH formed a multidisciplinary guideline panel, including 3 patient representatives, and applied strategies to minimize potential bias from conflicts of interest. The McMaster University Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process, including performing systematic evidence reviews (up to January 2022). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the GRADE approach to assess evidence and make recommendations, which were subject to public comment. This is an update to guidelines published in February 2021 and May 2021 as part of the living phase of these guidelines. RESULTS The panel made 1 additional recommendation: a conditional recommendation for the use of prophylactic-intensity over therapeutic-intensity anticoagulation for patients with COVID-19-related critical illness who do not have suspected or confirmed VTE. The panel emphasized the need for an individualized assessment of thrombotic and bleeding risk. CONCLUSIONS This conditional recommendation was based on very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials comparing different intensities of anticoagulation for patients with COVID-19-related critical illness.
Collapse
Affiliation(s)
- Adam Cuker
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - Eric K. Tseng
- Division of Hematology/Oncology; St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada
| | - Holger J. Schünemann
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
- Institut für Evidence in Medicine, Medical Center & Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Pantep Angchaisuksiri
- Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | | | - Kathryn Dane
- Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD
| | - Maria T. DeSancho
- Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY
| | | | - Daniel O. Griffin
- Division of Infectious Diseases, College of Physicians & Surgeons of Columbia University, New York, NY
- Research and Development at United Health Group, Minnetonka, MN
- Prohealth NY, Lake Success, NY
| | - Susan R. Kahn
- Department of Medicine, McGill University, Montreal, QC, Canada
| | - Frederikus A. Klok
- Department of Medicine–Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands
| | - Alfred Ian Lee
- Section of Hematology, Yale School of Medicine, New Haven, CT
| | - Ignacio Neumann
- Escuela de Medicina, Facultad de Medicina y Ciencia, Universidad San Sebastian, Santiago, Chile
| | - Ashok Pai
- Division of Hematology & Oncology, Kaiser Permanente, Oakland/Richmond, CA
| | - Marc Righini
- Division of Angiology and Hemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | | | - Deborah M. Siegal
- Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
| | | | - Deirdra R. Terrell
- Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK
| | | | - Elie A. Akl
- Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
| | | | | | - Mary Boulos
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Romina Brignardello-Petersen
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Rana Charide
- Clinical Research Institute, American University of Beirut, Beirut, Lebanon
| | - Luis E. Colunga-Lozano
- Department of Clinical Medicine, Health Science Center, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
| | - Karin Dearness
- Library Services, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada
| | - Andrea J. Darzi
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Samer G. Karam
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Gian Paolo Morgano
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Rami Z. Morsi
- Department of Neurology, University of Chicago, Chicago, IL; and
| | - Binu A. Philip
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Yetiani Roldan Benitez
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Adrienne Stevens
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Karla Solo
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Wojtek Wiercioch
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| | - Reem A. Mustafa
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
- Department of Internal Medicine, Division of Nephrology, University of Kansas Medical Center, Kansas City, KS
| | - Robby Nieuwlaat
- Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada
| |
Collapse
|
17
|
Rooke DR, Ali A, Fender T, Shah F, Chaganti S, Burns D, Stevens A, Vydianath B, Amel-Kashipaz R, Hock YL, Irwin C, Scarisbrick J. Chemotherapy provides less durable disease control in comparison to other systemic therapies in advanced-stage mycosis fungoides and Sezary syndrome. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00642-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
18
|
Patel RR, Rooke B, Shah F, Stevens A, Vydianath B, Amel-Kashipaz R, Hock YL, Irwin C, Scarisbrick JJ. Primary cutaneous large cell anaplastic lymphoma and lymphomatoid papulosis: patient demographics, treatment and outcomes from a supraregional skin lymphoma service. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00627-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
19
|
Beck A, Hamel C, Thuku M, Esmaeilisaraji L, Bennett A, Shaver N, Skidmore B, Colman I, Grigoriadis S, Nicholls SG, Potter BK, Ritchie K, Vasa P, Shea BJ, Moher D, Little J, Stevens A. Screening for depression among the general adult population and in women during pregnancy or the first-year postpartum: two systematic reviews to inform a guideline of the Canadian Task Force on Preventive Health Care. Syst Rev 2022; 11:176. [PMID: 35996176 PMCID: PMC9396828 DOI: 10.1186/s13643-022-02022-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Accepted: 07/08/2022] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Depression affects an individual's physical health and mental well-being and, in pregnant and postpartum women, has specific adverse short- and long-term effects on maternal, child, and family health. The aim of these two systematic reviews is to identify evidence on the benefits and harms of screening for depression compared to no screening in the general adult and pregnant and postpartum populations in primary care or non-mental health clinic settings. These reviews will inform recommendations by the Canadian Task Force on Preventive Health Care. METHODS We searched MEDLINE, Embase, PsycINFO, CINAHL, and the Cochrane Library using a randomized controlled trial filter, where applicable, October 4, 2018, and updated to May 11, 2020. We also searched for gray literature (e.g., websites of organizations of health professionals and patients). Study selection for depression screening trials was performed first on title and abstract, followed by full-text screening. Data extraction, assessment of the risk of bias using the Cochrane risk of bias tool, and application of Grading of Recommendations Assessment, Development and Evaluation were performed by one reviewer and validated by a second reviewer. RESULTS A total of three trials were included. All three trials were included in the general adult review, while one of the three trials was included in the pregnant and postpartum review. We did not pool results due to substantial differences between studies and high risk of bias. In the general adult review, the first trial (n = 1001) evaluated whether screening for depression in adults with acute coronary syndrome compared to usual care improves health-related quality of life, depression symptoms, or harms of screening at 6, 12, and 18 months. There were little to no differences between the groups at 18 months for the outcomes. The second trial included adults (n = 1412) undergoing initial consultation for osteoarthritis, evaluated for depression and general health (mental and physical) after initial consultation and at 3, 6, and 12 months. The physical component score was statistically significantly lower (worse health) in the screened group at 6 months; however, this difference was not significant at 3 or at 12 months. There were no clinically important or statistically significant differences for other outcomes between groups at any time. The third trial (included in both reviews) reported on 462 postpartum women. At 6 months postpartum, fewer women in the screening group were identified as possibly depressed compared to the control group (RR 0.59, 95% confidence interval (CI) 0.39 to 0.89) and mean EPDS scores were also statistically significantly lower in the screened group (standardized mean difference 0.34 lower (95% CI 0.15 to 0.52 lower)). All other outcomes did not differ between groups at follow-up. There were serious concerns about the cut-offs used for the questionnaire used to screen, diagnostic confirmation, selective outcome reporting, and the reported magnitude of effects. DISCUSSION There are limitations of the evidence included in the reviews. There was moderate certainty in the evidence from one trial that screening for depression in the general adult population in primary care or non-mental health clinic settings likely results in little to no difference on reported outcomes; however, the evidence was uncertain from the other two included trials. The evidence is very uncertain about the effect of screening for depression in pregnant or postpartum women in primary care or non-mental health clinic settings. Well-conducted and better-reported trials are needed that meet the screening trial criteria used in this review. SYSTEMATIC REVIEW REGISTRATION Both protocols have been registered in the International Prospective Registry of Systematic Reviews (PROSPERO) [adult: CRD42018099690 ; pregnancy and postpartum: CRD42018099689 ] and published ( https://systematicreviewsjournal.biomedcentral.com/track/pdf/10.1186/s13643-018-0930-3 ).
Collapse
Affiliation(s)
- Andrew Beck
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. .,School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
| | - Candyce Hamel
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Micere Thuku
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Leila Esmaeilisaraji
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Alexandria Bennett
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Nicole Shaver
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Becky Skidmore
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Ian Colman
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Sophie Grigoriadis
- Department of Psychiatry, University of Toronto, Toronto, Canada.,Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Stuart Gordon Nicholls
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Beth K Potter
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Kerri Ritchie
- Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.,School of Psychology, University of Ottawa, Ottawa, Ontario, Canada
| | - Priya Vasa
- Department of Family and Community Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Beverley J Shea
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.,School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - David Moher
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.,School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Julian Little
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Adrienne Stevens
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| |
Collapse
|
20
|
Stevens A. The validity of clinicians’ diagnoses: Is it bread and butter? Eur Psychiatry 2022. [PMCID: PMC9567089 DOI: 10.1192/j.eurpsy.2022.158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Major depression has become one of the most frequent diagnoses in Germany. It is also quite prominent in cases referred for medicolegal assessment in insurance, compensation or disability claims. This report evaluates the validity of clinicians’ diagnoses of major depression in a sample of claimants. In 2015, n = 127 consecutive cases were examined for medicolegal assessment. All had been diagnosed with major depression by clinicians. All testees underwent a psychiatric interview, a physical examination, they answered questionnaires for depressive symptoms according to DSM-5, embitterment disorder, post-concussion syndrome (PCS) and unspecific somatic complaints. Performance and symptom validity tests were administered. Only 31% of the sample fulfilled the diagnostic criteria for DSM-5 major depression according to self-report, while none did so according to psychiatric assessment. Negative response bias was found in 64% of cases, feigned neurologic symptoms in 22%. Symptom exaggeration was indiscriminate rather than depression-specific. By self-report (i.e. symptom endorsement in questionnaires), 64% of the participants qualified for embitterment disorder and 93% for PCS. In conclusion, clinicians’ diagnoses of depression seem frequently erroneous. The reasons are improper assessment of the diagnostic criteria, confusion of depression with bereavement or embitterment and a failure to assess for response bias.
Disclosure
No significant relationships.
Collapse
|
21
|
Geerling B, Kelders S, Stevens A, Kupka R, Bohlmeijer E. Developing an online positive psychology application for people with bipolar disorder; ‘How expectations of consumers and professionals turned into an intervention.’. Eur Psychiatry 2022. [PMCID: PMC9567335 DOI: 10.1192/j.eurpsy.2022.1039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction In Bipolar Disorder (BD), people report a lower quality of life and lower levels of well-being than the general population. Additionally, patients with bipolar disorder have unmet needs which are closely linked to elements of positive psychology. Objectives The current study aimed to gain insight from patients with BD and care professionals about their thoughts of online Positive Psychology Interventions (PPI) to develop an app containing PPI’s for people with BD. Methods The study is conducted in accordance with the CeHRes roadmap principles. Data were collected by focus groups, questionnaires, rapid prototyping and online feedback from the participants. Three focus groups meetings (FGM) were held with consumers (8) and professionals (5). Results The FGM reveals a need for positive psychology interventions to cover some of the unmet needs that can be applied in an app in addition to the guidelines-advised treatment. Patients and professionals expect that PPIs in the current treatment in BD can meet some of the needs that are currently still unmet, specifically offering hope, increasing self-esteem, expressing feelings, acceptation and preventing social isolation. The process of contextual inquiry and value specification is helpful to guide this process. Conclusions The consensus on the different topics about the use of positive psychology intervention shows that both consumers and professionals underline the importance of applying PPI’s in BD. The use during subsyndrome and mild depressive episodes seem the most beneficial periods for patients with BD. A more extended study has to be conducted to confirm if these findings are more generalizable Disclosure No significant relationships.
Collapse
|
22
|
Dewidar O, Lotfi T, Langendam MW, Parmelli E, Saz Parkinson Z, Solo K, Chu DK, Mathew JL, Akl EA, Brignardello-Petersen R, Mustafa RA, Moja L, Iorio A, Chi Y, Canelo-Aybar C, Kredo T, Karpusheff J, Turgeon AF, Alonso-Coello P, Wiercioch W, Gerritsen A, Klugar M, Rojas MX, Tugwell P, Welch VA, Pottie K, Munn Z, Nieuwlaat R, Ford N, Stevens A, Khabsa J, Nasir Z, Leontiadis G, Meerpohl J, Piggott T, Qaseem A, Matthews M, Schünemann HJ. Good or best practice statements: proposal for the operationalisation and implementation of GRADE guidance. BMJ Evid Based Med 2022; 28:189-196. [PMID: 35428694 DOI: 10.1136/bmjebm-2022-111962] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/28/2022] [Indexed: 02/05/2023]
Abstract
An evidence-based approach is considered the gold standard for health decision-making. Sometimes, a guideline panel might judge the certainty that the desirable effects of an intervention clearly outweigh its undesirable effects as high, but the body of supportive evidence is indirect. In such cases, the application of the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach for grading the strength of recommendations is inappropriate. Instead, the GRADE Working Group has recommended developing ungraded best or good practice statement (GPS) and developed guidance under which circumsances they would be appropriate.Through an evaluation of COVID-1- related recommendations on the eCOVID Recommendation Map (COVID-19.recmap.org), we found that recommendations qualifying a GPS were widespread. However, guideline developers failed to label them as GPS or transparently report justifications for their development. We identified ways to improve and facilitate the operationalisation and implementation of the GRADE guidance for GPS.Herein, we propose a structured process for the development of GPSs that includes applying a sequential order for the GRADE guidance for developing GPS. This operationalisation considers relevant evidence-to-decision criteria when assessing the net consequences of implementing the statement, and reporting information supporting judgments for each criterion. We also propose a standardised table to facilitate the identification of GPS and reporting of their development. This operationalised guidance, if endorsed by guideline developers, may palliate some of the shortcomings identified. Our proposal may also inform future updates of the GRADE guidance for GPS.
Collapse
Affiliation(s)
- Omar Dewidar
- Methods Centre, Bruyère Research Institute, Ottawa, Ontario, Canada
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Tamara Lotfi
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada
| | - Miranda W Langendam
- Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
| | - Elena Parmelli
- Joint Research Centre, European Commission, Ispra, Lombardia, Italy
| | - Zuleika Saz Parkinson
- Instituto de Salud Carlos III, Agencia de Evaluación de Tecnologías Sanitarias, Madrid, Spain
| | - Karla Solo
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
| | - Derek K Chu
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Joseph L Mathew
- Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India
| | - Elie A Akl
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
| | - Romina Brignardello-Petersen
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
| | - Reem A Mustafa
- Internal Medicine, Division of Nephrology and Hypertension, University of Kansas School of Medicine, Kansas City, Kansas, USA
| | - Lorenzo Moja
- Department of Health Product Policy and Standards, World Health Organization, Geneva, Switzerland
| | - Alfonso Iorio
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
| | - Yuan Chi
- Yealth Network, Beijing Yealth Technology Co., Ltd, Beijing, China
- Cochrane Campbell Global Ageing Partnership, London, UK
| | - Carlos Canelo-Aybar
- Iberoamerican Cochrane Center, Biomedical Research Institute Sant Pau-CIBERESP, Barcelona, Spain
| | - Tamara Kredo
- Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa
- Clinical Pharmacology, Department of Medicine, Stellenbosch University, Cape Town, South Africa
| | | | - Alexis F Turgeon
- Centre de Recherche du Centre Hospitalier Affilié Universitaire de Québec (CHA), CHA-Hôpital de l'Enfant-Jésus, Université Laval, Québec City, Québec, Canada
- Department of Anesthesiology and Critical Care Medicine, Université Laval, Québec City, Québec, Canada
| | - Pablo Alonso-Coello
- Iberoamerican Cochrane Center, Biomedical Research Institute Sant Pau-CIBERESP, Barcelona, Spain
| | - Wojtek Wiercioch
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada
| | - Annette Gerritsen
- Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa
| | - Miloslav Klugar
- Czech National Centre for Evidence-Based Healthcare and Knowledge Translation, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
| | - María Ximena Rojas
- Department of Clinical Epidemiology and Public Health, Institut d'Investigació Biomèdica Sant Pau IIB Sant Pau, Barcelona, Spain
| | - Peter Tugwell
- Department of Medicine, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Vivian Andrea Welch
- Methods Centre, Bruyère Research Institute, Ottawa, Ontario, Canada
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Kevin Pottie
- Deparatment of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Zachary Munn
- Joanna Briggs Institute, University of Adelaide, Adelaide, South Australia, Australia
| | - Robby Nieuwlaat
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada
| | - Nathan Ford
- Department of HIV, Hepatitis and Sexually Transmitted Infections, World Health Organization, Geneva, Switzerland
| | - Adrienne Stevens
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
| | - Joanne Khabsa
- Clinical Research Institute, American University of Beirut, Beirut, Lebanon
| | - Zil Nasir
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada
| | - Grigorios Leontiadis
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Joerg Meerpohl
- Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany
- Medical Center - University of Freiburg, Institute for Evidence in Medicine, Freiburg, Germany
| | - Thomas Piggott
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada
| | - Amir Qaseem
- American College of Physicians, Philadelphia, Pennsylvania, USA
| | - Micayla Matthews
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada
| | - Holger J Schünemann
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Michael G DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada
- WHO Collaborating Center for Infectious Diseases, Research Methods and Recommendations, McMaster University, Hamilton, Ontario, Canada
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada
- Department of Biomedical Sciences Humanitas University, Humanitas University, Milan, Italy
- Cochrane Canada, Hamilton, Ontario, Canada
| |
Collapse
|
23
|
Ghaddar Y, Stevens A, Pearl M, Sivagnanam T, Sheriff SP. 760 IMPROVING THE MANAGEMENT AND DURATION OF RESOLUTION OF ACUTE KIDNEY INJURY IN THE ELDERLY. Age Ageing 2022. [DOI: 10.1093/ageing/afac034.760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Acute Kidney Injury (AKI) is prevalent in elderly populations due to several factors: polypharmacy, anatomic/physiologic changes of the kidneys associated with aging. AKI can contribute to increased length of stay, morbidity and mortality. This audit sets out to establish if the guidance established by NICE is being followed and how it may be better implemented.
Method
This study audited patients ≥65 years, who were admitted with AKI/developed an AKI during admission. Patients were excluded if they were on renal replacement therapy or under palliative care. Data was collected from case notes and Clinical Work Station. Data collection points used included: senior review within 24 hours; assessment of fluid status; medication review; strict fluid balance; examine for retention +/− catheter; daily U&E and appropriate imaging. Our independent variable was an AKI sticker, this included a revised checklist for above data collection points that was applied to patients’ medical notes. In addition to this, we used posters on appropriate wards which explained the guidance and management of AKI. Awareness was continued by presenting at Care of The Elderly teaching and medical grand round. Then re-audited the following month.
Results
Both cycles involved 45 patients. After implementation, improvements in urine analysis (5%vs35%), assessments of retention (0%vs38%) and assessments of fluid balance (55%vs78%) were seen. In cycle 2, medication was reviewed more frequently, specifically a 30% increase in the review of nephrotoxics. While senior review within 24 hours remains high in both cycles. We measured the outcome by checking the resolution time of AKI. Mean Resolution time was reduced by 1.4 days.
Conclusion
This audit has demonstrated an increase in the optimisation of the management of AKI through ensuring all appropriate interventions and examinations are completed and reducing resolution time by using stickers and the posters.
Collapse
Affiliation(s)
- Y Ghaddar
- Care Of The Elderly, Royal Gwent Hospital, Aneurin Bevan Health Board
| | - A Stevens
- Care Of The Elderly, Royal Gwent Hospital, Aneurin Bevan Health Board
| | - M Pearl
- Care Of The Elderly, Royal Gwent Hospital, Aneurin Bevan Health Board
| | - T Sivagnanam
- Care Of The Elderly, Royal Gwent Hospital, Aneurin Bevan Health Board
| | - S P Sheriff
- Care Of The Elderly, Royal Gwent Hospital, Aneurin Bevan Health Board
| |
Collapse
|
24
|
Soulsby WD, Balmuri N, Cooley V, Gerber LM, Lawson E, Goodman S, Onel K, Mehta B, Abel N, Abulaban K, Adams A, Adams M, Agbayani R, Aiello J, Akoghlanian S, Alejandro C, Allenspach E, Alperin R, Alpizar M, Amarilyo G, Ambler W, Anderson E, Ardoin S, Armendariz S, Baker E, Balboni I, Balevic S, Ballenger L, Ballinger S, Balmuri N, Barbar-Smiley F, Barillas-Arias L, Basiaga M, Baszis K, Becker M, Bell-Brunson H, Beltz E, Benham H, Benseler S, Bernal W, Beukelman T, Bigley T, Binstadt B, Black C, Blakley M, Bohnsack J, Boland J, Boneparth A, Bowman S, Bracaglia C, Brooks E, Brothers M, Brown A, Brunner H, Buckley M, Buckley M, Bukulmez H, Bullock D, Cameron B, Canna S, Cannon L, Carper P, Cartwright V, Cassidy E, Cerracchio L, Chalom E, Chang J, Chang-Hoftman A, Chauhan V, Chira P, Chinn T, Chundru K, Clairman H, Co D, Confair A, Conlon H, Connor R, Cooper A, Cooper J, Cooper S, Correll C, Corvalan R, Costanzo D, Cron R, Curiel-Duran L, Curington T, Curry M, Dalrymple A, Davis A, Davis C, Davis C, Davis T, De Benedetti F, De Ranieri D, Dean J, Dedeoglu F, DeGuzman M, Delnay N, Dempsey V, DeSantis E, Dickson T, Dingle J, Donaldson B, Dorsey E, Dover S, Dowling J, Drew J, Driest K, Du Q, Duarte K, Durkee D, Duverger E, Dvergsten J, Eberhard A, Eckert M, Ede K, Edelheit B, Edens C, Edens C, Edgerly Y, Elder M, Ervin B, Fadrhonc S, Failing C, Fair D, Falcon M, Favier L, Federici S, Feldman B, Fennell J, Ferguson I, Ferguson P, Ferreira B, Ferrucho R, Fields K, Finkel T, Fitzgerald M, Fleming C, Flynn O, Fogel L, Fox E, Fox M, Franco L, Freeman M, Fritz K, Froese S, Fuhlbrigge R, Fuller J, George N, Gerhold K, Gerstbacher D, Gilbert M, Gillispie-Taylor M, Giverc E, Godiwala C, Goh I, Goheer H, Goldsmith D, Gotschlich E, Gotte A, Gottlieb B, Gracia C, Graham T, Grevich S, Griffin T, Griswold J, Grom A, Guevara M, Guittar P, Guzman M, Hager M, Hahn T, Halyabar O, Hammelev E, Hance M, Hanson A, Harel L, Haro S, Harris J, Harry O, Hartigan E, Hausmann J, Hay A, Hayward K, Heiart J, Hekl K, Henderson L, Henrickson M, Hersh A, Hickey K, Hill P, Hillyer S, Hiraki L, Hiskey M, Hobday P, Hoffart C, Holland M, Hollander M, Hong S, Horwitz M, Hsu J, Huber A, Huggins J, Hui-Yuen J, Hung C, Huntington J, Huttenlocher A, Ibarra M, Imundo L, Inman C, Insalaco A, Jackson A, Jackson S, James K, Janow G, Jaquith J, Jared S, Johnson N, Jones J, Jones J, Jones J, Jones K, Jones S, Joshi S, Jung L, Justice C, Justiniano A, Karan N, Kaufman K, Kemp A, Kessler E, Khalsa U, Kienzle B, Kim S, Kimura Y, Kingsbury D, Kitcharoensakkul M, Klausmeier T, Klein K, Klein-Gitelman M, Kompelien B, Kosikowski A, Kovalick L, Kracker J, Kramer S, Kremer C, Lai J, Lam J, Lang B, Lapidus S, Lapin B, Lasky A, Latham D, Lawson E, Laxer R, Lee P, Lee P, Lee T, Lentini L, Lerman M, Levy D, Li S, Lieberman S, Lim L, Lin C, Ling N, Lingis M, Lo M, Lovell D, Lowman D, Luca N, Lvovich S, Madison C, Madison J, Manzoni SM, Malla B, Maller J, Malloy M, Mannion M, Manos C, Marques L, Martyniuk A, Mason T, Mathus S, McAllister L, McCarthy K, McConnell K, McCormick E, McCurdy D, Stokes PMC, McGuire S, McHale I, McMonagle A, McMullen-Jackson C, Meidan E, Mellins E, Mendoza E, Mercado R, Merritt A, Michalowski L, Miettunen P, Miller M, Milojevic D, Mirizio E, Misajon E, Mitchell M, Modica R, Mohan S, Moore K, Moorthy L, Morgan S, Dewitt EM, Moss C, Moussa T, Mruk V, Murphy A, Muscal E, Nadler R, Nahal B, Nanda K, Nasah N, Nassi L, Nativ S, Natter M, Neely J, Nelson B, Newhall L, Ng L, Nicholas J, Nicolai R, Nigrovic P, Nocton J, Nolan B, Oberle E, Obispo B, O’Brien B, O’Brien T, Okeke O, Oliver M, Olson J, O’Neil K, Onel K, Orandi A, Orlando M, Osei-Onomah S, Oz R, Pagano E, Paller A, Pan N, Panupattanapong S, Pardeo M, Paredes J, Parsons A, Patel J, Pentakota K, Pepmueller P, Pfeiffer T, Phillippi K, Marafon DP, Phillippi K, Ponder L, Pooni R, Prahalad S, Pratt S, Protopapas S, Puplava B, Quach J, Quinlan-Waters M, Rabinovich C, Radhakrishna S, Rafko J, Raisian J, Rakestraw A, Ramirez C, Ramsay E, Ramsey S, Randell R, Reed A, Reed A, Reed A, Reid H, Remmel K, Repp A, Reyes A, Richmond A, Riebschleger M, Ringold S, Riordan M, Riskalla M, Ritter M, Rivas-Chacon R, Robinson A, Rodela E, Rodriquez M, Rojas K, Ronis T, Rosenkranz M, Rosolowski B, Rothermel H, Rothman D, Roth-Wojcicki E, Rouster-Stevens K, Rubinstein T, Ruth N, Saad N, Sabbagh S, Sacco E, Sadun R, Sandborg C, Sanni A, Santiago L, Sarkissian A, Savani S, Scalzi L, Schanberg L, Scharnhorst S, Schikler K, Schlefman A, Schmeling H, Schmidt K, Schmitt E, Schneider R, Schollaert-Fitch K, Schulert G, Seay T, Seper C, Shalen J, Sheets R, Shelly A, Shenoi S, Shergill K, Shirley J, Shishov M, Shivers C, Silverman E, Singer N, Sivaraman V, Sletten J, Smith A, Smith C, Smith J, Smith J, Smitherman E, Soep J, Son M, Spence S, Spiegel L, Spitznagle J, Sran R, Srinivasalu H, Stapp H, Steigerwald K, Rakovchik YS, Stern S, Stevens A, Stevens B, Stevenson R, Stewart K, Stingl C, Stokes J, Stoll M, Stringer E, Sule S, Sumner J, Sundel R, Sutter M, Syed R, Syverson G, Szymanski A, Taber S, Tal R, Tambralli A, Taneja A, Tanner T, Tapani S, Tarshish G, Tarvin S, Tate L, Taxter A, Taylor J, Terry M, Tesher M, Thatayatikom A, Thomas B, Tiffany K, Ting T, Tipp A, Toib D, Torok K, Toruner C, Tory H, Toth M, Tse S, Tubwell V, Twilt M, Uriguen S, Valcarcel T, Van Mater H, Vannoy L, Varghese C, Vasquez N, Vazzana K, Vehe R, Veiga K, Velez J, Verbsky J, Vilar G, Volpe N, von Scheven E, Vora S, Wagner J, Wagner-Weiner L, Wahezi D, Waite H, Walker J, Walters H, Muskardin TW, Waqar L, Waterfield M, Watson M, Watts A, Weiser P, Weiss J, Weiss P, Wershba E, White A, Williams C, Wise A, Woo J, Woolnough L, Wright T, Wu E, Yalcindag A, Yee M, Yen E, Yeung R, Yomogida K, Yu Q, Zapata R, Zartoshti A, Zeft A, Zeft R, Zhang Y, Zhao Y, Zhu A, Zic C. Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis. Pediatr Rheumatol Online J 2022; 20:18. [PMID: 35255941 PMCID: PMC8903717 DOI: 10.1186/s12969-022-00676-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Accepted: 02/07/2022] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Social determinants of health (SDH) greatly influence outcomes during the first year of treatment in rheumatoid arthritis, a disease similar to polyarticular juvenile idiopathic arthritis (pJIA). We investigated the correlation of community poverty level and other SDH with the persistence of moderate to severe disease activity and functional disability over the first year of treatment in pJIA patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. METHODS In this cohort study, unadjusted and adjusted generalized linear mixed effects models analyzed the effect of community poverty and other SDH on disease activity, using the clinical Juvenile Arthritis Disease Activity Score-10, and disability, using the Child Health Assessment Questionnaire, measured at baseline, 6, and 12 months. RESULTS One thousand six hundred eighty-four patients were identified. High community poverty (≥20% living below the federal poverty level) was associated with increased odds of functional disability (OR 1.82, 95% CI 1.28-2.60) but was not statistically significant after adjustment (aOR 1.23, 95% CI 0.81-1.86) and was not associated with increased disease activity. Non-white race/ethnicity was associated with higher disease activity (aOR 2.48, 95% CI: 1.41-4.36). Lower self-reported household income was associated with higher disease activity and persistent functional disability. Public insurance (aOR 1.56, 95% CI 1.06-2.29) and low family education (aOR 1.89, 95% CI 1.14-3.12) was associated with persistent functional disability. CONCLUSION High community poverty level was associated with persistent functional disability in unadjusted analysis but not with persistent moderate to high disease activity. Race/ethnicity and other SDH were associated with persistent disease activity and functional disability.
Collapse
Affiliation(s)
- William Daniel Soulsby
- University of California, San Francisco, 550 16th Street, 4th Floor, Box #0632, San Francisco, CA, 94158, USA.
| | - Nayimisha Balmuri
- grid.239915.50000 0001 2285 8823Hospital for Special Surgery, New York, NY USA ,grid.5386.8000000041936877XWeill Cornell Medicine, New York, NY USA
| | - Victoria Cooley
- grid.5386.8000000041936877XWeill Cornell Medicine, New York, NY USA
| | - Linda M. Gerber
- grid.5386.8000000041936877XWeill Cornell Medicine, New York, NY USA
| | - Erica Lawson
- grid.266102.10000 0001 2297 6811University of California, San Francisco, 550 16th Street, 4th Floor, Box #0632, San Francisco, CA 94158 USA
| | - Susan Goodman
- grid.239915.50000 0001 2285 8823Hospital for Special Surgery, New York, NY USA ,grid.5386.8000000041936877XWeill Cornell Medicine, New York, NY USA
| | - Karen Onel
- grid.239915.50000 0001 2285 8823Hospital for Special Surgery, New York, NY USA ,grid.5386.8000000041936877XWeill Cornell Medicine, New York, NY USA
| | - Bella Mehta
- grid.239915.50000 0001 2285 8823Hospital for Special Surgery, New York, NY USA ,grid.5386.8000000041936877XWeill Cornell Medicine, New York, NY USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Lunny C, Reid EK, Neelakant T, Chen A, Zhang JH, Shinger G, Stevens A, Tasnim S, Sadeghipouya S, Adams S, Zheng YW, Lin L, Yang PH, Dosanjh M, Ngsee P, Ellis U, Shea BJ, Wright JM. A new taxonomy was developed for overlap across 'Overviews of systematic reviews': a meta-research study of research waste. Res Synth Methods 2021; 13:315-329. [PMID: 34927388 PMCID: PMC9303867 DOI: 10.1002/jrsm.1542] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Revised: 12/15/2021] [Accepted: 12/16/2021] [Indexed: 11/09/2022]
Abstract
Multiple ‘overviews of reviews’ conducted on the same topic (“overlapping overviews”) represent a waste of research resources and can confuse clinicians making decisions amongst competing treatments. We aimed to assess the frequency and characteristics of overlapping overviews. MEDLINE, Epistemonikos and Cochrane Database of Systematic Reviews were searched for overviews that: synthesized reviews of health interventions and conducted systematic searches. Overlap was defined as: duplication of PICO eligibility criteria, and not reported as an update nor a replication. We categorized overview topics according to 22 WHO ICD‐10 medical classifications, overviews as broad or narrow in scope, and overlap as identical, nearly identical, partial, or subsumed. Subsummation was defined as when broad overviews subsumed the populations, interventions and at least one outcome of another overview. Of 541 overviews included, 169 (31%) overlapped across similar PICO, fell within 13 WHO ICD‐10 medical classifications, and 62 topics. 148/169 (88%) overlapping overviews were broad in scope. Fifteen overviews were classified as having nearly identical overlap (9%); 123 partial overlap (73%), and 31 subsumed (18%) others. One third of overviews overlapped in content and a majority covered broad topic areas. A multiplicity of overviews on the same topic adds to the ongoing waste of research resources, time, and effort across medical disciplines. Authors of overviews can use this study and the sample of overviews to identify gaps in the evidence for future analysis, and topics that are already studied, which do not need to be duplicated.
Collapse
Affiliation(s)
- Carole Lunny
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, 2176 Health Science Mall, Vancouver, BC, Canada
| | - Emma K Reid
- Nova Scotia Health, Halifax, Nova Scotia, Canada
| | - Trish Neelakant
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, 2176 Health Science Mall, Vancouver, BC, Canada.,Royal College of Surgeons in Ireland
| | - Alyssa Chen
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, 2176 Health Science Mall, Vancouver, BC, Canada
| | - Jia He Zhang
- Faculty of Pharmaceutical Science, University of British Columbia, 2176 Health Science Mall, Vancouver, BC, Canada
| | - Gavindeep Shinger
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, 2176 Health Science Mall, Vancouver, BC, Canada
| | - Adrienne Stevens
- Michael G. DeGroote Cochrane Canada Centre, Department of Health Research Methods, Evidence, and Impact, McMaster University, Ontario, Canada
| | - Sara Tasnim
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, 2176 Health Science Mall, Vancouver, BC, Canada
| | - Shadi Sadeghipouya
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, 2176 Health Science Mall, Vancouver, BC, Canada
| | - Stephen Adams
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, 2176 Health Science Mall, Vancouver, BC, Canada
| | - Yi Wen Zheng
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, 2176 Health Science Mall, Vancouver, BC, Canada
| | - Lester Lin
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, 2176 Health Science Mall, Vancouver, BC, Canada
| | - Pei Hsuan Yang
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, 2176 Health Science Mall, Vancouver, BC, Canada
| | - Manpreet Dosanjh
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, 2176 Health Science Mall, Vancouver, BC, Canada
| | - Peter Ngsee
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, 2176 Health Science Mall, Vancouver, BC, Canada
| | - Ursula Ellis
- Woodward Library, University of British Columbia, Vancouver, BC, Canada
| | - Beverley J Shea
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada
| | - James M Wright
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, 2176 Health Science Mall, Vancouver, BC, Canada
| |
Collapse
|
26
|
Meier J, Stevens A, Berger M, Hogan TP, Reisch J, Cullum CM, Lee SC, Skinner CS, Zeh H, Brown CJ, Balentine CJ. Use of local anesthesia for inguinal hernia repair has decreased over time in the VA system. Hernia 2021; 26:1069-1075. [PMID: 34743254 PMCID: PMC9076752 DOI: 10.1007/s10029-021-02532-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Accepted: 10/22/2021] [Indexed: 11/26/2022]
Abstract
PURPOSE In 2003, randomized trials demonstrated potentially improved outcomes when local instead of general anesthesia is used for inguinal hernia repair. Our study aimed to evaluate how the use of local anesthesia for this procedure changed over time following the publication of the trials' level 1 evidence. METHODS We used the 1998-2018 Veterans Affairs Surgical Quality Improvement Program database to identify adults who underwent open, unilateral inguinal hernia repair under local or general anesthesia. Our primary outcome was the percentage of cases performed under local anesthesia. We used a time-series design to examine the trend and rate of change of the use of local anesthesia. RESULTS We included 97,437 veterans, of which 22,333 (22.9%) had hernia surgery under local anesthesia. The median age of veterans receiving local anesthesia remained stable at 64-67 years over time. The use of local anesthesia decreased steadily, from 38.2% at the beginning year to 15.1% in the final year (P < 0.0001). The publication of results from randomized trials (in 2003) did not appear to increase the overall use or change the rate of decline in the use of local anesthesia. Overall, we found that the use of local anesthesia decreased by about 1.5% per year. CONCLUSION The utilization of local anesthesia for inguinal hernia repair in the VA has steadily declined over the last 20 + years, despite data showing equivalence or superiority to general anesthesia. Future studies should explore barriers to the use of local anesthesia for hernia repair.
Collapse
Affiliation(s)
- J Meier
- Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- North Texas VA Health Care System, 4500 S. Lancaster Road, Dallas, TX, 75216, USA.
- Implementation, and Novel Interventions (S-COIN), University of Texas Southwestern Surgical Center for Outcomes, Dallas, TX, USA.
| | - A Stevens
- Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA
- North Texas VA Health Care System, 4500 S. Lancaster Road, Dallas, TX, 75216, USA
- Implementation, and Novel Interventions (S-COIN), University of Texas Southwestern Surgical Center for Outcomes, Dallas, TX, USA
| | - M Berger
- Department of Anesthesiology, Duke University, Durham, NC, USA
| | - T P Hogan
- Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA
- Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA
- Center for Healthcare Organization and Implementation Research, VA Bedford Health Care System, US Department of Veterans Affairs, Bedford, MA, USA
| | - J Reisch
- Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - C M Cullum
- Departments of Psychiatry, Neurology, and Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - S C Lee
- Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - C S Skinner
- Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - H Zeh
- Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - C J Brown
- Department of Medicine, LA State University-New Orleans, New Orleans, Louisiana, USA
| | - C J Balentine
- Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA
- North Texas VA Health Care System, 4500 S. Lancaster Road, Dallas, TX, 75216, USA
- Implementation, and Novel Interventions (S-COIN), University of Texas Southwestern Surgical Center for Outcomes, Dallas, TX, USA
| |
Collapse
|
27
|
Boet S, Etherington C, Nicola D, Beck A, Bragg S, Carrigan ID, Larrigan S, Mendonca CT, Miao I, Postonogova T, Walker B, De Wit J, Mohamed K, Balaa N, Lalu MM, McIsaac DI, Moher D, Stevens A, Miller D. Correction to: Anesthesia interventions that alter perioperative mortality: a scoping review. Syst Rev 2021. [PMID: 34670618 DOI: 10.1186/s13643-021-01827-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
- Sylvain Boet
- Department of Anesthesiology and Pain Medicine, The Ottawa Hospital, University of Ottawa, General Campus, 501 Smyth Rd, Critical Care Wing 1401, Ottawa, Ontario, K1H 8L6, Canada.
| | - Cole Etherington
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
| | - David Nicola
- Family Medicine, McGill University, Montreal, Canada
| | - Andrew Beck
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
| | - Susan Bragg
- Department of Anesthesia, University of Toronto, Toronto, Canada
| | - Ian D Carrigan
- Faculty of Medicine, University of Ottawa, Ottawa, Canada
| | - Sarah Larrigan
- Faculty of Medicine, University of Ottawa, Ottawa, Canada.,University of Ottawa, Ottawa, Canada
| | - Cassandra T Mendonca
- Department of Anesthesiology and Pain Medicine, The Ottawa Hospital, University of Ottawa, General Campus, 501 Smyth Rd, Critical Care Wing 1401, Ottawa, Ontario, K1H 8L6, Canada
| | - Isaac Miao
- Department of Anesthesiology and Pain Medicine, The Ottawa Hospital, University of Ottawa, General Campus, 501 Smyth Rd, Critical Care Wing 1401, Ottawa, Ontario, K1H 8L6, Canada
| | | | - Benjamin Walker
- Department of Anesthesia, University of Utah, Salt Lake City, UT, 84132, USA
| | - José De Wit
- Department of Anesthesiology and Pain Medicine, The Ottawa Hospital, University of Ottawa, General Campus, 501 Smyth Rd, Critical Care Wing 1401, Ottawa, Ontario, K1H 8L6, Canada
| | - Karim Mohamed
- Department of Anesthesiology and Pain Medicine, The Ottawa Hospital, University of Ottawa, General Campus, 501 Smyth Rd, Critical Care Wing 1401, Ottawa, Ontario, K1H 8L6, Canada
| | - Nadia Balaa
- Department of Family Medicine, Montfort Hospital, University of Ottawa, Ottawa, Canada
| | - Manoj Mathew Lalu
- Department of Anesthesiology and Pain Medicine, The Ottawa Hospital, Ottawa, Canada.,Clinical Epidemiology and Regenerative Medicine Programs, Ottawa Hospital Research Institute, Ottawa, Canada
| | - Daniel I McIsaac
- Department of Anesthesiology and Pain Medicine, The Ottawa Hospital, University of Ottawa, General Campus, 501 Smyth Rd, Critical Care Wing 1401, Ottawa, Ontario, K1H 8L6, Canada.,School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, K1G 5Z3, Canada
| | - David Moher
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
| | - Adrienne Stevens
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
| | - Donald Miller
- Department of Anesthesiology and Pain Medicine, The Ottawa Hospital, University of Ottawa, General Campus, 501 Smyth Rd, Critical Care Wing 1401, Ottawa, Ontario, K1H 8L6, Canada
| | | |
Collapse
|
28
|
Lunny C, Neelakant T, Chen A, Shinger G, Stevens A, Tasnim S, Sadeghipouya S, Adams S, Zheng YW, Lin L, Yang PH, Dosanjh M, Ngsee P, Ellis U, Shea BJ, Reid EK, Wright JM. Bibliometric study of 'overviews of systematic reviews' of health interventions: Evaluation of prevalence, citation and journal impact factor. Res Synth Methods 2021; 13:109-120. [PMID: 34628727 DOI: 10.1002/jrsm.1530] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Revised: 09/08/2021] [Accepted: 10/05/2021] [Indexed: 11/07/2022]
Abstract
Overviews synthesising the results of multiple systematic reviews help inform evidence-based clinical practice. In this first of two companion papers, we evaluate the bibliometrics of overviews, including their prevalence and factors affecting citation rates and journal impact factor (JIF). We searched MEDLINE, Epistemonikos and Cochrane Database of Systematic Reviews (CDSR). We included overviews that: (a) synthesised reviews, (b) conducted a systematic search, (c) had a methods section and (d) examined a healthcare intervention. Multivariable regression was conducted to determine the association between citation density, JIF and six predictor variables. We found 1218 overviews published from 2000 to 2020; the majority (73%) were published in the most recent 5-year period. We extracted a selection of these overviews (n = 541; 44%) dated from 2000 to 2018. The 541 overviews were published in 307 journals; CDSR (8%), PLOS ONE (3%) and Sao Paulo Medical Journal (2%) were the most prevalent. The majority (70%) were published in journals with impact factors between 0.05 and 3.97. We found a mean citation count of 10 overviews per year, published in journals with a mean JIF of 4.4. In multivariable analysis, overviews with a high number of citations and JIFs had more authors, larger sample sizes, were open access and reported the funding source. An eightfold increase in the number of overviews was found between 2009 and 2020. We identified 332 overviews published in 2020, which is equivalent to one overview published per day. Overviews perform above average for the journals in which they publish.
Collapse
Affiliation(s)
- Carole Lunny
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Trish Neelakant
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
- Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Alyssa Chen
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Gavindeep Shinger
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Adrienne Stevens
- Michael G. DeGroote Cochrane Canada Centre, Department of Health Research Methods, Evidence, and Impact, McMaster University, Ontario, Canada
| | - Sara Tasnim
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Shadi Sadeghipouya
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Stephen Adams
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Yi Wen Zheng
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Lester Lin
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Pei Hsuan Yang
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Manpreet Dosanjh
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Peter Ngsee
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Ursula Ellis
- Woodward Library, University of British Columbia, Vancouver, British Columbia, Canada
| | - Beverley J Shea
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada
| | - Emma K Reid
- Nova Scotia Health, Halifax, Nova Scotia, Canada
| | - James M Wright
- Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
29
|
Lotfi T, Hajizadeh A, Moja L, Akl EA, Piggott T, Kredo T, Langendam MW, Iorio A, Klugar M, Klugarová J, Neumann I, Wiercioch W, Leontiadis GI, Mbuagbaw L, Turgeon AF, Meerpohl J, Stevens A, Brozek J, Santesso N, Pottie K, Dewidar O, Flottorp SA, Karpusheff J, Saz-Parkinson Z, Rojas MX, Parmelli E, Chu DK, Tugwell P, Welch V, Avey MT, Brignardello-Petersen R, Mathew JL, Munn Z, Nieuwlaat R, Ford N, Qaseem A, Askie LM, Schünemann HJ. A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations. J Clin Epidemiol 2021; 141:161-171. [PMID: 34562579 DOI: 10.1016/j.jclinepi.2021.09.028] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 09/06/2021] [Accepted: 09/17/2021] [Indexed: 12/25/2022]
Abstract
OBJECTIVE To propose a taxonomy and framework that identifies and presents actionable statements in guidelines. STUDY DESIGN AND SETTING We took an iterative approach reviewing case studies of guidelines produced by the World Health Organization and the American Society of Hematology to develop an initial conceptual framework. We then tested it using randomly selected recommendations from published guidelines addressing COVID-19 from different organizations, evaluated its results, and refined it before retesting. The urgency and availability of evidence for development of these recommendations varied. We consulted with experts in research methodology and guideline developers to improve the final framework. RESULTS The resulting taxonomy and framework distinguishes five types of actional statements: formal recommendations; research recommendations; good practice statements; implementation considerations, tools and tips; and informal recommendations. These statements should respond to a priori established criteria and require a clear structure and recognizable presentation in a guideline. Most importantly, this framework identifies informal recommendations that differ from formal recommendations by how they consider evidence and in their development process. CONCLUSION The identification, standardization and explicit labelling of actionable statements according to the framework may support guideline developers to create actionable statements with clear intent, avoid informal recommendations and improve their understanding and implementation by users.
Collapse
Affiliation(s)
- Tamara Lotfi
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton ,ON, Canada; Michael G. DeGroote Cochrane Canada and GRADE Centre, McMaster University, Hamilton , ON, Canada
| | - Anisa Hajizadeh
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton ,ON, Canada
| | - Lorenzo Moja
- Department of Health Product Policy and Standards, World Health Organization, Geneva, Switzerland
| | - Elie A Akl
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton ,ON, Canada; Michael G. DeGroote Cochrane Canada and GRADE Centre, McMaster University, Hamilton , ON, Canada; Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
| | - Thomas Piggott
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton ,ON, Canada
| | - Tamara Kredo
- Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa; Clinical Pharmacology, Department of Medicine, Stellenbosch University, Cape Town, South Africa
| | - Miranda W Langendam
- Amsterdam University Medical Centers, location Academic Medical Center, University of Amsterdam, Amsterdam Public Health research institute, Amsterdam, The Netherlands
| | - Alfonso Iorio
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton ,ON, Canada; Department of Medicine, McMaster University, Hamilton ,ON, Canada
| | - Miloslav Klugar
- The Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech CEBHC: JBI Centre of Excellence, Masaryk University GRADE Centre); Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic
| | - Jitka Klugarová
- The Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech CEBHC: JBI Centre of Excellence, Masaryk University GRADE Centre); Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic
| | - Ignacio Neumann
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton ,ON, Canada; Department of Internal Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile
| | - Wojtek Wiercioch
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton ,ON, Canada; Michael G. DeGroote Cochrane Canada and GRADE Centre, McMaster University, Hamilton , ON, Canada
| | | | - Lawrence Mbuagbaw
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton ,ON, Canada; Biostatistics Unit/The Research Institute, St Joseph's Healthcare, Hamilton ,ON, Canada
| | - Alexis F Turgeon
- Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Université Laval, Québec City ,QC, Canada; Population Health and Optimal Health Practices Research Unit, CHU de Québec - Université Laval Research Center, Québec City ,QC, Canada
| | - Joerg Meerpohl
- Institute for Evidence in Medicine, Medical Center & Faculty of Medicine, University of Freiburg, Freiburg, Germany; Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany
| | - Adrienne Stevens
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton ,ON, Canada; Michael G. DeGroote Cochrane Canada and GRADE Centre, McMaster University, Hamilton , ON, Canada
| | - Jan Brozek
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton ,ON, Canada; Michael G. DeGroote Cochrane Canada and GRADE Centre, McMaster University, Hamilton , ON, Canada
| | - Nancy Santesso
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton ,ON, Canada; Michael G. DeGroote Cochrane Canada and GRADE Centre, McMaster University, Hamilton , ON, Canada
| | - Kevin Pottie
- School of Epidemiology and Public Health, University of Ottawa, Canada; Departments of Family Medicine and Epidemiology and Community Medicine, University of Ottawa; Bruyère Research Institute, Ottawa, Canada; Departments of Family Medicine and Epidemiology and Community Medicine, University of Ottawa
| | - Omar Dewidar
- School of Epidemiology and Public Health, University of Ottawa, Canada; Departments of Family Medicine and Epidemiology and Community Medicine, University of Ottawa; Bruyère Research Institute, Ottawa, Canada; Departments of Family Medicine and Epidemiology and Community Medicine, University of Ottawa
| | - Signe A Flottorp
- Norwegian Institute of Public Health, Oslo, Norway; University of Oslo, Oslo, Norway
| | | | - Zuleika Saz-Parkinson
- Instituto de Salud Carlos III, Agencia de Evaluación de Tecnologías Sanitarias. Madrid, Spain
| | - María X Rojas
- Department of Clinical Epidemiology and Public Health, Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau)
| | - Elena Parmelli
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Derek K Chu
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton ,ON, Canada; Department of Medicine, McMaster University, Hamilton ,ON, Canada
| | - Peter Tugwell
- School of Epidemiology and Public Health, University of Ottawa, Canada; Departments of Family Medicine and Epidemiology and Community Medicine, University of Ottawa; Bruyère Research Institute, Ottawa, Canada; Departments of Family Medicine and Epidemiology and Community Medicine, University of Ottawa
| | - Vivian Welch
- School of Epidemiology and Public Health, University of Ottawa, Canada; Departments of Family Medicine and Epidemiology and Community Medicine, University of Ottawa; Bruyère Research Institute, Ottawa, Canada; Departments of Family Medicine and Epidemiology and Community Medicine, University of Ottawa
| | | | | | - Joseph L Mathew
- Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Zachary Munn
- Joanna Briggs Institute Faculty of Health and Medical Sciences The University of Adelaide, Australia
| | - Robby Nieuwlaat
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton ,ON, Canada
| | - Nathan Ford
- Department of HIV, Hepatitis and Sexually Transmitted Infections, World Health Organization, Geneva, Switzerland
| | - Amir Qaseem
- American College of Physicians, Philadelphia, PA, USA
| | - Lisa M Askie
- Quality Assurance of Norms and Standards Department, Science Division, World Health Organization, Geneva, Switzerland
| | - Holger J Schünemann
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton ,ON, Canada; Michael G. DeGroote Cochrane Canada and GRADE Centre, McMaster University, Hamilton , ON, Canada; Department of Medicine, McMaster University, Hamilton ,ON, Canada; Dipartimento di Scienze Biomediche Humanitas University, Milan, Italy.
| |
Collapse
|
30
|
Lotfi T, Stevens A, Akl EA, Falavigna M, Kredo T, Mathew JL, Schünemann HJ. Getting trustworthy guidelines into the hands of decision-makers and supporting their consideration of contextual factors for implementation globally: recommendation mapping of COVID-19 guidelines. J Clin Epidemiol 2021; 135:182-186. [PMID: 33836255 PMCID: PMC8022513 DOI: 10.1016/j.jclinepi.2021.03.034] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Accepted: 03/28/2021] [Indexed: 12/27/2022]
Abstract
Published research on COVID-19 is increasing rapidly and integrated in guidelines. The trustworthiness of guidelines can vary depending on the methods used to assemble and evaluate the evidence, the completeness and transparency of reporting on the process undertaken and how conflicts of interest are addressed. With a global consortium of partners and collaborators, we have created a catalogue of COVID-19 recommendations as our direct response to the increased need for structured access to high quality guidance in the field. The COVID19 map of recommendations and gateway to contextualization (https://covid19.recmap.org) is a living project: emerging guideline literature is added on an ongoing basis, allowing granular access to individual recommendations. Building on prior work on mapping recommendations for the World Health Organization tuberculosis guidelines, a novel feature of this map is the self-directed contextualization of the recommendations using the GRADE-Adolopment approach to adopt, adapt or synthesize de novo recommendations for context specific questions. Through our map, stakeholders access the evidence underpinning a recommendation, select what needs to be contextualized and go through the steps of development of adapted recommendations. This one-stop shop portal of evidence-informed recommendations, built with intuitive functionalities, easy to navigate and with a support team ready to guide users across the maps, represents a long-needed tool for decision-makers, guideline developers and the public at large.
Collapse
Affiliation(s)
- Tamara Lotfi
- Department of Health Research Methods, Evidence, and Impact, World Health Organization Collaborating Center for Infectious Diseases, McMaster University, Hamilton, Ontario, Canada; Michael G. DeGroote Cochrane Canada Centre, McMaster University, Hamilton, Ontario, Canada; McMaster GRADE Centre, McMaster University, Hamilton, Ontario, Canada
| | - Adrienne Stevens
- Michael G. DeGroote Cochrane Canada Centre, McMaster University, Hamilton, Ontario, Canada; McMaster GRADE Centre, McMaster University, Hamilton, Ontario, Canada
| | - Elie A Akl
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Clinical Research Institute, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| | - Maicon Falavigna
- National Institute for Health Technology Assessment, Federal Univesity of Rio Grande do Sul, PortoAlegre, Brazil; Hospital Moinhos de Vento, Porto Alegre, Brazil
| | - Tamara Kredo
- South African Medical Research Council, Cape Town, South Africa
| | - Joseph L Mathew
- Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Holger J Schünemann
- Department of Health Research Methods, Evidence, and Impact, World Health Organization Collaborating Center for Infectious Diseases, McMaster University, Hamilton, Ontario, Canada; Michael G. DeGroote Cochrane Canada Centre, McMaster University, Hamilton, Ontario, Canada; McMaster GRADE Centre, McMaster University, Hamilton, Ontario, Canada.
| | | |
Collapse
|
31
|
Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K, Davila J, DeSancho MT, Diuguid D, Griffin DO, Kahn SR, Klok FA, Lee AI, Neumann I, Pai A, Pai M, Righini M, Sanfilippo KM, Siegal D, Skara M, Touri K, Akl EA, Bou Akl I, Boulos M, Brignardello-Petersen R, Charide R, Chan M, Dearness K, Darzi AJ, Kolb P, Colunga-Lozano LE, Mansour R, Morgano GP, Morsi RZ, Noori A, Piggott T, Qiu Y, Roldan Y, Schünemann F, Stevens A, Solo K, Ventresca M, Wiercioch W, Mustafa RA, Schünemann HJ. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv 2021; 5:872-888. [PMID: 33560401 PMCID: PMC7869684 DOI: 10.1182/bloodadvances.2020003763] [Citation(s) in RCA: 254] [Impact Index Per Article: 84.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Accepted: 12/18/2020] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Coronavirus disease 2019 (COVID-19)-related critical illness and acute illness are associated with a risk of venous thromboembolism (VTE). OBJECTIVE These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for thromboprophylaxis for patients with COVID-19-related critical illness and acute illness who do not have confirmed or suspected VTE. METHODS ASH formed a multidisciplinary guideline panel and applied strict management strategies to minimize potential bias from conflicts of interest. The panel included 3 patient representatives. The McMaster University GRADE Centre supported the guideline-development process, including performing systematic evidence reviews (up to 19 August 2020). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. RESULTS The panel agreed on 2 recommendations. The panel issued conditional recommendations in favor of prophylactic-intensity anticoagulation over intermediate-intensity or therapeutic-intensity anticoagulation for patients with COVID-19-related critical illness or acute illness who do not have confirmed or suspected VTE. CONCLUSIONS These recommendations were based on very low certainty in the evidence, underscoring the need for high-quality, randomized controlled trials comparing different intensities of anticoagulation. They will be updated using a living recommendation approach as new evidence becomes available.
Collapse
Affiliation(s)
- Adam Cuker
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - Eric K Tseng
- St. Michael's Hospital, Division of Hematology/Oncology, University of Toronto, Toronto, ON, Canada
| | - Robby Nieuwlaat
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Pantep Angchaisuksiri
- Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | | | - Kathryn Dane
- Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD
| | - Jennifer Davila
- Children's Hospital at Montefiore, Division of Pediatric Hematology, Oncology, and Cellular Therapies, Albert Einstein College of Medicine, Bronx, NY
| | - Maria T DeSancho
- Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, NY
| | - David Diuguid
- Department of Medicine, College of Physicians and Surgeons and
| | - Daniel O Griffin
- Division of Infectious Diseases, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY
- Research and Development at United Health Group, Minnetonka, MN
- Prohealth NY, Lake Success, NY
| | - Susan R Kahn
- Department of Medicine, McGill University, Montreal, QC, Canada
| | - Frederikus A Klok
- Thrombosis and Hemostasis, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Alfred Ian Lee
- Section of Hematology, School of Medicine, Yale University, New Haven, CT
| | - Ignacio Neumann
- Department of Internal Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Ashok Pai
- Division of Hematology and Oncology, Kaiser Permanente, Oakland/Richmond, CA
| | - Menaka Pai
- Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Marc Righini
- Division of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospitals, University of Geneva, Geneva, Switzerland
| | - Kristen M Sanfilippo
- Department of Medicine, Washington University School of Medicine St. Louis, St. Louis, MO
| | - Deborah Siegal
- Department of Medicine and
- Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
| | | | | | - Elie A Akl
- Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
| | - Imad Bou Akl
- Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
| | - Mary Boulos
- Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
| | | | - Rana Charide
- Clinical Research Institute, American University of Beirut, Beirut, Lebanon
| | - Matthew Chan
- Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Karin Dearness
- Library Services, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
| | - Andrea J Darzi
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Philipp Kolb
- Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
| | - Luis E Colunga-Lozano
- Department of Clinical Medicine, Health Science Center, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
| | - Razan Mansour
- Office of Scientific Affairs and Research, King Hussein Cancer Center, Amman, Jordan
| | - Gian Paolo Morgano
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Rami Z Morsi
- Department of Neurology, University of Chicago, Chicago, IL
| | - Atefeh Noori
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
- The Michael G. DeGroote National Pain Center, McMaster University, Hamilton, ON, Canada
| | - Thomas Piggott
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Yuan Qiu
- Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
| | - Yetiani Roldan
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Finn Schünemann
- Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany
| | - Adrienne Stevens
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Karla Solo
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Matthew Ventresca
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Wojtek Wiercioch
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Reem A Mustafa
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
- Department of Internal Medicine, Division of Nephrology, University of Kansas Medical Center, Kansas City, KS; and
| | - Holger J Schünemann
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- Institute for Evidence in Medicine, Medical Center/Faculty of Medicine, University of Freiburg, Freiburg, Germany
| |
Collapse
|
32
|
Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K, Davila J, DeSancho MT, Diuguid D, Griffin DO, Kahn SR, Klok FA, Lee AI, Neumann I, Pai A, Pai M, Righini M, Sanfilippo KM, Siegal D, Skara M, Touri K, Akl EA, Bou Akl I, Boulos M, Brignardello-Petersen R, Charide R, Chan M, Dearness K, Darzi AJ, Kolb P, Colunga-Lozano LE, Mansour R, Morgano GP, Morsi RZ, Noori A, Piggott T, Qiu Y, Roldan Y, Schünemann F, Stevens A, Solo K, Ventresca M, Wiercioch W, Mustafa RA, Schünemann HJ. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv 2021. [PMID: 33560401 DOI: 10.1182/blood-advances.2020003763] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/14/2023] Open
Abstract
BACKGROUND Coronavirus disease 2019 (COVID-19)-related critical illness and acute illness are associated with a risk of venous thromboembolism (VTE). OBJECTIVE These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for thromboprophylaxis for patients with COVID-19-related critical illness and acute illness who do not have confirmed or suspected VTE. METHODS ASH formed a multidisciplinary guideline panel and applied strict management strategies to minimize potential bias from conflicts of interest. The panel included 3 patient representatives. The McMaster University GRADE Centre supported the guideline-development process, including performing systematic evidence reviews (up to 19 August 2020). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. RESULTS The panel agreed on 2 recommendations. The panel issued conditional recommendations in favor of prophylactic-intensity anticoagulation over intermediate-intensity or therapeutic-intensity anticoagulation for patients with COVID-19-related critical illness or acute illness who do not have confirmed or suspected VTE. CONCLUSIONS These recommendations were based on very low certainty in the evidence, underscoring the need for high-quality, randomized controlled trials comparing different intensities of anticoagulation. They will be updated using a living recommendation approach as new evidence becomes available.
Collapse
Affiliation(s)
- Adam Cuker
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - Eric K Tseng
- St. Michael's Hospital, Division of Hematology/Oncology, University of Toronto, Toronto, ON, Canada
| | - Robby Nieuwlaat
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Pantep Angchaisuksiri
- Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | | | - Kathryn Dane
- Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD
| | - Jennifer Davila
- Children's Hospital at Montefiore, Division of Pediatric Hematology, Oncology, and Cellular Therapies, Albert Einstein College of Medicine, Bronx, NY
| | - Maria T DeSancho
- Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, NY
| | - David Diuguid
- Department of Medicine, College of Physicians and Surgeons and
| | - Daniel O Griffin
- Division of Infectious Diseases, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY
- Research and Development at United Health Group, Minnetonka, MN
- Prohealth NY, Lake Success, NY
| | - Susan R Kahn
- Department of Medicine, McGill University, Montreal, QC, Canada
| | - Frederikus A Klok
- Thrombosis and Hemostasis, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Alfred Ian Lee
- Section of Hematology, School of Medicine, Yale University, New Haven, CT
| | - Ignacio Neumann
- Department of Internal Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Ashok Pai
- Division of Hematology and Oncology, Kaiser Permanente, Oakland/Richmond, CA
| | - Menaka Pai
- Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Marc Righini
- Division of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospitals, University of Geneva, Geneva, Switzerland
| | - Kristen M Sanfilippo
- Department of Medicine, Washington University School of Medicine St. Louis, St. Louis, MO
| | - Deborah Siegal
- Department of Medicine and
- Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
| | | | | | - Elie A Akl
- Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
| | - Imad Bou Akl
- Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
| | - Mary Boulos
- Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
| | | | - Rana Charide
- Clinical Research Institute, American University of Beirut, Beirut, Lebanon
| | - Matthew Chan
- Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Karin Dearness
- Library Services, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
| | - Andrea J Darzi
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Philipp Kolb
- Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
| | - Luis E Colunga-Lozano
- Department of Clinical Medicine, Health Science Center, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
| | - Razan Mansour
- Office of Scientific Affairs and Research, King Hussein Cancer Center, Amman, Jordan
| | - Gian Paolo Morgano
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Rami Z Morsi
- Department of Neurology, University of Chicago, Chicago, IL
| | - Atefeh Noori
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
- The Michael G. DeGroote National Pain Center, McMaster University, Hamilton, ON, Canada
| | - Thomas Piggott
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Yuan Qiu
- Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
| | - Yetiani Roldan
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Finn Schünemann
- Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany
| | - Adrienne Stevens
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Karla Solo
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Matthew Ventresca
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Wojtek Wiercioch
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Reem A Mustafa
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
- Department of Internal Medicine, Division of Nephrology, University of Kansas Medical Center, Kansas City, KS; and
| | - Holger J Schünemann
- Michael G. DeGroote Cochrane Canada Centre
- McGRADE Centre, and
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- Institute for Evidence in Medicine, Medical Center/Faculty of Medicine, University of Freiburg, Freiburg, Germany
| |
Collapse
|
33
|
Thabet P, Joshi A, MacDonald E, Hutton B, Cheng W, Stevens A, Kanji S. Clinical and pharmacokinetic/dynamic outcomes of prolonged infusions of beta-lactam antimicrobials: An overview of systematic reviews. PLoS One 2021; 16:e0244966. [PMID: 33481817 PMCID: PMC7822342 DOI: 10.1371/journal.pone.0244966] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Accepted: 12/19/2020] [Indexed: 12/29/2022] Open
Abstract
OBJECTIVE This overview of reviews aims to map and compare of objectives, methods, and findings of existing systematic reviews to develop a greater understanding of the information available about prolonged beta-lactam infusions in hospitalized patients with infection. DESIGN Overview of systematic reviews. DATA SOURCES Medline, Embase, PROSPERO and the Cochrane Library were systematically searched from January, 1990 to June, 2019 using a peer reviewed search strategy. Grey literature was also searched for relevant reviews. ELIGIBILITY CRITERIA FOR SELECTING REVIEWS Systematic reviews were sought that compared two or more infusion strategies for intravenous beta-lactam antimicrobials and report clinical cure or mortality. Populations of included reviews were restricted to hospitalized patients with infection, without restrictions on age, infection type, or disease. DATA EXTRACTION AND ANALYSIS Abstract screening, data extraction, quality and risk of bias assessment were conducted by two independent reviewers. Overlap between reviews was assessed using a modified corrected covered area. Overview findings are reported in accordance with Cochrane's recommendation for overview conduct. Clinical outcomes extracted included survival, clinical cure, treatment failure, microbiological cure, length of stay, adverse events, cost, and emergence of resistance. RESULTS The search strategy identified 3327 unique citations from which 21 eligible reviews were included. Reviews varied by population, intervention and outcomes studied. Between reviews, overlap of primary studies was generally high, methodologic quality generally low and risk of bias variable. Nine of 14 reviews that quantitatively evaluated mortality and clinical cure identified a benefit with prolonged infusions of beta lactams when compared with intermittent infusions. Evidence of mortality and clinical cure benefit was greater among critically ill patients when compared to less sick patients and lower in randomized controlled trials when compared with observational studies. CONCLUSIONS Findings from our review demonstrate a consistent and reproducible lack of harm with prolonged infusions of beta-lactam antibiotics with variability in effect size and significance of benefits. Despite 21 systematic reviews addressing prolonged infusions of beta-lactams, this overview supports the continued need for a definitive systematic review given variability in populations, interventions and outcomes in the current systematic reviews. Subsequent systematic reviews should have more rigorous and transparent methods, only include RCTs and evaluate the proposed benefits found in various subgroup-analyses-i.e. high risk of mortality. TRIAL REGISTRATION Prospero registry, CRD42019117118.
Collapse
Affiliation(s)
| | - Anchal Joshi
- University of Waterloo, Waterloo, Ontario, Canada
| | | | - Brian Hutton
- Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
- University of Ottawa School of Epidemiology and Public Health, Ottawa, Canada
| | - Wei Cheng
- Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | | | - Salmaan Kanji
- The Ottawa Hospital, Ottawa, Ontario, Canada
- Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
- University of Ottawa School of Epidemiology and Public Health, Ottawa, Canada
- * E-mail:
| |
Collapse
|
34
|
Beck A, LeBlanc JC, Morissette K, Hamel C, Skidmore B, Colquhoun H, Lang E, Moore A, Riva JJ, Thombs BD, Patten S, Bragg H, Colman I, Goldfield GS, Nicholls SG, Pajer K, Potter BK, Meeder R, Vasa P, Hutton B, Shea BJ, Graham E, Little J, Moher D, Stevens A. Screening for depression in children and adolescents: a protocol for a systematic review update. Syst Rev 2021; 10:24. [PMID: 33436094 PMCID: PMC7802305 DOI: 10.1186/s13643-020-01568-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Accepted: 12/21/2020] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Major depressive disorder is common, debilitating, and affects feelings, thoughts, mood, and behaviors. Childhood and adolescence are critical periods for the development of depression and adolescence is marked by an increased incidence of mental health disorders. This protocol outlines the planned scope and methods for a systematic review update that will evaluate the benefits and harms of screening for depression in children and adolescents. METHODS This review will update a previously published systematic review by Roseman and colleagues. Eligible studies are randomized controlled trials (RCTs) assessing formal screening in primary care to identify children or adolescents not already self-reporting symptoms of, diagnosed with, or treated for depression. If no or only a single RCT is available, we will consider controlled studies without random assignment. Studies of participants with characteristics associated with an elevated risk of depression will be analyzed separately. Outcomes of interest are symptoms of depression, classification of major depressive disorder based on a validated diagnostic interview, suicidality, health-related quality of life, social function, impact on lifestyle behavior (e.g., substance use, school performance, lost time at work, or school), false-positive results, overdiagnosis, overtreatment, labeling, and other harms such as those arising from treatment. We will search MEDLINE, Embase, PsycINFO, CINAHL, the Cochrane Library, and grey literature sources. Two reviewers will independently screen the titles and abstracts using the liberal accelerated method. Full-text screening will be performed independently by two reviewers using pre-specified eligibility criteria. Data extraction and risk of bias assessments will be performed independently by two reviewers. Pre-planned analyses, including subgroup and sensitivity analyses, are detailed within this protocol. Two independent reviewers will assess and finalize through consensus the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, and prepare GRADE evidence profiles and summary of findings tables for each outcome of interest. DISCUSSION The systematic review will provide a current state of the evidence of benefits and harms of depression screening in children and adolescents. These findings will be used by the Canadian Task Force on Preventive Health Care to inform the development of recommendations on depression screening. SYSTEMATIC REVIEW REGISTRATION PROSPERO CRD42020150373.
Collapse
Affiliation(s)
- Andrew Beck
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Centre for Practice-Changing Research, 501 Smyth Road, Box 201, Ottawa, ON K1H 8L6 Canada
| | - John C. LeBlanc
- Department of Pediatrics, Dalhousie University, Halifax, NS Canada
| | | | - Candyce Hamel
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Centre for Practice-Changing Research, 501 Smyth Road, Box 201, Ottawa, ON K1H 8L6 Canada
| | - Becky Skidmore
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Centre for Practice-Changing Research, 501 Smyth Road, Box 201, Ottawa, ON K1H 8L6 Canada
| | - Heather Colquhoun
- Department of Occupational Science and Occupational Therapy, University of Toronto, Toronto, ON Canada
| | - Eddy Lang
- University of Calgary Cumming School of Medicine, Calgary, AB Canada
- Alberta Health Services, Calgary, AB Canada
| | - Ainsley Moore
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON Canada
- Department of Family Medicine, McMaster University, David Braley Health Sciences Centre, Hamilton, ON Canada
| | - John J. Riva
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON Canada
- Department of Family Medicine, McMaster University, David Braley Health Sciences Centre, Hamilton, ON Canada
| | - Brett D. Thombs
- Lady Davis Institute of the Jewish General Hospital, Montreal, QC Canada
- Faculty of Medicine, McGill University, Montreal, QC Canada
| | - Scott Patten
- Department of Community Health Services and Department of Psychiatry, University of Calgary, Calgary, AB Canada
| | - Heather Bragg
- Children’s Hospital of Eastern Ontario, Ottawa, ON Canada
| | - Ian Colman
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON Canada
| | - Gary S. Goldfield
- Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON Canada
| | | | - Kathleen Pajer
- Department of Psychiatry, Children’s Hospital of Eastern Ontario, Ottawa Faculty of Medicine, Ottawa, ON Canada
| | - Beth K. Potter
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON Canada
| | - Robert Meeder
- Waypoint Centre For Mental Health Care, Penetanguishene, ON Canada
| | - Priya Vasa
- Department of Family and Community Medicine, St. Michael’s Hospital, University of Toronto, Toronto, ON Canada
| | - Brian Hutton
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Centre for Practice-Changing Research, 501 Smyth Road, Box 201, Ottawa, ON K1H 8L6 Canada
| | - Beverley J. Shea
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Centre for Practice-Changing Research, 501 Smyth Road, Box 201, Ottawa, ON K1H 8L6 Canada
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON Canada
| | - Eva Graham
- Public Health Agency of Canada, Ottawa, ON Canada
| | - Julian Little
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON Canada
| | - David Moher
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Centre for Practice-Changing Research, 501 Smyth Road, Box 201, Ottawa, ON K1H 8L6 Canada
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON Canada
| | - Adrienne Stevens
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Centre for Practice-Changing Research, 501 Smyth Road, Box 201, Ottawa, ON K1H 8L6 Canada
| |
Collapse
|
35
|
Garritty C, Gartlehner G, Nussbaumer-Streit B, King VJ, Hamel C, Kamel C, Affengruber L, Stevens A. Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews. J Clin Epidemiol 2020; 130:13-22. [PMID: 33068715 PMCID: PMC7557165 DOI: 10.1016/j.jclinepi.2020.10.007] [Citation(s) in RCA: 367] [Impact Index Per Article: 91.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Revised: 08/31/2020] [Accepted: 10/08/2020] [Indexed: 11/02/2022]
Abstract
OBJECTIVES To develop methods guidance to support the conduct of rapid reviews (RRs) produced within Cochrane and beyond, in response to requests for timely evidence syntheses for decision-making purposes including urgent health issues of high priority. STUDY DESIGN AND SETTING Interim recommendations were informed by a scoping review of the underlying evidence, primary methods studies conducted, and a survey sent to 119 representatives from 20 Cochrane entities, who were asked to rate and rank RR methods across stages of review conduct. Discussions among those with expertise in RR methods further informed the list of recommendations with accompanying rationales provided. RESULTS Based on survey results from 63 respondents (53% response rate), 26 RR methods recommendations are presented for which there was a high or moderate level of agreement or scored highest in the absence of such agreement. Where possible, how recommendations align with Cochrane methods guidance for systematic reviews is highlighted. CONCLUSION The Cochrane Rapid Reviews Methods Group offers new, interim guidance to support the conduct of RRs. Because best practice is limited by the lack of currently available evidence for some RR methods shortcuts taken, this guidance will need to be updated as additional abbreviated methods are evaluated.
Collapse
Affiliation(s)
- Chantelle Garritty
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Canada; TRIBE Graduate Program, University of Split School of Medicine, Croatia.
| | - Gerald Gartlehner
- Cochrane Austria, Danube University Krems, Krems a.d. Donau, Austria; RTI International, Research Triangle Park, NC, USA
| | | | - Valerie J King
- The Center for Evidence-based Policy, Oregon Health & Science University, Portland, OR, USA
| | - Candyce Hamel
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Canada; TRIBE Graduate Program, University of Split School of Medicine, Croatia
| | | | - Lisa Affengruber
- Cochrane Austria, Danube University Krems, Krems a.d. Donau, Austria
| | | |
Collapse
|
36
|
Hamel C, Michaud A, Thuku M, Affengruber L, Skidmore B, Nussbaumer-Streit B, Stevens A, Garritty C. Few evaluative studies exist examining rapid review methodology across stages of conduct: a systematic scoping review. J Clin Epidemiol 2020; 126:131-140. [DOI: 10.1016/j.jclinepi.2020.06.027] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Revised: 06/18/2020] [Accepted: 06/23/2020] [Indexed: 10/24/2022]
|
37
|
Garritty C, Hamel C, Hersi M, Butler C, Monfaredi Z, Stevens A, Nussbaumer-Streit B, Cheng W, Moher D. Assessing how information is packaged in rapid reviews for policy-makers and other stakeholders: a cross-sectional study. Health Res Policy Syst 2020; 18:112. [PMID: 32993657 PMCID: PMC7523380 DOI: 10.1186/s12961-020-00624-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2019] [Accepted: 08/30/2020] [Indexed: 01/08/2023] Open
Abstract
Background Rapid reviews (RRs) are useful products to healthcare policy-makers and other stakeholders, who require timely evidence. Therefore, it is important to assess how well RRs convey useful information in a format that is easy to understand so that decision-makers can make best use of evidence to inform policy and practice. Methods We assessed a diverse sample of 103 RRs against the BRIDGE criteria, originally developed for communicating clearly to support healthcare policy-making. We modified the criteria to increase assessability and to align with RRs. We identified RRs from key database searches and through searching organisations known to produce RRs. We assessed each RR on 26 factors (e.g. organisation of information, lay language use). Results were descriptively analysed. Further, we explored differences between RRs published in journals and those published elsewhere. Results Certain criteria were well covered across the RRs (e.g. all aimed to synthesise research evidence and all provided references of included studies). Further, most RRs provided detail on the problem or issue (96%; n = 99) and described methods to conduct the RR (91%; n = 94), while several addressed political or health systems contexts (61%; n = 63). Many RRs targeted policy-makers and key stakeholders as the intended audience (66%; n = 68), yet only 32% (n = 33) involved their tacit knowledge, while fewer (27%; n = 28) directly involved them reviewing the content of the RR. Only six RRs involved patient partners in the process. Only 23% (n = 24) of RRs were prepared in a format considered to make information easy to absorb (i.e. graded entry) and 25% (n = 26) provided specific key messages. Readability assessment indicated that the text of key RR sections would be hard to understand for an average reader (i.e. would require post-secondary education) and would take 42 (± 36) minutes to read. Conclusions Overall, conformity of the RRs with the modified BRIDGE criteria was modest. By assessing RRs against these criteria, we now understand possible ways in which they could be improved to better meet the information needs of healthcare decision-makers and their potential for innovation as an information-packaging mechanism. The utility and validity of these items should be further explored. Protocol availability The protocol, published on the Open Science Framework, is available at: osf.io/68tj7
Collapse
Affiliation(s)
- Chantelle Garritty
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, CPCR Building, 501 Smyth Rd, Box 201B, Ottawa, ON, K1H 8L6, Canada. .,TRIBE Graduate Program, University of Split School of Medicine, Split, Croatia.
| | - Candyce Hamel
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, CPCR Building, 501 Smyth Rd, Box 201B, Ottawa, ON, K1H 8L6, Canada.,TRIBE Graduate Program, University of Split School of Medicine, Split, Croatia
| | - Mona Hersi
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, CPCR Building, 501 Smyth Rd, Box 201B, Ottawa, ON, K1H 8L6, Canada
| | - Claire Butler
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, CPCR Building, 501 Smyth Rd, Box 201B, Ottawa, ON, K1H 8L6, Canada
| | - Zarah Monfaredi
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, CPCR Building, 501 Smyth Rd, Box 201B, Ottawa, ON, K1H 8L6, Canada
| | - Adrienne Stevens
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, CPCR Building, 501 Smyth Rd, Box 201B, Ottawa, ON, K1H 8L6, Canada
| | | | - Wei Cheng
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, CPCR Building, 501 Smyth Rd, Box 201B, Ottawa, ON, K1H 8L6, Canada
| | - David Moher
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, CPCR Building, 501 Smyth Rd, Box 201B, Ottawa, ON, K1H 8L6, Canada.,School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada
| |
Collapse
|
38
|
Garritty C, Hersi M, Hamel C, Stevens A, Monfaredi Z, Butler C, Tricco AC, Hartling L, Stewart LA, Welch V, Thavorn K, Cheng W, Moher D. Assessing the format and content of journal published and non-journal published rapid review reports: A comparative study. PLoS One 2020; 15:e0238025. [PMID: 32845906 PMCID: PMC7449464 DOI: 10.1371/journal.pone.0238025] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2019] [Accepted: 08/08/2020] [Indexed: 01/23/2023] Open
Abstract
BACKGROUND As production of rapid reviews (RRs) increases in healthcare, knowing how to efficiently convey RR evidence to various end-users is important given they are often intended to directly inform decision-making. Little is known about how often RRs are produced in the published or unpublished domains, and what and how information is structured. OBJECTIVES To compare and contrast report format and content features of journal-published (JP) and non-journal published (NJP) RRs. METHODS JP RRs were identified from key databases, and NJP RRs were identified from a grey literature search of 148 RR producing organizations and were sampled proportionate to cluster size by organization and product type to match the JP RR group. We extracted and formally compared 'how' (i.e., visual arrangement) and 'what' information was presented. RESULTS We identified 103 RRs (52 JP and 51 NJP) from 2016. A higher percentage of certain features were observed in JP RRs compared to NJP RRs (e.g., reporting authors; use of a traditional journal article structure; section headers including abstract, methods, discussion, conclusions, acknowledgments, conflict of interests, and author contributions; and use of figures (e.g., Study Flow Diagram) in the main document). For NJP RRs, a higher percentage of features were observed (e.g., use non-traditional report structures; bannering of executive summary sections and appendices; use of typographic cues; and including outcome tables). NJP RRs were more than double in length versus JP RRs. Including key messages was uncommon in both groups. CONCLUSIONS This comparative study highlights differences between JP and NJP RRs. Both groups may benefit from better use of plain language, and more clear and concise design. Alternative innovative formats and end-user preferences for content and layout should be studied further with thought given to other considerations to ensure better packaging of RR results to facilitate uptake into policy and practice. STUDY REGISTRATION The full protocol is available at: https://osf.io/29xvk/.
Collapse
Affiliation(s)
- Chantelle Garritty
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
- TRIBE Graduate Program, University of Split School of Medicine, Split, Croatia
| | - Mona Hersi
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
| | - Candyce Hamel
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
- TRIBE Graduate Program, University of Split School of Medicine, Split, Croatia
| | - Adrienne Stevens
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
| | - Zarah Monfaredi
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
| | - Claire Butler
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
| | - Andrea C. Tricco
- Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada
- Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
| | - Lisa Hartling
- Alberta Research Centre for Health Evidence, Department of Pediatrics, University of Alberta, Edmonton, Canada
| | - Lesley A. Stewart
- Centre for Reviews and Dissemination, University of York, York, United Kingdom
| | - Vivian Welch
- Methods Centre, Bruyère Research Institute, Ottawa, Canada
| | - Kednapa Thavorn
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada
| | - Wei Cheng
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
| | - David Moher
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada
| |
Collapse
|
39
|
Stevens A, Fischer A, Bartels M, Buchkremer G. Electroconvulsive therapy: a review on indications, methods, risks and medication. Eur Psychiatry 2020; 11:165-74. [DOI: 10.1016/0924-9338(96)88386-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/1995] [Accepted: 07/12/1995] [Indexed: 10/17/2022] Open
Abstract
SummaryThis paper reviews and presents data of practical impact for those administering electroconvulsive therapy (ECT). In the first section, physical and physiological aspects of the stimulus as well as methods of stimulation are discussed. The second section deals with indications for ECT, efficacy and treatment modalities such as seizure duration, treatment frequency and total number of ECT applications. The last section is devoted to side effects, risks, comedication and comorbidity.
Collapse
|
40
|
Hamel C, Ahmadzai N, Beck A, Thuku M, Skidmore B, Pussegoda K, Bjerre L, Chatterjee A, Dennis K, Ferri L, Maziak DE, Shea BJ, Hutton B, Little J, Moher D, Stevens A. Screening for esophageal adenocarcinoma and precancerous conditions (dysplasia and Barrett's esophagus) in patients with chronic gastroesophageal reflux disease with or without other risk factors: two systematic reviews and one overview of reviews to inform a guideline of the Canadian Task Force on Preventive Health Care (CTFPHC). Syst Rev 2020; 9:20. [PMID: 31996261 PMCID: PMC6990541 DOI: 10.1186/s13643-020-1275-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Accepted: 01/07/2020] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Two reviews and an overview were produced for the Canadian Task Force on Preventive Health Care guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease (GERD) without alarm symptoms. The goal was to systematically review three key questions (KQs): (1) The effectiveness of screening for these conditions; (2) How adults with chronic GERD weigh the benefits and harms of screening, and what factors contribute to their preferences and decision to undergo screening; and (3) Treatment options for Barrett's esophagus (BE), dysplasia or stage 1 EAC (overview of reviews). METHODS Bibliographic databases (e.g. Ovid MEDLINE®) were searched for each review in October 2018. We also searched for unpublished literature (e.g. relevant websites). The liberal accelerated approach was used for title and abstract screening. Two reviewers independently screened full-text articles. Data extraction and risk of bias assessments were completed by one reviewer and verified by another reviewer (KQ1 and 2). Quality assessments were completed by two reviewers independently in duplicate (KQ3). Disagreements were resolved through discussion. We used various risk of bias tools suitable for study design. The GRADE framework was used for rating the certainty of the evidence. RESULTS Ten studies evaluated the effectiveness of screening. One retrospective study reported no difference in long-term survival (approximately 6 to 12 years) between those who had a prior esophagogastroduodenoscopy and those who had not (adjusted HR 0.93, 95% confidence interval (CI) 0.58-1.50). Though there may be higher odds of a stage 1 diagnosis than a more advanced diagnosis (stage 2-4) if an EGD had been performed in the previous 5 years (OR 2.27, 95% CI 1.00-7.67). Seven studies compared different screening modalities, and showed little difference between modalities. Three studies reported on patients' unwillingness to be screened (e.g. due to anxiety, fear of gagging). Eleven systematic reviews evaluated treatment modalities, providing some evidence of early treatment effect for some outcomes. CONCLUSIONS Little evidence exists on the effectiveness of screening and values and preferences to screening. Many treatment modalities have been evaluated, but studies are small. Overall, there is uncertainty in understanding the effectiveness of screening and early treatments. SYSTEMATIC REVIEW REGISTRATIONS PROSPERO (CRD42017049993 [KQ1], CRD42017050014 [KQ2], CRD42018084825 [KQ3]).
Collapse
Affiliation(s)
- Candyce Hamel
- Ottawa Hospital Research Institute, Knowledge Synthesis Group, 501 Smyth Road, Ottawa, ON, Canada.
| | - Nadera Ahmadzai
- Ottawa Hospital Research Institute, Knowledge Synthesis Group, 501 Smyth Road, Ottawa, ON, Canada
| | - Andrew Beck
- Ottawa Hospital Research Institute, Knowledge Synthesis Group, 501 Smyth Road, Ottawa, ON, Canada
| | - Micere Thuku
- Ottawa Hospital Research Institute, Knowledge Synthesis Group, 501 Smyth Road, Ottawa, ON, Canada
| | - Becky Skidmore
- Ottawa Hospital Research Institute, Knowledge Synthesis Group, 501 Smyth Road, Ottawa, ON, Canada
| | - Kusala Pussegoda
- Ottawa Hospital Research Institute, Knowledge Synthesis Group, 501 Smyth Road, Ottawa, ON, Canada
| | - Lise Bjerre
- Department of Family Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Avijit Chatterjee
- Gastroenterology Department, Faculty of Medicine, Unveristy of Ottawa, Ottawa, ON, Canada
| | - Kristopher Dennis
- Ottawa Hospital Research Institute, Cancer Therapeutics Program, Ottawa, ON, Canada
| | - Lorenzo Ferri
- Division of Thoracic and Upper Gastrointestinal Surgery, McGill University, Montreal, QC, Canada
| | - Donna E Maziak
- Department of Surgery and The Ottawa Hospital, Department of Thoracic Surgery, University of Ottawa, Ottawa, ON, Canada
| | - Beverley J Shea
- Ottawa Hospital Research Institute, Knowledge Synthesis Group, 501 Smyth Road, Ottawa, ON, Canada
| | - Brian Hutton
- Ottawa Hospital Research Institute, Knowledge Synthesis Group, 501 Smyth Road, Ottawa, ON, Canada.,School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada
| | - Julian Little
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada
| | - David Moher
- Ottawa Hospital Research Institute, Knowledge Synthesis Group, 501 Smyth Road, Ottawa, ON, Canada.,School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada
| | - Adrienne Stevens
- Ottawa Hospital Research Institute, Knowledge Synthesis Group, 501 Smyth Road, Ottawa, ON, Canada
| |
Collapse
|
41
|
Pratt M, Stevens A, Thuku M, Butler C, Skidmore B, Wieland LS, Clemons M, Kanji S, Hutton B. Benefits and harms of medical cannabis: a scoping review of systematic reviews. Syst Rev 2019; 8:320. [PMID: 31823819 PMCID: PMC6905063 DOI: 10.1186/s13643-019-1243-x] [Citation(s) in RCA: 74] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Accepted: 11/24/2019] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND There has been increased interest in the role of cannabis for treating medical conditions. The availability of different cannabis-based products can make the side effects of exposure unpredictable. We sought to conduct a scoping review of systematic reviews assessing benefits and harms of cannabis-based medicines for any condition. METHODS A protocol was followed throughout the conduct of this scoping review. A protocol-guided scoping review conduct. Searches of bibliographic databases (e.g., MEDLINE®, Embase, PsycINFO, the Cochrane Library) and gray literature were performed. Two people selected and charted data from systematic reviews. Categorizations emerged during data synthesis. The reporting of results from systematic reviews was performed at a high level appropriate for a scoping review. RESULTS After screening 1975 citations, 72 systematic reviews were included. The reviews covered many conditions, the most common being pain management. Several reviews focused on management of pain as a symptom of conditions such as multiple sclerosis (MS), injury, and cancer. After pain, the most common symptoms treated were spasticity in MS, movement disturbances, nausea/vomiting, and mental health symptoms. An assessment of review findings lends to the understanding that, although in a small number of reviews results showed a benefit for reducing pain, the analysis approach and reporting in other reviews was sub-optimal, making it difficult to know how consistent findings are when considering pain in general. Adverse effects were reported in most reviews comparing cannabis with placebo (49/59, 83%) and in 20/24 (83%) of the reviews comparing cannabis to active drugs. Minor adverse effects (e.g., drowsiness, dizziness) were common and reported in over half of the reviews. Serious harms were not as common, but were reported in 21/59 (36%) reviews that reported on adverse effects. Overall, safety data was generally reported study-by-study, with few reviews synthesizing data. Only one review was rated as high quality, while the remaining were rated of moderate (n = 36) or low/critically low (n = 35) quality. CONCLUSIONS Results from the included reviews were mixed, with most reporting an inability to draw conclusions due to inconsistent findings and a lack of rigorous evidence. Mild harms were frequently reported, and it is possible the harms of cannabis-based medicines may outweigh benefits. SYSTEMATIC REVIEW REGISTRATION The protocol for this scoping review was posted in the Open Access (https://ruor.uottawa.ca/handle/10393/37247).
Collapse
Affiliation(s)
- Misty Pratt
- Knowledge Synthesis Group, Ottawa Methods Centre, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, 501 Smyth Road, Ottawa, Ontario K1H 8 L6 Canada
| | - Adrienne Stevens
- Knowledge Synthesis Group, Ottawa Methods Centre, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, 501 Smyth Road, Ottawa, Ontario K1H 8 L6 Canada
- TRIBE Graduate Program, University of Split School of Medicine, Split, Croatia
| | - Micere Thuku
- Knowledge Synthesis Group, Ottawa Methods Centre, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, 501 Smyth Road, Ottawa, Ontario K1H 8 L6 Canada
| | - Claire Butler
- Knowledge Synthesis Group, Ottawa Methods Centre, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, 501 Smyth Road, Ottawa, Ontario K1H 8 L6 Canada
- Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec H3A 2B4 Canada
| | | | - L. Susan Wieland
- Center for Integrative Medicine, University of Maryland School of Medicine, Baltimore, MD USA
| | - Mark Clemons
- School of Epidemiology and Public Health, University of Ottawa, 451 Smyth Road, Ottawa, Ontario K1H 8 M5 Canada
- Division of Medical Oncology and Department of Medicine, University of Ottawa, Ottawa, Canada
| | - Salmaan Kanji
- School of Epidemiology and Public Health, University of Ottawa, 451 Smyth Road, Ottawa, Ontario K1H 8 M5 Canada
- Department of Pharmacy, The Ottawa Hospital, Ottawa, Canada
- Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Canada
| | - Brian Hutton
- Knowledge Synthesis Group, Ottawa Methods Centre, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, 501 Smyth Road, Ottawa, Ontario K1H 8 L6 Canada
- School of Epidemiology and Public Health, University of Ottawa, 451 Smyth Road, Ottawa, Ontario K1H 8 M5 Canada
| |
Collapse
|
42
|
Engelina S, Saggu M, Yoo J, Shah F, Stevens A, Irwin C, Chaganti S, Scarisbrick J. Brentuximab a novel antibody therapy: real‐world use confirms efficacy and tolerability for CD30‐positive cutaneous lymphoma. Br J Dermatol 2019; 182:799-800. [DOI: 10.1111/bjd.18535] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- S. Engelina
- University Hospital Birmingham (UHB) Birmingham U.K
| | - M. Saggu
- University Hospital Birmingham (UHB) Birmingham U.K
| | - J. Yoo
- University Hospital Birmingham (UHB) Birmingham U.K
| | - F. Shah
- University Hospital Birmingham (UHB) Birmingham U.K
| | - A. Stevens
- University Hospital Birmingham (UHB) Birmingham U.K
| | - C. Irwin
- University Hospital Birmingham (UHB) Birmingham U.K
| | - S. Chaganti
- University Hospital Birmingham (UHB) Birmingham U.K
| | | |
Collapse
|
43
|
Ritchie S, Qureshi I, Molloy K, Yoo J, Shah F, Stevens A, Irwin C, Chaganti S, Scarisbrick J. Evaluation of haematopoietic stem cell transplantation in patients diagnosed with cutaneous T‐cell lymphoma at a tertiary care centre: should we avoid chemotherapy in conditioning regimes? Br J Dermatol 2019; 182:807-809. [DOI: 10.1111/bjd.18541] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- S. Ritchie
- University Hospital Birmingham (UHB) Birmingham U.K
| | - I. Qureshi
- University Hospital Birmingham (UHB) Birmingham U.K
| | - K. Molloy
- University Hospital Birmingham (UHB) Birmingham U.K
| | - J. Yoo
- University Hospital Birmingham (UHB) Birmingham U.K
| | - F. Shah
- University Hospital Birmingham (UHB) Birmingham U.K
| | - A. Stevens
- University Hospital Birmingham (UHB) Birmingham U.K
| | - C. Irwin
- University Hospital Birmingham (UHB) Birmingham U.K
| | - S. Chaganti
- University Hospital Birmingham (UHB) Birmingham U.K
| | | |
Collapse
|
44
|
Nussbaumer-Streit B, Klerings I, Dobrescu AI, Persad E, Stevens A, Garritty C, Kamel C, Affengruber L, King VJ, Gartlehner G. Excluding non-English publications from evidence-syntheses did not change conclusions: a meta-epidemiological study. J Clin Epidemiol 2019; 118:42-54. [PMID: 31698064 DOI: 10.1016/j.jclinepi.2019.10.011] [Citation(s) in RCA: 139] [Impact Index Per Article: 27.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Revised: 10/24/2019] [Accepted: 10/31/2019] [Indexed: 01/05/2023]
Abstract
OBJECTIVES We aimed to assess whether limiting the inclusion criteria solely to English-language publications affected the overall conclusions of evidence syntheses. STUDY DESIGN AND SETTING Our analyses used a dataset of a previous methods study that included 59 randomly selected Cochrane intervention reviews with no language restrictions. First, we ascertained the publication language of all 2,026 included publications. Next, we excluded studies based on the following criteria: (1) publication solely in non-English language, or (2) main publication (in case of multiple publications of the same study) in non-English language. We then re-calculated meta-analyses for outcomes that were presented in the main summary of findings tables of the Cochrane reports. If the direction of the effect estimate or the statistical significance changed, authors of the respective Cochrane reviews were consulted to assess whether the new evidence base would have changed their conclusions. The primary outcome of our analyses examined the proportion of conclusions that would change with the exclusion of non-English publications. We set the threshold for the approach as noninferior if the upper limit of the 95% confidence interval of the proportion of changed conclusions did not cross a margin of 10%. RESULTS Across all 59 Cochrane reviews, 29 (49%) included 80 non-English publications. For 16 (27%) of these Cochrane reviews, the exclusion of non-English publications resulted in the exclusion of at least one study. In the remaining 13 Cochrane reviews, the non-English publications were not the only or main publication of the study or they did not contribute to the main summary of the findings table, so their exclusion did not result in an exclusion of the study. Overall, the exclusion of non-English publications led to the exclusion of 31 studies contributing to 40 outcomes. For 38 of the 40 outcomes, the exclusion of non-English studies did not markedly alter the size or direction of effect estimates or statistical significance. In two outcomes, the statistical significance changed, but authors would have still drawn the same conclusion, albeit with less certainty. Thus, the proportion of changed conclusions in our sample was 0.0% (95% CI 0.0-0.6), which indicated the noninferiority of the approach. However, the majority of excluded studies were small. CONCLUSION Exclusion of non-English publications from systematic reviews on clinical interventions had a minimal effect on overall conclusions and could be a viable methodological shortcut, especially for rapid reviews.
Collapse
Affiliation(s)
- B Nussbaumer-Streit
- Cochrane Austria, Department for Evidence-based Medicine and Evaluation, Danube University Krems, Krems a.d. Donau, Austria.
| | - I Klerings
- Cochrane Austria, Department for Evidence-based Medicine and Evaluation, Danube University Krems, Krems a.d. Donau, Austria
| | - A I Dobrescu
- Cochrane Austria, Department for Evidence-based Medicine and Evaluation, Danube University Krems, Krems a.d. Donau, Austria
| | - E Persad
- Cochrane Austria, Department for Evidence-based Medicine and Evaluation, Danube University Krems, Krems a.d. Donau, Austria
| | - A Stevens
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
| | - C Garritty
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
| | - C Kamel
- HTA and Rapid Response, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, Canada
| | - L Affengruber
- Cochrane Austria, Department for Evidence-based Medicine and Evaluation, Danube University Krems, Krems a.d. Donau, Austria; Department of Family Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht University, The Netherlands
| | - V J King
- The Center for Evidence-based Policy, Oregon Health & Science University, Portland, Oregon, United States
| | - G Gartlehner
- Cochrane Austria, Department for Evidence-based Medicine and Evaluation, Danube University Krems, Krems a.d. Donau, Austria; RTI International, Research Triangle Park, NC, USA
| |
Collapse
|
45
|
Aplin J, Bennie S, Brison D, Westwood M, Stevens A, Ruane P. Early steps in trophoblast differentiation. Placenta 2019. [DOI: 10.1016/j.placenta.2019.06.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
46
|
Smith HL, Stevens A, Minogue B, Sneddon S, Shaw L, Wood L, Adeniyi T, Xiao H, Lio P, Kimber SJ, Brison DR. Systems based analysis of human embryos and gene networks involved in cell lineage allocation. BMC Genomics 2019; 20:171. [PMID: 30836937 PMCID: PMC6399968 DOI: 10.1186/s12864-019-5558-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2018] [Accepted: 02/22/2019] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Little is understood of the molecular mechanisms involved in the earliest cell fate decision in human development, leading to the establishment of the trophectoderm (TE) and inner cell mass (ICM) stem cell population. Notably, there is a lack of understanding of how transcriptional networks arise during reorganisation of the embryonic genome post-fertilisation. RESULTS We identified a hierarchical structure of preimplantation gene network modules around the time of embryonic genome activation (EGA). Using network models along with eukaryotic initiation factor (EIF) and epigenetic-associated gene expression we defined two sets of blastomeres that exhibited diverging tendencies towards ICM or TE. Analysis of the developmental networks demonstrated stage specific EIF expression and revealed that histone modifications may be an important epigenetic regulatory mechanism in preimplantation human embryos. Comparison to published RNAseq data confirmed that during EGA the individual 8-cell blastomeres are transcriptionally primed for the first lineage decision in development towards ICM or TE. CONCLUSIONS Using multiple systems biology approaches to compare developmental stages in the early human embryo with single cell transcript data from blastomeres, we have shown that blastomeres considered to be totipotent are not transcriptionally equivalent. Furthermore we have linked the developmental interactome to individual blastomeres and to later cell lineage. This has clinical implications for understanding the impact of fertility treatments and developmental programming of long term health.
Collapse
Affiliation(s)
- H. L. Smith
- Maternal and Fetal Health Research Centre, University of Manchester, Manchester Academic Health Sciences Centre, Oxford Road, Manchester, M13 9WL UK
- Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Oxford Road, Manchester, M13 9WL UK
| | - A. Stevens
- Division of Developmental Biology & Medicine, School of Medical Sciences, University of Manchester, Manchester Academic Health Sciences Centre, 5th Floor Research, Royal Manchester Children’s Hospital, Oxford Road, Manchester, M13 9WL UK
| | - B. Minogue
- Maternal and Fetal Health Research Centre, University of Manchester, Manchester Academic Health Sciences Centre, Oxford Road, Manchester, M13 9WL UK
- Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Oxford Road, Manchester, M13 9WL UK
| | - S. Sneddon
- Maternal and Fetal Health Research Centre, University of Manchester, Manchester Academic Health Sciences Centre, Oxford Road, Manchester, M13 9WL UK
- Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Oxford Road, Manchester, M13 9WL UK
| | - L. Shaw
- Maternal and Fetal Health Research Centre, University of Manchester, Manchester Academic Health Sciences Centre, Oxford Road, Manchester, M13 9WL UK
- Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Oxford Road, Manchester, M13 9WL UK
| | - L. Wood
- Department of Reproductive Medicine, Saint Mary’s Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Sciences Centre, Oxford Road, Manchester, M13 9WL UK
| | - T. Adeniyi
- Department of Reproductive Medicine, Saint Mary’s Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Sciences Centre, Oxford Road, Manchester, M13 9WL UK
| | - H. Xiao
- Computer Laboratory, William Gates Building, University of Cambridge, Cambridge, UK
| | - P. Lio
- Computer Laboratory, William Gates Building, University of Cambridge, Cambridge, UK
| | - S. J. Kimber
- Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Oxford Road, Manchester, M13 9WL UK
| | - D. R. Brison
- Maternal and Fetal Health Research Centre, University of Manchester, Manchester Academic Health Sciences Centre, Oxford Road, Manchester, M13 9WL UK
- Department of Reproductive Medicine, Saint Mary’s Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Sciences Centre, Oxford Road, Manchester, M13 9WL UK
| |
Collapse
|
47
|
Quaglino P, Maule M, Prince HM, Porcu P, Horwitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Guitart J, Papadavid E, Sanches JA, Hodak E, Sugaya M, Berti E, Ortiz-Romero P, Pimpinelli N, Servitje O, Pileri A, Zinzani PL, Estrach T, Knobler R, Stadler R, Fierro MT, Alberti Violetti S, Amitay-Laish I, Antoniou C, Astrua C, Chaganti S, Child F, Combalia A, Fabbro S, Fava P, Grandi V, Jonak C, Martinez-Escala E, Kheterpal M, Kim EJ, McCormack C, Miyagaki T, Miyashiro D, Morris S, Muniesa C, Nikolaou V, Ognibene G, Onida F, Osella-Abate S, Porkert S, Postigo-Llorente C, Ram-Wolff C, Ribero S, Rogers K, Sanlorenzo M, Stranzenbach R, Spaccarelli N, Stevens A, Zugna D, Rook AH, Geskin LJ, Willemze R, Whittaker S, Hoppe R, Scarisbrick J, Kim Y. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Ann Oncol 2019; 30:494. [PMID: 29947731 DOI: 10.1093/annonc/mdy207] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- P Quaglino
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - M Maule
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - H M Prince
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - P Porcu
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - S Horwitz
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - M Duvic
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - R Talpur
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - M Vermeer
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - M Bagot
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - J Guitart
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - E Papadavid
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - J A Sanches
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - E Hodak
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - M Sugaya
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - E Berti
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - P Ortiz-Romero
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - N Pimpinelli
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - O Servitje
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - A Pileri
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - P L Zinzani
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - T Estrach
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - R Knobler
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - R Stadler
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - M T Fierro
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - S Alberti Violetti
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - I Amitay-Laish
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - C Antoniou
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - C Astrua
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - S Chaganti
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - F Child
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - A Combalia
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - S Fabbro
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - P Fava
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - V Grandi
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - C Jonak
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - E Martinez-Escala
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - M Kheterpal
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - E J Kim
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - C McCormack
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - T Miyagaki
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - D Miyashiro
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - S Morris
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - C Muniesa
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - V Nikolaou
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - G Ognibene
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - F Onida
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - S Osella-Abate
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - S Porkert
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - C Postigo-Llorente
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - C Ram-Wolff
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - S Ribero
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - K Rogers
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - M Sanlorenzo
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - R Stranzenbach
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - N Spaccarelli
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - A Stevens
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - D Zugna
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - A H Rook
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - L J Geskin
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - R Willemze
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - S Whittaker
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - R Hoppe
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - J Scarisbrick
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| | - Y Kim
- Dermatologic Clinic, Department of Medical Sciences; Cancer Epidemiology Uni, Department of Medical Sciences, University of Torino, Torino, Italy; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, Melbourne, Australia; Division of Hematologic Malignancies, Ohio State University; Department of Medicine, Memorial Sloan-Kettering Cancer Centre, New York; Department of Dermatology and Pathology, MD Anderson Cancer Centre, Houston, USA; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Dermatology Department, Hospital St Louis, Paris, France; Department of Dermatology and Pathology, Northwestern University, Chicago, USA; 2nd Department of Dermatology and Venereology, Attikon General Hospital, University of Athens, Chaidari, Greece; Department of Dermatology, University of Sao Paulo Medical School, Sao Paulo, Brazil; Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Dermatolog, Faculty of Medicine, University of Tokyo, Tokyo, Japan; Department of Dermatology, Fondazione Ca' Granda, IRCCS, OMP, Milano, Italy; Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; Dermatologic Clinic, University of Florence, Florence, Italy; Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain; Dermatologic Clinic, University of Bologna, Bologna; Seragnoli Institute of Haematology, Bologna, Italy; Department of Dermatolog, Hospital Clinico, University of Barcelona, Barcelona, Spain; Dermatologic Clinic, University of Vienna Medical School, Vienna, Austria; University Clinic for Dermatolog, Venereology, Allergology and Phlebology, Minden, Germany; Cutaneous Lymphoma Service, University Hospital Birmingham, Birmingham; Kings College London, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Dermatology and Pathology, University of Pennsylvania, Philadelphia; Comprehensive Skin Cancer Center, Columbia University Medical Center; Department of Dermatology, Stanford University Medical Centre, USA
| |
Collapse
|
48
|
Abstract
Systematic reviews are the most common form of knowledge synthesis and remain a cornerstone of the practice of evidence-based medicine. They offer enhanced rigor and validity relative to traditional narrative review articles by reducing bias and increasing objectivity. In answering focused research questions, systematic reviews are directly applicable to clinical practice as well as the development of clinical guidelines and the identification of knowledge gaps, which may drive future primary research directions. Typically, such a rigorous process necessarily requires substantive time to carefully and systematically identify, screen, and synthesize all relevant available primary research on a topic. Further, other knowledge synthesis methods have emerged to address the varying needs of decision makers with respect to condensed timelines and more diverse research questions, as well as to allow incorporation of already synthesized evidence into reviews. These alternative methods include rapid reviews, scoping reviews, and overviews of systematic reviews, which are being used with increasing frequency by clinicians, decision-makers, and researchers. We encourage clinicians and researchers in nuclear medicine and other imaging sciences to acquire a greater familiarity with these methods and to consider them in clinical decision making, the development of clinical guidelines, and the planning of future research activities.
Collapse
Affiliation(s)
- C Garritty
- Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa Methods Centre, Ottawa, Canada
| | - A Stevens
- Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa Methods Centre, Ottawa, Canada
| | - C Hamel
- Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa Methods Centre, Ottawa, Canada
| | - M Golfam
- Edmundston Regional Hospital, Vitalite Health Network, New Brunswick, Canada
| | - B Hutton
- Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa Methods Centre, Ottawa, Canada; Ottawa University School of Epidemiology, Public Health and Preventive Medicine, Ottawa, Canada
| | - D Wolfe
- Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa Methods Centre, Ottawa, Canada.
| |
Collapse
|
49
|
Hersi M, Traversy G, Thombs BD, Beck A, Skidmore B, Groulx S, Lang E, Reynolds DL, Wilson B, Bernstein SL, Selby P, Johnson-Obaseki S, Manuel D, Pakhale S, Presseau J, Courage S, Hutton B, Shea BJ, Welch V, Morrow M, Little J, Stevens A. Effectiveness of stop smoking interventions among adults: protocol for an overview of systematic reviews and an updated systematic review. Syst Rev 2019; 8:28. [PMID: 30660199 PMCID: PMC6339342 DOI: 10.1186/s13643-018-0928-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/29/2018] [Accepted: 12/20/2018] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Tobacco smoking is the leading cause of cancer, preventable death, and disability. Smoking cessation can increase life expectancy by nearly a decade if achieved in the third or fourth decades of life. Various stop smoking interventions are available including pharmacotherapies, electronic cigarettes, behavioural support, and alternative therapies. This protocol outlines an evidence review which will evaluate the benefits and harms of stop smoking interventions in adults. METHODS The evidence review will consist of two stages. First, an overview of systematic reviews evaluating the benefits and harms of various stop smoking interventions delivered in or referred from the primary care setting will be conducted. The second stage will involve updating a systematic review on electronic cigarettes identified in the overview; randomized controlled trials will be considered for outcomes relating to benefits while randomized controlled trials, non-randomized controlled trials, and comparative observational studies will be considered for evaluating harms. Search strategies will be developed and peer-reviewed by medical information specialists. The search strategy for the updated review on e-cigarettes will be developed using that of the candidate systematic review. The MEDLINE®, PsycINFO, Embase, and the Cochrane Library electronic databases will be searched as of 2008 for the overview of reviews and from the last search date of the selected review for the updated review. Organizational websites and trial registries will be searched for unpublished or ongoing reviews/studies. Two reviewers will independently screen the title and abstracts of citations using the liberal accelerated method. Full-text screening will be performed independently by two reviewers. Extracted data will be verified by a second reviewer. Disagreements regarding full-text screening and data extraction will be resolved by consensus or third-party adjudication. The methodological quality of systematic reviews, risk of bias of randomized and non-randomized trials, and methodological quality of cohort studies will be evaluated using AMSTAR 2, the Cochrane risk of bias tool, and a modified version of the Scottish Intercollegiate Guidelines Network critical appraisal tool, respectively. The GRADE framework will be used to assess the quality of the evidence for outcomes. DISCUSSION The evidence review will evaluate the benefits and harms of various stop smoking interventions for adults. Findings will be used to inform a national tobacco cessation guideline by the Canadian Task Force on Preventive Health Care. SYSTEMATIC REVIEW REGISTRATION PROSPERO (CRD42018099691, CRD42018099692).
Collapse
Affiliation(s)
- Mona Hersi
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Centre for Practice-Changing Research, 501 Smyth Road, Box 201, Ottawa, Ontario K1H 8L6 Canada
| | | | - Brett D. Thombs
- Lady Davis Institute of the Jewish General Hospital, Montreal, Quebec Canada
- Department of Psychiatry, McGill University, Montreal, Quebec Canada
| | - Andrew Beck
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Centre for Practice-Changing Research, 501 Smyth Road, Box 201, Ottawa, Ontario K1H 8L6 Canada
| | - Becky Skidmore
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Centre for Practice-Changing Research, 501 Smyth Road, Box 201, Ottawa, Ontario K1H 8L6 Canada
| | - Stéphane Groulx
- Department of Community Health Sciences, University of Sherbrooke, Sherbrooke, Quebec Canada
- Centre de recherche Charles-Le Moyne – Saguenay–Lac-Saint-Jean sur les innovations en santé (CR-CSIS), Université de Sherbrooke, Quebec, Quebec Canada
| | - Eddy Lang
- University of Calgary Cumming School of Medicine, Calgary, Alberta Canada
- Alberta Health Services, Calgary, Alberta Canada
| | - Donna L. Reynolds
- Department of Family and Community Medicine, University of Toronto, Toronto, Ontario Canada
- Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario Canada
| | - Brenda Wilson
- Division of Community Health and Humanities, Memorial University of Newfoundland, St. John’s, Newfoundland Canada
| | - Steven L. Bernstein
- Department of Emergency Medicine, Yale School of Medicine, New Haven, CT USA
| | - Peter Selby
- Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario Canada
- Addictions Division, Centre for Addiction and Mental Health, Toronto, Ontario Canada
| | - Stephanie Johnson-Obaseki
- Department of Otolaryngology, University of Ottawa, Ottawa, Ontario Canada
- The Ottawa Hospital, Ottawa, Ontario Canada
| | - Douglas Manuel
- The Ottawa Hospital, Ottawa, Ontario Canada
- Department of Family Medicine, University of Ottawa, Ottawa, Ontario Canada
- Ottawa Hospital Research Institute, Ottawa, Ontario Canada
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario Canada
- Bruyere Research Institute, Ottawa, Ontario Canada
| | - Smita Pakhale
- The Ottawa Hospital, Ottawa, Ontario Canada
- Ottawa Hospital Research Institute, Ottawa, Ontario Canada
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario Canada
| | - Justin Presseau
- Ottawa Hospital Research Institute, Ottawa, Ontario Canada
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario Canada
- School of Psychology, University of Ottawa, Ottawa, Ontario Canada
| | - Susan Courage
- Public Health Agency of Canada, Ottawa, Ontario Canada
| | - Brian Hutton
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Centre for Practice-Changing Research, 501 Smyth Road, Box 201, Ottawa, Ontario K1H 8L6 Canada
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario Canada
| | - Beverley J. Shea
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Centre for Practice-Changing Research, 501 Smyth Road, Box 201, Ottawa, Ontario K1H 8L6 Canada
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario Canada
| | - Vivian Welch
- Ottawa Hospital Research Institute, Ottawa, Ontario Canada
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario Canada
- Bruyere Research Institute, Ottawa, Ontario Canada
| | - Matt Morrow
- Patient representative, Vancouver, British Columbia Canada
| | - Julian Little
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario Canada
| | - Adrienne Stevens
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Centre for Practice-Changing Research, 501 Smyth Road, Box 201, Ottawa, Ontario K1H 8L6 Canada
| |
Collapse
|
50
|
Hamel C, Lang E, Morissette K, Beck A, Stevens A, Skidmore B, Colquhoun H, LeBlanc J, Moore A, Riva JJ, Thombs BD, Colman I, Grigoriadis S, Nicholls SG, Potter BK, Ritchie K, Robert J, Vasa P, Lauria-Horner B, Patten S, Vigod SN, Hutton B, Shea BJ, Shanmugasegaram S, Little J, Moher D. Screening for depression in women during pregnancy or the first year postpartum and in the general adult population: a protocol for two systematic reviews to update a guideline of the Canadian Task Force on Preventive Health Care. Syst Rev 2019; 8:27. [PMID: 30660183 PMCID: PMC6339426 DOI: 10.1186/s13643-018-0930-3] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Accepted: 12/25/2018] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND In 2018, the World Health Organization reported that depression is the most common cause of disability worldwide, with over 300 million people currently living with depression. Depression affects an individual's physical health and well-being, impacts psychosocial functioning, and has specific negative short- and long-term effects on maternal health, child health, developmental trajectories, and family health. The aim of these reviews is to identify evidence on the benefits and harms of screening for depression in the general adult population and in pregnant and postpartum women. METHODS Search strategies were developed and tested through an iterative process by an experienced medical information specialist in consultation with the review team. We will search MEDLINE, Embase, PsycINFO, CINAHL, and the Cochrane Library, and a randomized controlled trial filter will be used. The general adult review will be an update of a systematic review previously used by the Canadian Task Force on Preventive Health Care for their 2013 guideline recommendation. The search strategy will be updated and will start from the last search date of the previous review (May 2012). The pregnant and postpartum review will be a de novo review with no date restriction. For both reviews, we will search for unpublished documents following the CADTH Grey Matters checklist and relevant websites. Titles and abstracts will be screened using the liberal accelerated method. Two reviewers will independently screen full-text articles for relevance using pre-specified eligibility criteria and assess the risk of bias of included studies using the Cochrane Risk of Bias tool. Outcomes of interest for the general adult population review include symptoms of depression or diagnosis of major depressive disorder, health-related quality of life, day-to-day functionality, lost time at work/school, impact on lifestyle behaviour, suicidality, false-positive result, labelling/stigma, overdiagnosis or overtreatment, and harms of treatment. Outcomes of interest for the pregnant and postpartum review include mental health outcomes (e.g. diagnosis of major depressive disorder), parenting outcomes (e.g. mother-child interactions), and infant outcomes (e.g. infant health and development). DISCUSSION These two systematic reviews will offer informative evaluations of depression screening. The findings will be used by the Task Force to help develop guideline recommendations on depression screening in the general adult population and in pregnant and postpartum women in Canada. SYSTEMATIC REVIEW REGISTRATION PROSPERO (CRD42018099690).
Collapse
Affiliation(s)
- Candyce Hamel
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
| | - Eddy Lang
- University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.,Alberta Health Services, Calgary, Alberta, Canada
| | | | - Andrew Beck
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Adrienne Stevens
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Becky Skidmore
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Heather Colquhoun
- Department of Occupational Science and Occupational Therapy, University of Toronto, Toronto, Canada
| | - John LeBlanc
- Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Ainsley Moore
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada.,Department of Family Medicine, McMaster University, David Braley Health Sciences Centre, Hamilton, Canada
| | - John J Riva
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada.,Department of Family Medicine, McMaster University, David Braley Health Sciences Centre, Hamilton, Canada
| | - Brett D Thombs
- Lady Davis Institute of the Jewish General Hospital, Montreal, Quebec, Canada.,Department of Psychiatry, McGill University, Montreal, Quebec, Canada
| | - Ian Colman
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Sophie Grigoriadis
- Department of Psychiatry, University of Toronto, Toronto, Canada.,Sunnybrook Health Sciences Centre, Toronto, Canada.,Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada
| | | | - Beth K Potter
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Kerri Ritchie
- Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.,School of Psychology, University of Ottawa, Ottawa, Ontario, Canada.,Department of Psychology, The Ottawa Hospital, Ottawa, Ontario, Canada
| | | | - Priya Vasa
- Department of Family and Community Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
| | | | - Scott Patten
- Department of Community Health Services and Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada
| | - Simone N Vigod
- Department of Psychiatry, University of Toronto, Toronto, Canada.,Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada
| | - Brian Hutton
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.,School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Beverley J Shea
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.,School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | | | - Julian Little
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - David Moher
- Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.,School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.,Centre for Journalology, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| |
Collapse
|